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General Introduction 
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Abdominal aortic aneurysm 
An Abdominal Aortic Aneurysm (AAA) is a vascular disorder in 
which the abdominal aorta becomes permanently dilated to at least 1.5 
times its normal diameter.1, 2 The prevalence of AAA is increasing rapidly 
during the last decade, and aneurysmal rupture is now the 13th commonest 
cause of death in the Western world.3 Rupture of the AAA accounts for 1-
2% of deaths in men over 65 years of age.4  
From outside to inside, the aorta is composed of the intima, media, and 
adventitia. The intima, the innermost layer, is thin, delicate, lined by 
endothelium, and easily traumatized. The media is responsible for 
imparting strength to the aorta and is composed of laminated but 
intertwining sheets of elastic tissue. The arrangement of these sheets in a 
spiral provides the aorta with its maximum allowable tensile strength. The 
aortic media contains very little smooth muscle and collagen between the 
elastic layers and thus has increased distensibility, elasticity, and tensile 
strength. This contrasts with peripheral arteries, which, in comparison, 
have more smooth muscle and collagen between the elastic layers. The 
outermost layer of the aorta is the adventitia, which largely consists of 
collagen and the vasa vasorum, which supplies blood to the outer portion 
of the aortic wall, within the adventitia.5  
Aneurysms occur in segments of the aorta between branches or 
bifurcations where there is no fixation by surrounding structures.6 
Aneurysmal development is caused by weakness in the muscular tunica 
media and stretching of the tunica intima and adventitial layers. 
Additionally, progressive enlargement of the vessel is caused by blood 
pressure within the aneurysm.7 As an aneurysm expands, the velocity of 
blood flow adjacent to the wall of the aneurysm diminishes. This 
diminished velocity predisposes to thrombus formation, and the lumen of 
an aneurysm is often lined with clot. The presence of thrombus whitin an 
aneurysm has no particular prognostic significance, although intraluminal 
clot sporadically causes aortic thrombosis and distal embolization.6 
The majority of the patients seeking treatment for their aneurysm 
are of advanced age. With aging, the elasticity and distensibility of the 
aorta declines, resulting in an increase of the pulse pressure in elderly 
individuals. This process is accelerated in patients with hypertension, 
coronary artery disease, or hypercholesterolemia.5 
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Risk factors for AAA include advanced age (i.e., 55 years or 
higher), male gender, a family history of aortic aneurysm, atherosclerosis, 
smoking, hypertension, diabetes and previous vascular surgery.8 
Population-based screening demonstrated that smoking and male gender 
are the greatest risk factors for development of an AAA.9 In addition, 
patients with peripheral vascular disease develop two times as frequently 
an AAA compared to a group whithout peripheral vascular disease.10  
Risk factors for aneurysm rupture are large aneurysm size, female 
gender, current smoking, poor lung function and higher mean blood 
pressure. Effective control of blood pressure and cessation of smoking are 
the health measures most likely to alter the natural history of AAA, by 
diminishing the risk for rupture.4 
The majority of discovered aneurysms are asymptomatic. When an 
AAA is asymptomatical, it presents as a pulsatile, periumbilical mass with 
or without a bruit and is detected typically during routine physical 
examination, by use of ultrasound, or with x-rays performed for other 
reasons. Symptomatic presentation of an AAA may include severe low 
back, abdominal, or flank pain. If this pain is unrelieved by changing 
positions, the aneurysm may be ruptured or leaking.11  
 
 
Endovascular Abdominal aortic aneurysm repair 
One of the major advancements of vascular surgery in the past 
decade has been the introduction of endovascular techniques for treating 
aortic aneurysms. The combination of specific skills from both vascular 
surgeons and interventional radiologists was a prerequisite for successful 
development of this technique. Another factor that contributed to the 
successful introduction of endovascular repair was the growing popularity 
of minimally invasive surgical techniques. Traditionally aneurysms were 
exclusively treated by open surgical repair. This operation involves 
exposure of the abdominal aorta, aortic, iliac artery clamping and 
replacement of the aneurysmal segment with a prosthetic graft. During the 
early nineties endovascular repair of abdominal aortic aneurysms (EVAR) 
has been introduced by Parodi and Volodos.12,13 This technique typically 
involves two small incisions in the groin to expose the femoral or iliac 
arteries. Laparotomy is avoided with this approach. With the use of guide 
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wires, catheters and specially designed introducer systems, an endograft is 
under radiological guidance delivered inside the AAA and it’s separate 
components assembled. The stent-graft is positioned properly proximally 
and distally of the aneurysmal segment of the aorta, to exclude the 
aneurysm sac from the circulation. Endovascular repair has several 
advantages over conventional surgery. It is a much less invasive technique 
than the traditional operation. This is of major importance for patients with 
coexistent diseases, who would be at high risk for conventional surgery. 
With endovascular treatment operative trauma, blood loss and disturbance 
of systemic hemodynamics and ventilation is minimal. Moreover, the 
hospital stay and the reconvalescence period have been reduced 
significantly, typically from ten to three days for hospital stay and from 
six weeks to eleven days for recovery time.14,15  
Two categories of criteria are important at the initial assessment of 
patients being considered for endovascular stent-graft repair of an AAA. 
The first category addresses patients' medical condition, life expectancy, 
and risk category for open repair of their aneurysm. The second category 
is the patients' anatomy which correlates with the level of complexity of 
the endovascular approach. Anatomical considerations that may exclude a 
patient from the endovascular treatment include the length, shape, and 
angulation of the infrarenal neck of the aorta, common iliac artery 
aneurysmal involvement or severe occlusive disease of the common iliac 
artery, occlusive disease or marked tortuosity of the iliofemoral access 
vessels, severe vessel angulation, or small diameter iliac vessels. Other 
aspects of patient selection for endovascular stent-graft repair are based on 
the surgeon's judgment.16 Many potential intraoperative complications 
may occur and these must be resolved for the surgery to be successful. The 
potential complications of endovascular repair of an AAA include 
endoleaks, trauma to arteries caused by the large catheters being 
introduced into the vessel, occlusion of the renal or hypogastric arteries as 
a result of incorrect endograft positioning, renal impairment from contrast 
induced nephropathy and infection. An endoleak is defined as   blood flow 
in the aneurysm sac, between the endovascular graft and the aortic wall. 
This condition does not indicate leakage into the abdominal cavity.17 
Endoleaks are the most frequent complication with the endovascular 
approach. Endoleaks are categorized as type I, II, III, IV or V. Type I 
endoleaks are defined as an inadequate seal between the stent-graft and the 
vessel wall at either the proximal or distal attachment points. Type II 
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endoleaks are caused by retrograde flow from the lumbar, hypogastric, or 
inferior mesenteric artery into the aortic sac. Type III endoleaks are caused 
by a tear in the fabric of the stent-graft, or by modular graft disconnection 
or disintegration. Type IV endoleaks result from a seeping of blood 
because of porosity of the graft fabric. Finally, endotension, which is 
usually defined as aneurysm enlargement in absence of identifiable 
perigraft flow, is listed as type V endoleak. Device related endoleaks (type 
I and III) are associated with an increased rupture rate, and need to be 
treated without delay. Reperfusion or branch endoleaks (type II) do not 
need urgent treatment, however they may not be harmless since they were 
frequently associated with aneurysm enlargement.18 
The repair of abdominal aortic aneurysms by endovascular 
technique has been demonstrated to be feasible in properly selected 
patients. Short-term benefits such as patient-friendliness, savings on 
hospital stay and perioperative complications are well documented. 
However, uncertainty remains with respect to eligibility criteria, long-term 
side-effects, durability of the endoprothesis, and the optimal method and 
frequency of follow-up.5 Risk factors associated with complications after 
endovascular repair can be patient, morphologic, or device related. The 
research questions that were addressed in this thesis can be summarised 
by: What is the influence of patient, device, anatomic, and surveillance 
related risk factors on outcome after EVAR? 
 
 
The EUROSTAR registry 
To answer our research question we used the EUROpean 
collaborators on Stent-graft Techniques for Abdominal aortic aneurysm 
Repair (EUROSTAR) registry, which was established in 1996. The 
objective of this voluntary multi-centre registry was collecting and 
analysing information on the results of endovascular treatment, from 
centres across Europe. Data were entered mostly prospectively on an 
intention to treat basis. Information from patients, operated before July 
1996 was retrieved retrospectively from hospital notes and outpatient 
records. 
Collected baseline data included information about co-morbidity, 
fitness for open surgery (classification according to the American Society 
 12
of Anaesthesiology, ASA), aneurysm anatomy and operative details. The 
information was recorded by the participating institutions on case record 
forms and submitted for inclusion to the continental European data 
registry center. Findings at follow-up visits, which involved clinical 
examination and principally computerised tomography (CT) assessment, 
were recorded on data forms and returned at regular intervals to the data 
registry centres for processing and analysis. After 2003 data entry was 
directly performed by the participating institutions on the website 
www.eurostar-online.org . There was no outside monitoring of the centres 
or involvement of a core laboratory for the evaluation of the CT-scanning 
or other imaging studies. Early complications included intraoperative 
device-related problems (including inability to advance the delivery 
system, to deploy the device, stent-graft migration, occlusion and 
stenosis), arterial injuries, and postoperatively systemic complications 
(including cardiac, pulmonary and renal function impairment) and 
neurological complications. Outcome reporting adhered to the guidelines 
from the ad hoc Committee for Standardised Reporting Practises in 
Vascular Surgery of the Society for Vascular Surgery / American 
Association for Vascular Surgery (SVS / AAVS).19 
 Different brands of stent-grafts have been developed during the 
years of the registry. Commercially available devices included in the 
EUROSTAR registry are the following: Anaconda (Sulzer Vascutek, 
Austin, TX, USA), AneuRx (Medtronic, Sunnyvale, CA, USA), 
Endologix (Endologix, Irvine, CA, USA), EVT/Ancure (Guidant 
Endovascular Technologies, Menlo park, CA, USA), Excluder (W.L. 
Gore, Flagstaff, AZ, USA), Fortron (Cordis, Waterloo, Belgium), Lifepath 
(Edwards, Irvine, CA, USA), Stentor (MinTec, La Ciotat, France), Talent 
(World Medical Manufacturing, Sunrise, FL, USA), Vanguard (Boston 
Scientific Corporation, Oakland, NJ USA), and Zenith (Cook, 
Indianapolis, OH, USA).  
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Purpose of this thesis 
Section 1 includes a general introduction to endovascular AAA 
repair.  
In Section 2 the first part of our research question will be addressed: 
What is the relationship between complications after endovascular aortic 
aneurysm repair (EVAR) and patient characteristics? In the three chapters 
constituting this section we discussed the influence of diabetes mellitus, 
advanced age, and preoperative statin use on outcomes after EVAR.  
Section 3 addresses the second risk factor, which involves the stent-
graft and this analysis addressed the following question: What is the 
influence of device-specific characteristics on outcomes after EVAR? We 
presented an overview of all stent-graft brands recorded in the 
EUROSTAR registry and their influence on registered complications. 
Secondly we looked specifically at the impact on results after EVAR of 
the first and third generation commercially available endografts.  
Section 4, addresses anatomic factors: How do characteristics of the 
aortoiliac morphology influence results after EVAR?  In addition we 
looked in detail at a number of aspects regarding the infra-renal neck, such 
as dilatation of this anatomic segment and the influence of the infra-renal 
neck length on outcome of EVAR. The infra-renal neck length was 
defined as the distance between the most distal renal artery and the 
aneurysm.  
Section 5 evaluates the final study question: What determines 
surveillance intensity after endovascular abdominal aortic aneurysm 
repair and what are the consequences of variations?  
Section 6 provides a general discussion, the implications of this 
study, future developments and how to assess these developments.  
Section 7 contains an overall summary of this thesis. 
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Chapter 2.1 
 
Influence of diabetes mellitus on the 
endovascular treatment of abdominal 
aortic aneurysms 
 
Lina J. Leurs, MSc; Robert J.F. Laheij, PhD; Jacob Buth, MD on behalf of 
the EUROSTAR Collaborators 
 
J Endovasc Ther 2005; 12(3); 288-296. 
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PURPOSE: To investigate the influence of diabetes mellitus on outcome 
after endovascular abdominal aortic aneurysm (AAA) repair.  
 
METHODS: Of 6017 patients enrolled in the EUROSTAR registry after 
undergoing endovascular AAA repair between May 1994 and December 
2003, 731 (12%) had diabetes mellitus (690 men; mean age 72 years, 
range 37–100). Patient demographics, risk factors, aneurysm morphology, 
operative and procedural details, complications, major events, and regular 
follow-up information were compared. The relationships of complications 
and events to diabetes mellitus, which were tested with multivariate 
logistic regression analysis and Cox proportional hazards modelling, are 
expressed as odds ratios (OR) and hazard rates (HR) with 95% confidence 
intervals (CI). Survival was compared with life-table analysis. 
 
RESULTS: A significantly higher risk of device-related complications 
was observed in diabetic patients (8% versus 6%, p<0.049; OR 1.35, 95% 
CI 1.00 to 1.82). The greatest difference in the groups was in mortality, 
which was significantly higher in the diabetic population (13%) compared 
to the nondiabetic patients (10%, p<0.039; OR 1.27, 95% CI 1.01 to 1.59). 
Deaths, which occurred at a higher frequency within the 30-day 
perioperative period in diabetic patients, were primary due to cardiac 
complications. Insulin-controlled type 2 diabetic patients had significantly 
lower rates of early and late endoleaks and secondary interventions than 
diet-controlled type 2 diabetics (p=0.002, p=0.0001, and p=0.0008, 
respectively) and nondiabetic patients (p=0.002, p=0.0005, and p=0.0025, 
respectively). The cumulative survival after 48 months did not differ 
significantly: 74% in diabetics and 79% in the population without 
diabetes. 
 
CONCLUSIONS: Patients with diabetes mellitus had a significantly 
higher early mortality rate after EVAR, but their long-term survival was 
similar to nondiabetic patients. 
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INTRODUCTION 
Endovascular aneurysm repair (EVAR) has become increasingly 
common for the treatment of abdominal aortic aneurysm (AAA). This 
minimally invasive approach is of particular benefit to patients with 
coexistent diseases who would be at high risk for conventional surgery.1,2 
Early and midterm success of endovascular AAA treatment has been 
documented extensively in a number of articles.3–6 Recently, the early 
benefits versus open surgery (lower 30-day morbidity/mortality and 
reduced hospital stay) were confirmed in two randomized clinical trials.7,8 
Diabetes mellitus has not been widely assessed as a comorbid 
factor that might impact the risk or outcome of EVAR. Diabetes is 
associated with accelerated rates of mortality, particularly from 
cardiovascular causes, and several chronic diseases, such as renal and 
peripheral occlusive diseases.9 These comorbidities may increase the risk 
of open aneurysm repair, so it may be advantageous for diabetic patients 
with AAA to undergo EVAR. In this report, we investigate if patients with 
diabetes mellitus had different EVAR outcome than nondiabetics. 
 
METHODS 
Study Design  
In July 1996, the EUROSTAR project was established with the 
objective of collecting and analyzing various aspects of endovascular 
AAA treatment. Data from patients operated before the start of the registry 
were retrieved retrospectively from hospital notes and patient records. 
Patient demographics, risk factors, aneurysm morphology, operative and 
procedural details, incidence of complications and major events (death, 
rupture, and conversion to open repair), and regular follow-up information 
were collected on standardized EUROSTAR Case Record Forms. The 
American Society of Anaesthesiologists (ASA) risk classification and the 
Society for Vascular Surgery (SVS) risk score10 were used to represent the 
patient risk profile. In the latter, risk scores of 1 and 2 indicated diet-
controlled (oral hypoglycaemic agent) or insulin-controlled type 2 
diabetes, respectively; type 1 diabetes was indicated by a risk score of 3. 
Intraoperative complications encompassed device-related sequelae, 
procedural failure, and arterial complications. Postoperative (in-hospital) 
complications were grouped into systemic, procedure- and device-related, 
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and access site/lower limb. Endoleaks discovered at the completion 
angiogram were also included in the 30-day complication assessment. Late 
complications included endoleaks, kinking, thrombosis, and migration 
occurring after 30 days. Follow-up examinations were performed at 1, 3, 
6, 12, 18, and 24 months and yearly thereafter.15 
 
Patient Population 
Between May 1994 and December 2003, 6017 patients underwent 
endovascular AAA repair in 163 European centers (Appendix). Of these, 
731 patients (690 men; mean age 72 years, range 37–100) had diabetes 
mellitus: 21 patients with type 1, 505 with diet-controlled type 2, and 205 
with insulin-controlled type 2.  
 
Data Analysis 
Data were recorded on a computerized database. Odds ratios (OR) 
with 95% confidence intervals (CI) were calculated for time-independent 
variables with multivariate logistic regression analysis, while hazard rates 
(HR) were calculated using the Cox proportional hazards model for time-
dependent characteristics. Both tests were used to test associations 
between complications and diabetes. The models were adjusted for patient 
age, sex, ASA classification, SVS risk factors, obesity, and unfitness for 
traditional open surgery or general anaesthesia. In the Cox proportional 
hazard model for follow-up events, the immediate failures, patients lost to 
follow-up, and event-free observations were censored. Analyses were first 
performed for diabetic versus nondiabetic patients, and then the type 2 
diabetic population was categorized as diet-controlled (oral 
hypoglycaemic agent) versus insulin-controlled patients. Life-table 
analyses and Kaplan-Meier survival estimates were used to analyze 
survival. Statistical significance was set at p<0.05. Data analyses were 
performed with SAS statistical software (version 8.0; SAS Institutes, Cary, 
NC, USA). 
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RESULTS 
The diabetic population had significantly higher proportions of 
several risk factors (Table 1), including hypertension (76% versus 61%), 
hyperlipemia (25% versus 15%), impaired cardiac function (41% versus 
30%), carotid disease (11% versus 5%), renal disease (33% versus 17%), 
poor pulmonary status (25% versus 18%), and obesity (39% versus 24%). 
Owing to the greater preponderance of ASA class 3 risk (p<0.0001), 
diabetic patients were considered significantly more unfit for open surgery 
and general anaesthesia (p<0.0001). 
 
Table 1: Patient demographics 
 
Diabetic 
n=731 
Nondiabetics 
n=5286 
Men 690 (94.39%) 4933 (93.32%) 
Mean age, y (range) 71.9 (37 – 100) 71.7 (28 – 100)  
Age > 70 y 451 (61.70%) 3213 (60.82%) 
ASA ≥ 3* 493 (67.44%) 2640 (49.94%) 
SVS-ISCVS   
     Smoking 196 (26.81%) 1286 (24.33%) 
     Hypertension* 555 (75.92%) 3208 (60.69%) 
     Hyperlipemia* 183 (25.03%) 814 (15.40%) 
     Cardiac status* 299 (40.90%) 1560 (29.51%) 
     Carotid disease* 79 (10.81%) 268 (5.07%) 
     Renal status* 238 (32.56%) 889 (16.82%) 
     Pulmonary status* 183 (25.03%) 976 (18.46%) 
Indication for EVAR   
    Previous laparotomy* 243 (33.24%) 1414 (26.79%) 
     Obesity* 286 (39.12%) 1240 (23.50%) 
     Unfit for open procedure* 222 (30.37%) 1111 (21.07%) 
     Unfit for general anaesthesia* 100 (13.74%) 360 (6.83%) 
Max AAA diameter > 60 mm 224 (31.33%) 1488 (28.81%) 
ASA: American Society on Anesthesiologists, SVS: Society for Vascular Surgery 
* Significant difference between the diabetic and nondiabetic patients (p<0.0001)
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Table 2: Early (30-day) complications 
 
Diabetic 
Patients 
n=731 
Nondiabetic 
Patients 
n=5286 
Adjusted 
Odds 
Ratio 
95% CI 
Intraoperative     
     Device-related* 58 (7.96%) 338 (6.41%) 1.35 1.00-1.82 
     Failed procedure 17 (2.33%) 90 (1.71%) 1.37 0.79-2.35 
     Arterial 36 (4.94%) 201 (3.81%) 1.27 0.87-1.85 
     Thrombus/emboli 2 (0.38%) 36 (0.68%) 0.62 0.19-2.08 
     Occluded renal artery* 8 (1.10%) 16 (0.30%) 3.21 1.31-7.84 
In-Hospital     
     Systemic 91 (12.48%) 681 (12.92%) 0.85 0.67-1.084 
     Procedure/device-related 26 (3.57%) 138 (2.62%) 1.46 0.94-2.26 
     Access/lower limb 62 (8.50%) 378 (7.17%) 1.19 0.88-1.59 
Endoleak 105 (14.36%) 864 (16.35%) 0.87 0.70-1.10 
     Type I (Proximal) 22 (3.01%) 160 (3.03%) 0.91 0.57-1.46 
     Type I (Distal) 15 (2.05%) 125 (2.36%) 0.88 0.51-1.53 
     Type II 51 (6.97%) 466 (8.82%) 0.86 0.63-1.17 
     Type III 12 (1.64%) 125 (2.36%) 0.66 0.36-1.22 
Early death* 29 (4.37%) 102 (2.11%) 1.67 1.71-2.61 
Early conversion 13 (1.81%) 62 (1.20%) 1.57 0.84-2.95 
Early rupture 0 1 (0.02%) - - 
Adjusted for patient age, gender, ASA classification, SVS/ISCVS risk factors, obesity, and unfitness 
for traditional open surgery or general anaesthesia. 
CI: confidence interval 
* Significant difference between the diabetic and non-diabetic patients (p<0.05) 
 
Device-related complications appeared significantly more often in 
diabetic patients (8% versus 6%, p<0.049) than in nondiabetics (OR 1.35, 
95% CI 1.00 to 1.82) (Table 2). Arterial complications, in particular, 
occlusion of the renal artery, occurred more frequently in patients with 
diabetes (1.1% versus 0.3%, p<0.010; OR 3.21, 95% CI 1.31 to 7.84). The 
30-day mortality rate in the diabetic group (4%) was significantly higher 
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than in the nondiabetic patients (2%, p<0.024; OR 1.67, 95% CI 1.07 to 
2.61). There was no difference in early conversion or rupture rates. The 
higher mortality in the diabetic population was caused predominantly by 
cardiac complications (Table 3). Additional analyses of type 2 diabetics 
(Table 4) demonstrated a significantly lower proportion of early endoleaks 
in insulin-controlled (8%) compared to diet-controlled patients (17%, 
p<0.0023) and the nondiabetic (16%, p<0.0021) cohort.  
 
Table 3: Cause of early mortality 
 
 
Diabetic Patients 
n=731 
Nondiabetic Patients 
n=5286 
Cardiac 14 (48.28%) 29 (28.43%) 
Pulmonary 5 (17.24%) 12 (11.76%) 
Renal 1 (3.45%) 2 (1.96%) 
Multi Organ Failure 1 (3.45%) 18 (17.65%) 
Sepsis 2 (6.90%) 13 (12.75%) 
Other/Unknown 6 (20.69%) 26 (25.49%) 
  
Over a mean follow-up of 19.36±18.88 months (range 0–96), 59 
patients were lost to follow-up (51 [1.0%] nondiabetics and 8 [1.1%] in 
the diabetic subgroup). Follow-up was complete in 70% of the population 
(Table 5). Different types of endoleaks occurred in similar proportions in 
diabetic and nondiabetic patients, as did kinking, stenosis, thrombosis, and 
migration. Late death occurred at comparable rates (both 9%). However, 
overall mortality was significantly higher in the diabetic population (13%) 
compared to the nondiabetic patients (10%, p<0.039; OR 1.27, 95% CI 
1.01 to 1.59). No differences were found between the groups in late 
conversion or rupture rates. The cumulative survival rates after 48 months 
did not differ significantly: 74% in diabetics and 79% in the population 
without diabetes (Figure). 
Further analysis of type 2 diabetic patients (Table 6) revealed that 
insulin-controlled patients had significantly fewer endoleaks (8% versus 
20% [p=0.0001] and 18% [p=0.0005]) and secondary interventions (4% 
versus 12% [p=0.0008] and 11% [p=0.0025]) compared to diet-controlled 
and nondiabetic patients, respectively. 
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Table 4: Early complications: diet vs. Insulin-controlled type 2 diabetics 
 
Diet-Controlled 
n=505 
Insulin-
Controlled 
n=205 
Adjusted 
Odds 
Ratio 
95% CI 
Intraoperative     
     Device-related 46 (9.13%)* 11 (5.39%) 0.57 0.29-1.12 
     Failed procedure 12 (2.38%) 4 (1.96%) 0.82 0.26-2.57 
     Arterial 23 (4.56%) 11 (5.39%) 1.19 0.57-2.49 
     Thrombus/emboli 2 (0.40%) 1 (0.49%)   
     Occluded renal artery 6 (1.19%)* 2 (0.98%) 0.82 0.16-4.11 
In-Hospital     
     Systemic 60 (11.90%) 30 (14.71%) 1.28 0.80-2.05 
     Procedure/device-
related 21 (4.17%)
* 5 (2.45%) 0.58 0.21-1.55 
     Access/lower limb 41 (8.13%) 19 (9.31%) 1.16 0.66-2.05 
Endoleak† 87 (17.23%)   17 (8.29%)‡ 0.43 0.25-0.75 
     Type I (Proximal)† 20 (3.96%) 1 (0.49%)‡ 0.12 0.02-0.89 
     Type I (Distal) 14 (2.77%) 1 (0.49%) 0.17 0.02-1.31 
     Type II  40 (7.92%) 10 (4.88%) 0.60 0.29-1.21 
     Type III 10 (1.98%) 2 (0.98%) 0.49 0.11-2.25 
Early death 22 (4.36%) 7 (3.41%) 0.78 0.33-1.85 
Adjusted for patient age, gender, ASA classification, SVS/ISCVS risk factors, obesity, and unfitness 
for traditional open surgery or general anaesthesia. 
CI: confidence interval 
*significant difference between the diet and insulin controlled diabetic patients 
† Significant difference between the insulin controlled diabetic patients and the non-diabetic 
patients 
‡ Significant difference between the diet controlled diabetic patients and the non-diabetic patients 
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Table 5: Late complications 
Major complication Diabetic Nondiabetic Adjusted 95% CI 
Endoleak 119 (16.28%) 953 (18.03%) 1.05 0.87-1.28 
     Type I (Proximal) 20 (2.74%) 157 (2.97%) 1.03 0.64-1.67 
     Type I (Distal) 27 (3.69%) 218 (4.12%) 1.09 0.72-1.63 
     Type II 67 (9.17%) 563 (10.65%) 0.96 0.74-1.25 
     Type III 28 (3.83%)  227 (4.29%) 1.19 0.80-1.78 
Kinking stent-graft 13 (1.91%) 183 (3.46%) 0.81 0.47-1.41 
Stenosis/thrombosis 38 (5.20%) 281 (5.32%) 1.08 0.76-1.53 
Graft migration 24 (3.28%) 275 (5.20%) 0.87 0.57-1.33 
Secundary intervention 71 (9.71%) 586 (11.09%) 1.07 0.83-1.38 
Late death 67 (9.16%) 452 (8.55%)  1.15 0.88-1.50 
Late conversion 11 (1.50%) 118 (2.23%) 1.02 0.54-1.91 
Late rupture 2 (0.27%) 43 (0.81%) 0.44 0.10-1.84 
Adjusted for patient age, gender, ASA classification, SVS/ISCVS risk factors, obesity, unfitness for 
traditional open surgery or general anaesthesia.  
CI: confidence interval 
 
Table 6: Late complications: diet vs. Insulin-controlled type 2 diabetes 
Major complication Diet-Controlled Insulin-Controlled Adjusted 95% CI 
Endoleak* 99 (19.60%) 16 (7.8%)† 0.35 0.20-0.61 
     Type I (Proximal) 14 (2.77%) 4 (1.95%) 0.71 0.23-2.21 
     Type I (Distal) 23 (4.55%) 3 (1.46%) 0.32 0.09-1.07 
     Type II* 55 (10.89%) 10 (4.88%)† 0.43 0.21-0.86 
      Type III 23 (4.55%)  5 (2.44%) 0.54 0.20-1.43 
Kinking stent-graft 12 (2.38%) 1 (0.49%) 0.21 0.03-1.60 
Stenosis / Thrombosis 27 (5.35%) 11 (5.37%) 1.03 0.50-2.13 
Graft migration 21 (4.16%) 3 (1.46%)†  0.35 0.10-1.19 
Secundary intervention* 62 (12.28%) 8 (3.9%)† 0.29 0.14-0.63 
Late death 46 (9.11%) 20 (9.76%) 1.08 0.62-1.87 
Late conversion 10 (1.98%) 1 (0.49%) 0.24 0.03-1.91 
Late rupture 1 (0.20%) 1 (0.49%) 2.47 0.15-39.69 
Adjusted for patient age, gender, ASA classification, SVS/ISCVS risk factors, obesity, and unfitness 
for traditional open surgery or general anaesthesia. 
CI: confidence interval 
* Significant difference between the diet and insulin controlled diabetic patients (p<0.015) 
 † Significant difference between the insulin controlled diabetic patients and the non-diabetic 
patients (p<0.025) 
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Figure: Life-table analysis of survival for diabetic versus nondiabetic evar 
patients 
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     Diabetics 731 708 597 558 500 379 278 213 119 
     Nondiabetics 5286 5191 4602 4324 3923 3148 2452 1981 1298 
 
DISCUSSION 
Diabetes mellitus is part of a complex of risk factors for 
cardiovascular disease that features glucose intolerance, insulin resistance, 
hyperinsulinemia, increased very-low-density lipoproteins and 
triglycerides, decreased high-density lipoproteins, and hypertension. 
Diabetes has a considerable influence on the vascular condition of 
patients. Indeed, in our series, a greater proportion of the diabetic 
population was considered unfit for open surgery. They suffered more 
Nondiabetics 
Diabetics 
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often from hypertension, hyperlipemia, and impaired cardiac and renal 
function than the nondiabetic study group. 
However, limited information is available with regard to the effect 
of diabetes on EVAR. Rayan et al.11 investigated diabetes as a risk factor 
for patients undergoing open AAA repair who enrolled in the Vascular 
Surgery Registry. Proportionally higher postoperative mortality was 
noticed in the diabetic population. However, long-term cumulative 
survival was identical for diabetic versus nondiabetic patients, which we 
found when analyzing the correlation between diabetes and endovascular 
AAA repair. 
In our investigation of the relationship between diabetes and 
EVAR, patients with diabetes more often experienced device-related 
complications and arterial sequelae, such as occlusion of the renal artery. 
The most striking finding was the significantly higher 30-day mortality 
rate (4%) in the diabetic group, which was caused primarily by cardiac 
insufficiency. However, this higher early mortality rate was still in the 0% 
to 7% range reported by other recent studies analyzing EVAR.1,5,12–14 de 
Virgilio et al.15 compared cardiac morbidity and mortality between 
conventional and endovascular AAA repair, but in their study, diabetes 
was not a predictive criterion for an adverse cardiac event (p=0.07). 
In type 2 diabetes, insulin treatment is used when diet, exercise, 
and oral agents are unable to establish adequate glycemic control. The 
United Kingdom Prospective Diabetes Study showed that improved 
glycemic condition in type 2 diabetes reduced vascular and all diabetes-
related complications.16,17 Some authors have demonstrated a relationship 
between the duration of diabetes and the incidence of vascular 
complications, although the issue is disputed by several other 
investigators.18–25 Type 2 diabetes mellitus was frequently missed at 
diagnosis because hyperglycemia frequently was not severe enough to 
provoke characteristic symptoms of diabetes. Nevertheless, in this stage, 
patients are at increased risk of developing macrovascular and 
microvascular complications.26,27 The fact that elevated blood glucose 
levels may have been present for several months or even years before the 
diagnosis of type 2 diabetes is made complicates the analyses. Hence, the 
actual duration of type 2 diabetes cannot easily be estimated. 
Compared to diet-controlled (oral hypoglycaemic) or nondiabetic 
patients in our study, insulin-controlled type 2 diabetics had a significantly 
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lower rate of endoleaks, which resulted in fewer secondary interventions. 
The lower incidence of endoleak in this patient group may be explained by 
the impact of diabetes on blood vessels. Diabetes affects the endothelial 
lining of arteries, causing them to become clogged with plaque, so the 
aortic side branches, including the lumbar, inferior mesenteric, internal 
iliac, and renal arteries, become less elastic and more occlusive. In 
addition, medication to help keep the blood glucose levels within a safe 
range or to control diabetes-related complications, such as high blood 
pressure or nephropathy (e.g., angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers), may influence the arterial condition and 
endoleak development.9,28 
Riambeau et al.29 analyzed the association between comorbidity 
and mortality after EVAR in patients considered unfit for open surgery. 
The survival curves in patients with poor medical condition were 
significantly worse than in those with a good medical status. However, the 
presence of co-existing diseases in patients unfit for open surgery did not 
affect the mortality rate. In our study population, the survival curves of 
diabetic and nondiabetic patients demonstrated similar cumulative survival 
after 4 years. 
EUROSTAR, like any voluntary registry, has its advantages and 
disadvantages. The main advantages are the ability to gather a large 
amount of data on a diverse patient population in a relatively short period 
of time, address upcoming questions, evaluate long-term effectiveness, 
and include new devices or improvements. Disadvantages are a large 
interobserver variation, and less accurate and complete data. Nevertheless, 
a registry population normally is a good reflection of common day clinical 
practice. 
 
CONCLUSIONS 
Patients with diabetes had a significantly higher 30-day mortality 
rate then patients without diabetes. After a lower initial success rate, long-
term survival was similar in both study groups. More assessment is needed 
to evaluate the effect of diabetes on EVAR outcome. 
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PURPOSE: To investigate the early and late outcome after endovascular 
treatment of abdominal aortic aneurysm (EVAR) in octogenarians 
compared with patients aged <80 years. 
 
METHODS: Patients treated for abdominal aortic aneurysm (AAA) with 
endovascular repair during the period 1996 to 2004 were collated in the 
EUROSTAR registry. This study group consisted of 697 patients aged ≥80 
years. Comparison was made with 4198 patients aged <80 years with 
regard to the incidence of preoperative characteristics and outcomes of the 
procedure. 
 
RESULTS: The proportion of octogenarians treated by EVAR increased 
during the study period, from 11% in the first year to 18% in the last year. 
Octogenarians more frequently had cardiac disease, impaired renal 
function, and pulmonary disease (P = .03, P < .0001 and P = .0001). 
Thirty-two percent of the octogenarians were recorded unfit for open 
surgery as opposed to 22% in younger patients (P < .0001); they also had a 
larger aneurysm diameter (62 vs 58 mm, respectively; P < .0001). The 30-
day and in-hospital mortality in octogenarians was 5% vs 2% in the 
younger group (P < .0001). More device-related complications and 
systemic complications, including cardiac disease, were noted in 
octogenarians (7% vs 5% and 19% vs 11%, P = .03 and P < .0001, 
respectively). This group of patients also had a higher incidence of 
postoperative hemorrhagic complications, including hematoma (7% vs 
3%, P < .0001, respectively). No differences in conversion to open repair 
and post-EVAR rupture rate were observed. Aneurysm-related mortality 
and late all-cause mortality was 7% vs 3% and 10% vs 7%, both P < 
.0001. 
 
CONCLUSION: Our study supports that EVAR might be considered 
when treating elderly patients, provided their aneurysms are anatomically 
suited for the endovascular technique. The risk for late complications 
compared with open repair may be outweighed by a lower early mortality 
as well as a shorter time for physical recovery. 
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INTRODUCTION 
Abdominal aortic aneurysm (AAA) is an age-related disease 
accounting for 1% to 2% of all deaths.1 The overall life expectancy of the 
population is increasing, and projections are that more elderly patients will 
present for AAA repair in the future. Elective operation is the most 
important measure to prevent rupture and death, but the risk of an open 
operation is considerable in octogenarians. Even in selected subcohorts, 
operative mortality rates of 5% to 10% were observed.2-8 Open repair in 
patients aged >80 years is often not even considered because of 
comorbidities or their advanced age in itself. 
Endovascular abdominal aortic aneurysm repair (EVAR) has 
emerged as an appealing alternative in patients with, on the one hand, an 
AAA with a high risk of rupture and, on the other hand, a reasonable life 
expectancy. So far, the results of EVAR for single institutions have 
included only a limited number of patients aged >80 years.9-15 Our 
objective was to study early and late outcome following treatment of AAA 
by EVAR in octogenarians compared with patients aged <80. 
 
METHODS 
Patients were recruited from 153 European institutions (Appendix). 
Only commercially available Communauté Europeénne (CE) approved 
stent-grafts were applied. Two categories were distinguished: patients 
aged >80 years and patients <80 years. There were no differences in 
device distribution between the two groups. 
Baseline data included information about patient comorbidity, 
fitness for open surgery, American Society of Anaesthesiologists (ASA) 
classification, and aneurysm anatomy. Operative aspects were assessed. 
The information was recorded by the participating institutions on case 
record forms and submitted to the EUROSTAR Data Register Center. 
Since 2001, most of the data submission has been performed by the 
EUROSTAR website, www.eurostar-online.org (design and maintenance 
by KIKA-medical, Nancy, France). 
Patients were enrolled in the EUROSTAR registry on an intention-
to-treat manner. Inclusion criteria, as defined in the EUROSTAR protocol, 
comprised elective treatment for AAA and a vascular anatomy suitable for 
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the implantation of a stent-graft. Follow-up investigation included a 
clinical examination, contrast enhanced computed tomography (CT) of the 
abdomen, and in a minority of cases (<4%), angiography or magnetic 
resonance imaging. There was no outside monitoring of the data and no 
involvement of a core laboratory for evaluation of CT scans or other 
imaging investigations. 
Preoperative risk assessment consisted of ASA class, ankle-
brachial index, Society of Vascular Surgery SVS/International Society for 
Vascular Specialists risk scores, previous laparotomy, obesity, estimate of 
fitness for open AAA repair and general anaesthesia,16 method of 
preoperative examination, iliac artery patency by angiography, anatomic 
aortic diameter and length measurements, arterial angulation, and AAA 
classification (degree of iliac involvement).17 Arterial diameters were 
measured from adventitia to adventitia. The diameter of the aneurysm was 
measured as its largest section between the outer walls on the axial CT 
slices. Angulations were considered significant when at least 60°. 
Procedural details, including date of operation, device make, type of 
anaesthesia, device configureuration, procedural duration, and endoleaks 
at the completion angiography were recorded. 
Early complications included intraoperative device-related 
problems, inability to advance the delivery system, inability to deploy the 
device, stent-graft migration, occlusion, stenosis, or arterial injuries. 
Postoperative systemic complications, including cardiac, pulmonary, and 
renal function impairment, were recorded. Primary technical success was 
defined as complete exclusion of the aneurysm. Patients were followed up 
at 1, 6, 12, 18, 24 months, and annually thereafter. Satisfactory finding at 
CT was defined by absence of endoleak, stent-graft migration, kinking, 
stenosis, thrombosis, and aneurysm expansion. Outcome reporting was 
performed according to the guidelines from the ad hoc committee for 
standardized reporting practices in vascular surgery of the Society for 
Vascular Surgery/American Association for Vascular Surgery.18 Other 
outcome events observed during follow-up included endoleak, graft 
migration, device disintegration, and continuing aneurysm expansion. 
Data were presented as means and ranges. Missing data were 
indicated as such in the tables. Deaths occurring ≤30 days of the initial 
procedure were categorized as operative deaths; and deaths occurring >30 
days were categorized as late deaths. Aneurysm-related deaths included 
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30-day deaths and deaths that occurred as a result of aneurysm rupture, 
endograft infection, or death ≤1 month after a secondary surgical 
procedure for late complications of the aneurysm.  
Preoperative patient characteristics, comorbidity, risk factors, 
aneurysmal morphology at the time of the initial procedure, and details 
regarding the procedure and devices were correlated with the defined 
study groups by univariate analysis. Differences in findings between the 
two groups were assessed univariate by χ2 test for discrete variables and 
by t test or Wilcoxon rank sum test, depending on distribution, for 
continuous variables. Multivariate regression analysis was used to correct 
for other risk factors. Outcomes during follow-up were assessed univariate 
by life-table analysis. Significant differences between study groups were 
assessed by log-rank testing. Multivariate analysis of time-dependent 
variables was assessed by the Cox proportional hazard model. P < .05 was 
considered to represent a significant difference. All statistical analyses 
were performed with SAS statistical software (v 8.0) (SAS Institute, 
Carey, NC). 
 
RESULTS 
During the period 1996 to 2004, 697 patients aged ≥80 years were 
treated by EVAR for AAA, and their operative and follow-up data were 
reported to the EUROSTAR register. This age group represents 14% of all 
patients in the register (Table 1). The annual number of enrolled 
octogenarians increased during the study period (P < .0001); 68 were 
women (9.8%) (Table 2), and the mean age was 83 years (range, 80 to 
100). In patients <80 years, the mean age was 70 years (range, 46 to 79). 
The mean age distribution in male and female gender (83 years) was 
similar in the octogenarians. In the younger patient group, the women 
were significantly older than the men (72 vs 70 years, P < .0001). A total 
of 4191 patients aged <80 years were used for controls. 
As expected, risk factors were different in octogenarians compared 
with younger patients (Table 2). Cardiac and pulmonary function was 
more frequently impaired. Smoking, hyperlipidemia, and obesity were less 
frequent, and more often an ankle-brachial index <0.87 was reported in 
patients >80. The unfavourable risk profile in octogenarians was reflected 
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by a higher proportion of ASA classification ≥3 (P < .0001), and 32% of 
the octogenarians were regarded unfit for open surgery (P < .0001). 
 
Table 1: Year of operation in octogenarians and patients less than 80 years 
treated by evar. 
Year of  peration Patients < 80 years Octogenarians  
 N Column % Row % N Column % Row % Row total 
≤1997 132 3.15% 89.19% 16 (2.29%) (10.81%) 148 
1998 338 8.06% 89.51% 30 (4.30%) (10.49%) 368 
1999 586 13.98% 91.85% 71 (10.19%) (8.15%) 657 
2000 728 17.37% 87.20% 107 (15.35%) (12.8%) 835 
2001 801 19.11% 86.41% 126 (18.08%) (13.59%) 927 
2002 800 19.09% 82.48% 170 (24.39%) (17.52%) 970 
≥2003 806 19.22% 81.99% 177 (25.39%) (18.01%) 983 
Column total 4191   697   4433 
The number of octogenarians treated by EVAR increased during the study period (p<.0001).  
 
Table 2: Patient demographic data, risk factors and cormorbidity. 
Patient characteristics Patients < 80 years 
(N=4191 – 85.7%) 
Octogenarians 
(N=697 – 14.3%) 
P-value 
Age at operation ± SD (range) 70.3 ± 6.5 (43-79) 83.4 ± 2.9 (80-100) <.0001 
Female gender  217 (5.2%) 68 (9.8%) <.0001 
Ankle-brachial index < 0.87 2388 (57.0%) 442 (63.4%) .0014 
ASA-class ≥3 1992 (47.5%) 411 (59.0%) <.0001 
Smoking 1057 (25.2%) 109 (15.6%) <.0001 
Hyperlipemia 1858 (44.3%) 230 (33.0%) <.0001 
Impaired cardiac status 2454 (58.6%) 439 (63.0%) .0276 
Impaired renal function 736 (17.6 %) 167 (24.0%) <.0001 
Impaired pulmonary function 1716 (40.9%) 340 (48.8%) .0001 
Previous laparotomy 1087 (26.0%) 212 (30.%) .0144 
Obesity  1131 (27.1%) 149 (21.44%) .0018 
Unfit for open surgery 914 (21.9%) 222 (32.0%) <.0001 
Unfit for general anaesthesia 322 (7.7%)   75 (10.9%) .0055 
ASA: American Society of Anaesthesiologists 
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Octogenarians had a slightly wider diameter of the aneurysmal neck, as 
well as maximum aneurysm diameter; maximum aneurysm diameter: 62 
mm compared with 58 mm in younger patients (Table 3). Aneurysmatic 
degeneration of the right or left common/external iliac artery and also 
angulation of the neck and the right and left iliac artery occurred more 
frequently in octogenarians. This is also reflected by a more frequent 
morphologic classification D and E, which refer to aneurysm involvement 
of the iliac arteries. 
 
Table 3: Anatomic details 
Aneurysm measurements Patients < 80 years 
(N=4191) 
Octogenarians 
(N=697) 
P-value 
Neck diameter 
mean ± SD (range)  
23.8 ± 3.1 (9-40) 24.1 ± 3.2 (12-38) .014 
Maximal aneurysmal diameter ± 
SD (range) 
57.6 ± 10.4 (40-145) 62.0 ± 12.2 (40-122) <.0001 
Aneurysm in R or L comm. or ext. 
iliac 
432 (10.3%) 95 (13.6%) .0088 
AAA-class D*, E* 578 (13.8%) 116 (16.6%) .0458 
Neck angulation 908 (21.7%) 207 (29.7%) <.0001 
R iliac angulation 1295 (30.9%) 266 (38.2%) .0001 
L iliac angulation 1485 (35.4%) 327 (46.9%) <.0001 
Blocking one internal iliac artery 563 (20.1%) 103 (24.6%) .0337 
* Reflects progressively aneurysmatic degeneration of the common iliac arteries 
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Table 4: Procedural details, anaesthesia and stay in hospital 
Procedure demographics 
 
Patients < 80 
years 
(N=4191) 
Octogenarians 
(N=697) 
P-value 
Aorto-uni-iliac device 212 (5.1%) 54 (7.8%) .0038 
Duration of procedure (min) mean ± 
SD (range) 
128.9 +/- 55.9 
(25-660) 
140.0 +/- 59.0 
(30-450) 
<.0001 
General anaesthesia 2947 (70.3%) 485 (69.6%) NS 
Regional “ 1012 (24.2%) 180 (25.8%) “ 
Local  “ 232 (5.5%) 32 (4.6%) “ 
Replaced blood volume (ml) mean ± 
SD (range) 
522.5 +/- 640.4 
(2-6000) 
726.0 +/- 833.2 
(40-5000) 
.0039 
Days until discharge  
mean ± SD (range) 
5.5 +/- 7.5 
(0-165) 
7.3 +/- 9.9 
(0-108) 
<.0001 
Follow-up (months)  
mean ± SD (range) 
18.9 +/- 18.6 
(0-84) 
14.3 +/- 13.7 
(0-72) 
<.0001 
 
A number of distinct differences with regard to the procedure and 
early outcome were observed in the group of octogenarians. An aorto-uni-
iliac device was used more often, 8 vs 5%, respectively; and the duration 
of the procedure as well as blood volume replacement were also higher in 
elderly patients (Table 4). Moreover, octogenarians had a longer stay in 
hospital, 7 vs. 5.5 days, respectively. No differences in the type of 
anaesthesia administrated in the two groups were observed. 
 
 41
Table 5: Early outcome 
Early complications Patients 
< 80 years 
(N=4191) (%) 
Octogenarians 
(N=697) 
(%) 
P-
value 
Adjusted 
p-value* 
OR 95% CI 
Type I - Proximal 
endoleak 
106 (2.5%) 28 (4.0%) .0259 NS .67 .43-1.04 
Device related 
complications 
200 (4.8%) 48 (6.9%) .0185 .05 .71 .50-1.00 
Inability to deploy 
stent 
15 (0.4%) 8 (1.2%) .0048 NS .43 .16-1.15 
Arterial complications 138 (3.3%) 39 (5.6%) .0026 0.026 .65 .44-.95 
Systemic complications 452 (10.8%) 135 (19.4%) <.0001 <.0001 .57 .45-.71 
     Cardiac 115 (2.8%) 52 (7.5%) <.0001 <.0001 .40 .27-.57 
     Cerebral 28 (0.7%) 10 (1.4%) .0329 NS .56 .26-1.19 
     Pulmonary 70 (1.7%) 31 (4.5%) <.0001 .0004 .50 .31-.81 
     Renal 77 (1.8%) 24 (3.5%) .0058 .019 .55 .34-.91 
Access site & lower 
limb complications 
240 (5.7%) 74 (10.6%) <.0001 <.0001 .56 .41-.75 
Bleeding,         
haematoma,... 
132 (3.2%) 50 (7.2%) <.0001 .0002 .45 .35-.72 
Arterial thrombosis 17 (0.4%) 7 (1.0%) .0363 .0217 .33 .13-.85 
Early death 89 (2.1%) 38 (5.5%) <.0001 .0007 .48 .31-.73 
Early conversion 40 (1.0%) 11 (1.6%) NS NS .58 .29-1.18 
Early rupture 1 (0.02%) - NS NS - - 
*Adjusted for gender, ASA-class, SVS-ISCVS risk scores, unfitness for open surgery, general 
anaesthesia and aneurysm size. The adjusted p-value calculated by multivariate regression analysis.  
 
The perioperative mortality of octogenarians was 5% compared 
with 2% in the younger group (Table 5). The perioperative all-cause 
complication rate was also higher in octogenarians; this included 
endoleaks and several other device- related and systemic complications. 
No significant difference was observed in the early conversion rate 
between the two groups (1% and 1.6%, respectively). Even after 
adjustment for other risk factors in the multivariate analysis, octogenarians 
were independently associated with more arterial, systemic, access site, 
lower-limb complications, and 30-day mortality rate (Table 5). 
 
 42
Table 6: Outcome during follow-up 
Late 
complications 
Patients 
< 80 years 
(N=4191) 
Octogenarians 
(N=697) 
P-value* Adjusted 
P-value† 
HR 95% CI 
Overall mortality 392 (9.4%) 109 (15.9%) <.0001 <.0001 1.65 1.32-2.06 
Late mortality 303 (7.2%) 71 (10.2%) <.0001 .0021 1.53 1.17-2.01 
AAA-related death 117 (2.8%) 49 (7.0%) <.0001 <.0001 2.15 1.52-3.05 
Overall conversion 95 (2.3%) 18 (2.6%) NS NS 1.35 .81-2.27 
Late conversion 55 (1.3%) 9 (1.0%) NS NS 1.03 .46-2.29 
Overall rupture 19 (0.5%) 3 (0.4%) NS NS 1.18 .34-4.06 
Late rupture 18 (0.4%) 3 (0.4%) NS NS 1.25 .36-4.34 
 N=4079‡ N=655‡     
Endoleaks 677 (16.2%) 148 (21.2%) <.0001 <.0001 1.46 1.21-1.76 
Type I - 
proximal 
97 (2.4%) 21 (3.2%) NS NS 1.29 .79-2.12 
Type I - distal 72 (1.8%) 17 (2.6%) NS NS 1.65 .94-2.89 
Type II 140 (3.4%) 33 (5.0%) .0044 .0059 1.87 1.20-2.91 
Type III 483 (11.8%) 97 (14.8%) .0030 .0056 1.40 1.10-1.76 
Aneurysm growth 
≥ 8mm 
253 (6.7%)$ 46 (7.6%)$ .0020 NS 1.26 .92-1.73 
*Calculated by Log-rank analysis 
†Adjusted for follow-up time, gender, ASA-class, SVS-ISCVS risk scores, unfitness for open 
surgery, general anaesthesia and aneurysm size. The adjusted p-value calculated by the Cox 
proportional hazard model.  
‡ Patients who had no follow-up visits (who suffered an early death, conversion or rupture), were 
excluded.   
$ N=3797 / N= 604 
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Figure 1. Kaplan-meier graph represents cumulative freedom from any 
endoleak in patients operated for abdominal aortic aneurysm with 
endovascular aneurysm repair 
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Figure 2. Kaplan-meier graph represents long-term survival after 
endovascular repair of abdominal aortic aneurysm in octogenarians and 
patients aged <80 years 
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The mean follow-up period was 14 months in octogenarians 
compared with 19 months in younger patients. The completeness of 
follow-up data was 85%. During the follow-up, the overall endoleak rate 
was higher in octogenarians compared with younger patients (47% vs 28% 
endoleak after 84 months, respectively) (Figure 1). More type II and type 
III endoleaks were observed in octogenarians (Table 6). A higher 
incidence of late complications was observed during the follow-up period, 
and all-cause mortality and aneurysm-related death were also higher in 
octogenarians. No differences were observed in the incidence of 
conversions and ruptures between the two groups. The mortality during 
follow-up was higher in octogenarians (Figure 2). Multivariate analysis 
revealed that being aged >80 years was an independent factor for higher 
mortality (P < .0001) and endoleak rate (P < .0001) during follow-up 
(Table 6). 
 
DISCUSSION 
A hospital mortality of 5% in a group of patients >80 years is on 
the lower end of the range of reported mortality rates in series treated by 
open surgery, where the early mortality varies from 5% to 10.5%.3,4,19 
Dardik et al20 and co-workers demonstrated a significant increase in the 
death rate after elective AAA repair with advanced age, from 2.2% for 
patients in the sixth decade of life to 7.3% for octogenarians. The rate of 
complication, in particular the systemic events, although higher than in 
younger patients, appears acceptable. The overall rate was 13%. Most of 
these systemic complications were cardiac, pulmonary, and renal adverse 
events. Although one would assume that these complications might 
adversely influence the quality of life, objective assessments on this matter 
have not been performed in the elderly age group. 
One should consider that this group of elderly patients has 
significant comorbidities. A proportion as high as 32% were regarded 
unfit for open repair.21 Previous studies have been published with regard 
to the influence of unfitness on outcome after EVAR.16,22 There was an 
increasing percentage of octogenarians treated by EVAR during the study 
period. A 10-fold increase of admissions of octogenarians has been 
reported by Reiss et al.23 The same investigators found an increase in the 
number of operations in octogenarians, from 1.1% to 5.1%, relative to all 
operations performed in one hospital during the period 1973 to 1989. This 
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may reflect a growing population of octogenarians, as well as a greater 
expectation of a successful outcome of surgery in this group of patients. 
Improved postoperative care, anaesthesia, and surgical methods may have 
promoted this development. In addition, increased experience with EVAR 
and newer generations of stent-grafts have led to fewer complications than 
in the earlier years of EVAR.24 Elderly patients may especially benefit 
from this improvement.25 
Octogenarians have a relatively high incidence of renal, 
pulmonary, and cardiac disease, which may explain why they often are 
regarded unfit for open surgery and why EVAR increasingly was selected 
as the preferred treatment. When a decision is made on which patients will 
be treated by open repair, it is likely that those with the most severe 
comorbidity or decreased life expectancy will be excluded. Ironically, this 
may lead to the exclusion of patients with the largest aneurysm and 
highest risk of rupture. This larger size observed in octogenarians may 
reflect a common tendency by referring physicians to delay referral of 
patients in this age group for surgical repair.10 
The association between comorbidity and aneurysm diameter has 
been demonstrated previously.26 One study assessing the risk of rupture in 
nonoperated aneurysm indicated an annual rupture rate of 18.6% when the 
diameter was >60 mm.27 In the present series, only three ruptures (0.4%) 
occurred after EVAR in the octogenarian study group during a follow-up 
period of 72 months. This is in agreement with the observation that if, 
perhaps, EVAR does not avert the risk of rupture entirely, it will be 
associated with a reduction of at least 96%.26 However, the appraisal of 
the net effect of any intervention in patients with advanced age is difficult 
because of the high natural mortality and complication rate. 
Some of the anatomic details, such as a larger diameter of the 
aneurysm neck, a higher incidence of angulation of the neck or the iliac 
arteries, and more type D and E aneurysms, may indicate that the disease 
was more advanced in octogenarians than in younger patients. They may 
therefore be less frequently suitable for EVAR. A similar observation has 
been made in patients with ruptured aneurysm28 and it has been suggested 
that the results after EVAR are less favourable the larger the aneurysm.26 
It is possible that better endoprostheses and the development of a 
possibility to apply side branches or fenestration may overcome these 
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problems. However, failure to complete the endovascular procedure in this 
series occurred only in 11 of the 696 octogenarians. 
After elective open repair of AAA, the quality of life may return to 
the preoperative status, although it may take from 3 to 6 months to recover 
completely from surgery.29 In one study, 36% of patients operated with 
open technique experienced a permanent lack of recovery to preoperative 
status, and 18% expressed the opinion that they would not choose again to 
undergo this operation.30 After EVAR, the health-related quality of life in 
the long run is similar to that observed after open surgery,31 but a better 
quality of life was observed in the first postoperative month after EVAR.32 
The more rapid normalization of physical and psychologic functions could 
be particularly important for the recovery in elderly patients.25 
Although there were significant differences between the two 
groups regarding procedural details, the overall impact of the procedure in 
the elderly was within reasonable limits. The longer stay in hospital of 7 
days in octogenarians is lower than after open repair.33,34 As expected, the 
complication rate was somewhat higher among octogenarians compared 
with younger patients. Procedural complications such as endoleak were 
only slightly more frequent in elderly patients. A higher incidence of 
hemorrhagic complications has also been observed after open surgery.19 
No difference in the rate of conversion to open surgery or rupture rate was 
observed during the follow-up period compared with the younger group. 
With a low event rate, however, it is possible that the lack of statistical 
power could disguise differences. An increased late mortality probably 
reflects the natural course in a cohort of octogenarians. O’Hara et al6 
reported an overall death rate of 9.6% in a 10-year period in a large series 
of electively treated octogenarians. 
As a greater proportion of the population lives longer, the 
complexity of surgical therapy in the elderly becomes an increasing 
concern and calls for less-invasive surgical treatment. Life expectancy, 
risks of the procedure, and postoperative quality of life play an important 
role in the decisions made by patients, surgeons, and anesthesiologists.10 
This concern is highlighted by the fact that there are currently at least 4 
million octogenarians in the United States, a Figure expected to grow to as 
high as 30 million by 2050.35 
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CONCLUSION 
Our study supports that EVAR might be considered when treating 
elderly patients who have a limited life expectancy, provided their 
aneurysms are anatomically suited for the endovascular technique.9-11 The 
risk for late complications compared with open repair may be outweighed 
by a lower early mortality and a shorter time for physical recovery.15,33
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BACKGROUND: It has been shown that preoperative statin therapy 
reduces all-cause and cardiovascular mortality in patients undergoing 
major non-cardiac vascular surgery. In this report we investigated the 
influence of statin use on early and late outcome following endovascular 
abdominal aortic aneurysm repair (EVAR). 
 
METHODS: The study population, consisting of patients collated in the 
EUROSTAR registry, was stratified in two groups according to statin use. 
Baseline characteristics between the two groups were compared by Chi 
Square and Wilcoxon rank sum tests for discrete variables and continuous 
variables. The effect of statin use on outcomes after EVAR were analysed 
by multivariate regression models. 
 
RESULTS: Of the 5892 patients enrolled in the EUROSTAR registry, 
731 (12.4 percent) patients used statins for hyperlipedemia. Statin users 
were younger, more obese, and had a higher prevalence of diabetes, 
cardiovascular disease and hypertension. After 5 years of follow-up, the 
cumulative survival rate was 77 percent for non-users of statin vs. 81 
percent for statin users (p=.005). After adjustment for age and other risk 
factors, statin use was still an independent predictor for improved survival 
(p=.03).   
 
CONCLUSION: Our results reveal that statin prescription was more 
frequent in younger patients. However, when adjusted for age and medical 
risk factors the use of statin in patients who underwent EVAR was still 
independently associated with reduced overall mortality.  
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INTRODUCTION 
The reported 30-day mortality rate after elective conventional 
abdominal aortic aneurysm (AAA) repair varies between 0 and 8.2 
percent.1-4 Still, the subsequent mid- and long-term survival rates in these 
patients are inferior to that of an age-matched population, due to a higher 
prevalence of co-morbidity. During a 2 year follow-up period, cardiac 
related death of 6.3 percent has been reported.5 The United Kingdom 
Small aneurysm trial experienced an incidence of 28 percent for death due 
to cardiovascular cause during a mean follow-up period of 8 years.6  
With the less invasive, endovascular AAA-repair technique, lower 
operative mortality rates have been achieved as compared to conventional 
open repair1-4, but in longer-term studies this early advantage did not 
sustain. 1,6-9 
Cardiac morbidity and mortality are frequently observed after 
surgery.10,11 The underlying pathophysiology is unclear. However, 
thrombus formation and subsequent vessel occlusion is considered the 
dominant causative mechanism.12 
The use of cholesterol-lowering drugs, 3-hydroxy-3-methylglutaryl 
co-enzyme A reductase, or statins, may have a beneficial influence 
because of the direct effect in the vascular function resulting in coronary 
plaque stabilization.13,14 In addition to the inhibition of atherosclerotic 
plaques development through the reduction of serum-cholesterol, they also 
have a stabilizing effect on vulnerable plaques, anti-inflammatory actions, 
and the improvement of the endothelial and coagulation function.15-19  
It has been shown that preoperative statin therapy reduces all-cause 
and cardiovascular mortality in patients undergoing major non-cardiac 
vascular surgery.20-25 Recently, also the reduction of hospital stay, vascular 
complications and improved long-term survival after vascular surgery was 
reported.26,27 However, the effects of preoperative statin use after 
endovascular repair of AAA has to our knowledge not been analysed 
previously. The objective of this study was to analyse the influence of 
statin use on early and late outcome following endovascular abdominal 
aortic aneurysm repair (EVAR). 
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METHODS 
Patients were recruited from 165 European institutions (see 
appendix). Only commercially available CE approved (Communauté 
Europeénne) stent-grafts were applied. Baseline data including 
information about co-morbidity, fitness for open surgery, ASA-
classification (classification according to the American Society of 
Anaesthesiologists), aneurysm anatomy and operative details were 
included. Among these recorded details at admission, the use of statins 
was included. The information was recorded by participating institutions 
on case record forms and submitted to the EUROSTAR Data Register 
Centre or entered online at the website www.eurostar-online.org. Follow-
up investigations included clinical examination, computed tomography 
scans (CT) and in some cases angiography or magnetic resonance 
imaging. There was no outside monitoring of the centres and no 
involvement of a core laboratory for evaluation of CT-scans or other 
imaging investigations. Early complications included intraoperative device 
related problems, inability to advance the delivery system, inability to 
deploy the device, stent-graft migration, occlusion, stenosis or arterial 
injuries. Postoperative systemic complications including cardiac, 
pulmonary and renal function impairment were recorded. Primary 
technical success was defined as complete exclusion of the aneurysm. 
Patients were followed up at 1, 3, 6, 12, 18, 24 months and annually 
thereafter. Satisfactory finding at CT was defined by absence of endoleak, 
stent-graft migration, kinking, stenosis and thrombosis. Outcome reporting 
was performed according to the guidelines from the ad-hoc committee for 
standardised reporting practices in vascular surgery of the Society for 
Vascular Surgery/American Association for Vascular Surgery.27 Death 
occurring within 30-days of the initial procedure was categorized as 
operative death and death after 30-days as late death. Aneurysm-related 
death included 30-day death and death that occurred as a result of 
aneurysm rupture, endograft infection or within one month after a 
secondary surgical procedure for late complications of the aneurysm.  
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Preoperative patient characteristics, co-morbidity, risk factors, 
aneurysmal morphology at the time of the initial procedure were 
correlated with the two study groups: (A) patients who were on statin 
medication and (B) patients who did not use statins, by univariate analysis. 
Differences in baseline characteristics between the two groups were 
assessed by Chi Square tests for discrete variables and by Wilcoxon rank 
sum test for continuous variables. Variables which were statistical 
significant different between the two study groups were included in the 
multivariate model. Early (30-day) outcomes after EVAR were analysed 
by multivariate logistic regression. Outcomes during follow-up were 
assessed by life-table analysis and log-rank testing. Multivariate Cox 
proportional hazard model was used to identify the effect of statin use on 
late outcomes with correction for potential confounders. A P-value less 
than 0.05 was considered to represent a significant difference. All 
statistical analyses were performed with SAS Statistical Software, version 
8.0 SAS Institute, 1C., Carey NC.  
 
RESULTS 
Of a total of 5892 patients, who were enrolled in the EUROSTAR 
registry, 731 (12.4 percent) patients were treated with statins for 
hyperlipedemia. Statin users were in average 2.5 years younger had a 
higher prevalence of diabetes, obesity, cardiovascular disease, and 
hypertension (Table 1). There were no significant differences in smoking 
habits, renal or pulmonary dysfunction. In the overall series the mean 
aneurysmal diameter was 58mm and approximately 25 percent of the 
patients were considered unfit for open surgery. Prescription of statin 
increased over the study period (from 4% in 1997 to 15% in 2004) 
(p<.0001) (Table 2). 
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Table 1: Patient characteristics and risk factors 
N=5892 Non-statin users 
N=5161 
Statin users 
N=731 
P-value 
 percent percent  
Age at operation    
     Mean ± SD (years) 72.6 ± 7.7 70.1 ± 7.3  <.0001 
Male sex 94.0 94.9 NS 
Moderate/Severe SVS/ISVS risk score    
     Diabetes 11.6 17.4 <.0001 
     Smoking 23.8 23.5 NS 
     Hypertension 62.7 73.0 <.0001 
     Cardiac disease 59.3 69.6 <.0001 
     Carotid disease 17.3 22.3 .0010 
     Renal disease 19.1 17.8 NS 
     Pulmonary disease 43.3 40.8 NS 
ASAclass    
      ≥III 50.6 46.1 .0237 
Obesity 26.5 33.7 <.0001 
Unfit for open surgery 25.0 24.2 NS 
Unfit for general anaesthesia 10.0 9.2 NS 
Maximal diameter of aneurysm    
     Mean ± SD (mm) 58.7 ± 11.1 58.2 ± 9.6  NS 
     > 55 mm 58.6 57.0 NS 
Aneurysm morphology class   NS 
     A 16.0 18.0  
     B 52.8 55.0  
     C 16.2 13.1  
     D 8.9 9.3  
     E 6.1 4.7  
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Table 2: Statin prescription over the years 
N=5892 Non-statin users 
N=5161 
Statin users 
N=731 
P-value 
 N (row percent) N (row percent)  
   1997 143 (96.0) 6 (4.0) <.0001 
   1998 349 (95.8) 31 (4.2)  
   1999 606 (93.0) 51 (7.0)  
   2000 785 (90.7) 81 (9.3)  
   2001 873 (86.6) 135 (13.4)  
   2002 944 (86.6) 146 (13.4)  
   2003 914 (83.0) 187 (17.0)  
≥ 2004 546 (85.3) 94 (14.7)  
 
Early outcomes 
The incidence of intraoperative complications including device 
related and arterial complications, was similar in the two groups (Table 3). 
The incidence of cardiac complications was 1.7 percent in the statin users 
and 3.4 percent in the non-statin users (p=0.01).  The incidence of 
endoleaks at completion angiogram was similar in both groups (16 and 17 
percent). Hospital stay was lower in statin users (mean 5 days) than in 
non-users (mean 6 days) (p=0.04). The 30-day mortality rate in statin 
users was 1.5 percent compared to 2.6 percent in the non-users (NS). The 
incidence of early conversion was higher in the non-statin users (1.1 
percent) as compared to the statin users (0.3 percent). 
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Table 3: Early complications 
 Non-statin 
users 
N=5161 
Statin 
users 
N=731 
P-value* 
 percent percent  
Intraoperative complications    
     Device related complications 4.9 3.6 NS 
     Failure to complete procedure 1.6 0.7 NS 
     Arterial complications 3.5 3.0 NS 
Complications from operation to 
discharge 
   
     Systemic complications 11.5 10.1 NS 
            Cardiac 3.4 1.7 .010 
            Pulmonary 2.0 0.1 NS 
            Sepsis 0.6 1.2 NS 
     Procedure & device related 2.8 2.2 NS 
     Access site & lower limb 
complications 
6.1 3.8 NS 
    
30-day mortality 2.6 1.5 NS 
30-day conversion 1.1 0.3 .046 
30-day AAA-rupture 0.02 - NS 
* Adjusted for differences in risk profile between the two study groups; ASA ≥ 3, diabetes, 
hypertension, cardiac and carotid impairment, obesity and patient age>70years.  
 
Follow-up  
The mean duration of follow-up was 17 months. Device-related 
complications recorded during follow-up including endoleak, migration, 
kinking, stenosis and thrombosis occurred in similar proportions in both 
study groups. A significant difference in survival was observed between 
the study groups. Overall 47 (6 percent) of the statin users died compared 
to 526 (10 percent) of the non-statin users. Conversion to open repair was 
necessary in 117 (2.3 percent) of the non-statin users and 9 (1.2 percent) 
of the statin-users. In the entire series late aneurysm related death occurred 
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only in 40 (0.7 percent) patients of which 25 (0.4 percent) were due to 
aneurysm rupture. Kaplan-Meier curves revealed an overall-survival rate 
of 77 percent and 81 percent after 5 years in respectively non-statin and 
statin users (p=.005) (Figure 1). After correction for age, and other risk 
factors the adjusted hazard rate for statin was 0.7 (p=.03) for overall 
survival (Table 4). Other independent predictors for survival were age, 
cardiac status and ASA-class three or higher. 
 
Table 5: Independent predictive variables of adverse outcome after EVAR 
 HR* 95 percent CI P-value 
Overall Survival    
     Statin use 0.72 0.54 – 0.98 .034 
     ASA ≥ 3 1.90 1.59 – 2.28 <.0001 
     Cardiac status 1.24 1.03 – 1.49 .022 
     Patient age > 70 1.96 1.62 – 2.38 <.0001 
AAA-related death    
     Statin use 0.57 0.32 - 1.03 NS 
     ASA ≥ 3 3.21 2.27 – 4.53 <.0001 
     Patient age > 70 2.38 1.63 – 3.48 <.0001 
Conversion    
     Statin use 0.58 0.29 – 1.13 NS 
AAA rupture    
     Statin use 1.19 0.35 – 3.98 NS 
     Patient age > 70 2.98 1.11 – 7.98 .030 
* Adjusted for differences in risk profile between the two study groups; ASA ≥ 3, diabetes, 
hypertension, cardiac and carotid impairment, obesity and patient age>70years. 
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Figure 1: Kaplan-meier curves of survival in statin and non-statin users 
Number of patients at risk for each time period 
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DISCUSSION 
The current report suggests that perioperative statin use reduces the 
risk of all-cause mortality during follow-up after EVAR. Statin use 
remains an independent predictor for improved survival even after 
correction for potential confounding due to differences in risk profile 
between statin users and non-users.  
Several studies have reported reduced perioperative mortality with 
statin use in patients undergoing major non-cardiac vascular surgery.20-24 
To our knowledge no previous research was performed on the effect of 
statin use on adverse outcomes after EVAR. Crude mortality rates after 
major non-cardiac vascular surgery of 2 percent for statin users and 3 a 4 
percent for non-users were reported.21,23 After conventional open 
abdominal aortic aneurysm surgery Kertai et al. reported perioperative 
mortality of 3.7 percent in patients using statins versus 11.0 percent in 
non-statin users.24 The difference in all-cause mortality after EVAR was 
less then in the series of Kertai, but still significantly lower in the statin 
group. The reported propensity to prescribe statin to younger patients, or 
persons with a history of cardiac disease, 23,24 has also been confirmed by 
our series. Statin users were in average 2.5 years younger and had 10% 
more frequently cardiac impairment. Conform to Parker et al. we found a 
reduction in length of hospital stay for statin users.26 Recently, also the 
beneficial effect of statin on long-term survival after various vascular 
surgical procedures has been reported.25,26 These researchers found a 
reduced risk of 50 to 60% for all-cause mortality after vascular surgery 
with statin use (HR=0.4 (95%CI=0.3–0.6) and HR=0.5 (95%CI=0.3-0.8). 
We noticed a 30% reduction in overall mortality after EVAR with 
perioperative statin use (HR=0.7, 95%CI=0.5-0.9).  
Life expectancy of patients with AAA is reduced compared to an 
age-matched population of persons without aneurysms, primarily due to 
associated cardiac disease.28 Reported survival after EVAR and 
conventional AAA surgery ranges between 64-75 percent and 64-77 
percent after 5 years, respectively.** We found an overall-survival rate 
after EVAR of 77 percent and 81 percent over a 5 year period in non-statin 
and statin users, respectively.  Even though statin users had different 
clinical characteristics associated with an adverse long-term outcome as 
compared with nonusers, including a higher prevalence of cardiovascular 
disease, the association between statin use and reduced mortality remained 
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after adjustment for potential confounding clinical risk factors. Many 
reports on late survival after successful AAA surgery have been published; 
indicating that the primary cause of late death often is of cardiovascular 
nature.29-31 An association between atherosclerosis and AAA has been 
suggested, which may explain the high proportion of late cardiovascular 
related mortality.15,32 Patients with vascular diseases often have extensive 
coronary artery disease, characterised by the presence of asymptomatic, 
though vulnerable atherosclerotic plaques.11 In this concept statins are 
beneficial in the prevention of late cardiac complications by the 
stabilization of vulnerable plaques, their anti-inflammatory effect and the 
inhibition of progressive coronary heart disease.13,33,34  
Other independent predictors for decreased survival were advanced 
age, a history of cardiac disease, and an ASA-class of three or more. These 
associations have previously been described by other researchers.35-39 
Recently, it has been reported that statins also decrease the serum 
concentrations of matrix metalloproteinase (MMP) type 3 and 9. MMP-3 
and 9 are associated with AAA formation and expansion. These data 
suggest a potentionally effective pharmacological therapy to inhibit further 
expansion of an established AAA.40 We could not analyse if there was 
reduced level of MMP-3 and MMP-9 in patients who were treated with 
statins in our study because no information on blood values were included. 
Cohort studies as the present one are useful for evaluating the 
outcomes of endovascular abdominal aortic aneurysm repair and the effect 
of a large range of variables including use of pharmacological agents 
prescribed for the prevention of cardiovascular events. Unfortunately the 
use of ß-blockers was not recorded in the database. Thus, the use of this 
other frequently prescribed cardiovascular drug could not be analysed. The 
major strength of EUROSTAR analyses is the large number of patients 
and the extensive follow-up. The fact that several centres have contributed 
to the study population may be responsible for significant inter-observer 
variation, limited data monitoring, and incompleteness of follow-up data. 
However, the size of the patient population and the random distribution of 
these disadvantages over the two groups, largely negate these limitations 
with regard to a useful comparison of outcomes. Moreover, the patient 
population in a registry is a good reflection of common day clinical 
practice. It must be noted that only pre-operative lipid-lowering 
medication-use was recorded by means of the SVS-ISCVS risk score. So 
patients who were prescribed statins only during the post-operative period 
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were not considered as statin users in this analysis. This may have led to 
an underestimation of difference between the two study groups, which 
only can increase the likelihood of a beneficial effect of statins. As statin 
use as a rule should not be discriminated, we have reason to believe that 
patients who were in this category at admission continued it’s use after the 
intervention. It has been suggested that compared to non-statin users, 
statin users tend to have a healthier lifestyle by consuming a better diet, 
having more physical activity, have stopped smoking habits, and be more 
compliant with therapy and screening.41-43 Of these factors, we only could 
assess the smoking status, which did not differ between statin users and 
non-users. To clarify the relationship between statin use and improved 
survival a placebo-controlled trial is required and we think the results in 
the present study indicates that such trial is warranted.  
 
In conclusion, our results reveal that pre-operative statin 
prescription occurred more frequent in younger patients and resulted in 
shorter hospital stay. After adjusted for differences in age and medical risk 
factors statin use was still associated with improved overall-survival after 
EVAR. 
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Risk-Adjusted Outcome Analysis of 
Endovascular Abdominal Aortic 
Aneurysm Repair in a Large Population: 
How Do Stent-Grafts Compare? 
 
Corine J. van Marrewijk, MSc; Lina J. Leurs, MSc; Srinivasa R. 
Vallabhaneni MD, FRCS; Peter L. Harris, MD, FRCS; Jacob Buth, MD; 
Robert J.F. Laheij, PhD on behalf of the EUROSTAR collaborators 
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PURPOSE: To compare differences in the applicability and incidence of 
postoperative adverse events among stent-grafts used for repair of 
infrarenal aortic aneurysms.  
 
METHODS: An analysis of 6787 patients from the EUROSTAR Registry 
database was conducted to compare aneurysm morphological features, 
patient characteristics, and postoperative events for the AneuRx, 
EVT/Ancure, Excluder, Stentor, Talent, and Zenith devices versus the 
Vanguard device (control) and each other. Annual incidence rates of 
complications were determined, and risks were compared using the Cox 
proportional hazards analysis. 
 
RESULTS: The annual incidence rates were: device-related endoleak 
(types I and III) 6% (range 4%–10%), type II endoleak 5% (range 0.3%–
11%), migration 3% (range 0.5%–5%), kinking 2% (range 1%–5%), 
occlusion 3% (range 1%–5%), rupture 0.5% (range 0%–1%), and all-cause 
mortality 7% (range 5%–8%). After adjustment for factors influencing 
outcome, AneuRx, Excluder, Talent, and Zenith devices were associated 
with a lower risk of migration, kinking, occlusion, and secondary 
intervention compared to the Vanguard device. Significant increased risk 
for conversion (EVT/Ancure) and reduced risk of aneurysm rupture 
(AneuRx and Zenith) and all-cause mortality (Excluder) were found 
compared to the Vanguard device. 
 
CONCLUSIONS: Significant differences exist between stent-grafts of 
different labels in terms of applicability and complications during 
intermediate to long-term follow-up. Since each stent-graft has its 
drawbacks, no single label can be identified as the best. It is reassuring 
that developments in stent-grafts indeed result in better performance than 
the early stent-grafts. However, a single device incorporating all the 
perceived improvements should still be pursued. 
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INTRODUCTION 
Endovascular repair of abdominal aortic aneurysm was introduced 
in the early 1990s as a minimal access alternative to conventional repair. 
The first stent-grafts implanted were homemade devices1,2 and served to 
establish the feasibility of the technique. These prototypes were followed 
by a range of commercially manufactured devices, which have been 
implanted in relatively large numbers of patients over the past decade.3–9 
To be effective, a stent-graft needs to maintain fixation, 
hemodynamic seal, mechanical integrity, and patency over many years. 
However, a stent-graft implanted in an aortic aneurysm is subjected to 
several adverse factors that tend to compromise these functions. Several 
modes of stent-graft failure have been documented, and the lessons 
learned from early experiences led to changes in various features of many 
endografts and withdrawal of some early models.10 
Stent-grafts provided by different manufacturers differ in their 
physical properties and design features. Each stent-graft system has its 
own characteristics, upon which the manufacturers claim specific 
advantages in terms of applicability and durability. However, no single 
device incorporating all the perceived improvements exists, which is at 
least in part due to patent/copyright protection of some of these design 
features. 
Published comparisons of outcomes with different stent-graft 
models are confined to short and intermediate-term analyses or small 
series.11–16 Comparison of several stent-graft models in large numbers of 
patients over mid to long-term follow-up may provide insights into 
relative strengths of each device. The aim of this study was to compare 
different models of endografts in terms of preoperative anatomical 
variables of the aneurysm and postoperative outcomes. The EUROSTAR 
series is ideally suited for such a comparative assessment because of the 
range of stent-graft models included. Comparative analysis is indeed one 
of the prime purposes of a voluntary multicenter registry of this kind.17 
This article provides an extensive amount of data to support detailed 
comparison among the stent-graft models. 
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METHODS 
EUROSTAR Project 
EUROSTAR (European Collaborators on Stent-graft Techniques 
for Abdominal Aortic Aneurysm Repair) project was launched in 1996 in 
response to the introduction of the new technique of repairing aortic 
aneurysms. The project was designed as a voluntary pan-European 
multicenter registry to allow collection of as much data as possible in as 
short a time as possible for expeditious scientific evaluation of this 
technique. Registration is done on an “intention-to-treat” basis, and data 
are collected prospectively by means of case record forms (paper or online 
format). Preoperative evaluation, operative details, and follow-up data are 
collected. Follow-up protocol requires patient assessment by contrast-
enhanced computed tomography (CT) at 1, 3, 6, 12, and 18 months after 
the operation and yearly thereafter. The surveillance protocol also includes 
annual plain radiography and clinical examination. The information is 
stored on an Oracle database (Oracle Corporation, Redwood Shores, CA, 
USA) for periodic analysis. Patients enrolled in the database received 
information about this registry and consented to have their data included 
in the study.18,19  
This analysis covered patients who received a commercially made 
stent-graft between January 1994 and August 2004: AneuRx (Medtronic 
Vascular, Santa Rosa, CA, USA), EVT/Ancure (Guidant Indianapolis, IN, 
USA), Excluder (W.L. Gore & Associates, Flagstaff, AZ, USA), Stentor 
(MinTec, La Ciotat, France), Talent (Medtronic Vascular), Vanguard 
(Boston Scientific, Natick, MA, USA), and Zenith (Cook, Indianapolis, 
IN, USA). The Stentor was regarded as a first-generation device, the 
Vanguard and EVT/Ancure as second-generation, and all other brands as 
third-generation stent-grafts. 
 
Definitions of Outcome Events 
Endoleaks, kinking, migration, and occlusion of the stent-graft 
occurring after the first postoperative month were included as reported by 
individual investigators. It is expected that current recommended reporting 
standards are followed for definition and diagnosis, but the absence of a 
central core laboratory facility means that these complications are not 
verified.  
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Device-related (types I and III) and isolated type II endoleaks were 
analyzed as separate events. Aneurysm growth and shrinkage were 
regarded only when the maximum transverse aneurysm diameter changed 
at least 8 mm from the preoperative measurement. Secondary 
interventions included all reinterventions other than conversion to open 
repair, which was regarded as a separate event. 
 
Patient Sample 
During the observation period, 6787 patients (6341 men; mean age 
72 years, range 28–100) from 181 hospitals (Appendix) in 19 countries 
were included in this analysis. The mean preoperative aneurysm diameter 
was 58 mm (range 30–145) and the mean duration of follow-up was 21 
months (range 0–108). The distribution of stent-graft models over time is 
given in Table 1. Preoperative anatomical characteristics of the aneurysms 
and other baseline patient characteristics are presented for each stent-graft 
in Table 2.  
 
Table 1: Annual number of registered stent-graft implantations 
 
Statistical Analyses 
The primary aim of the analysis was to compare patients who were 
treated by the different stent-graft models. Preoperative anatomical details 
of the aneurysm were analyzed to identify differences in the applicability 
of different endograft models. Adverse events during follow-up were 
examined to characterize the performance of different models. In order to 
render this comparison quantitative, annual incidence rates (IRann: number 
Device Total ≤1995 1996 1997 1998 1999 2000 2001 2002 ≥2003 
AneuRx 999 15% - 4 89 265 273 205 90 49 24 
EVT/Ancure 176 3% 11 10 41 30 34 16 6 23 5 
Excluder 808 12% - - - 29 90 108 153 190 238 
Stentor 308 5% 165 143 - - - - - - - 
Talent 1579 23% - 9 60 101 168 223 282 306 430 
Vanguard 929 14% - 89 372 304 149 15 - - - 
Zenith 1988 29% - - - 15 159 317 483 487 527 
Total 6787  176 255 562 744 873 884 1014 1055 1224 
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of events/person-years at risk) for each complication were calculated for 
the entire cohort and for each stent-graft model.  
 
Table 2: Percentage of preoperative characteristics per stent-graft label 
Characteristics  AneuRx 
EVT/ 
Ancure 
Excluder Stentor Talent Vanguard Zenith 
Follow-up (mo) 
Mean [range] 
 24 [0-72] 29 [0-96] 14 [0-60] 51 [0-108] 16 [0-84] 36 [0-96] 15 [0-72] 
Aortic neck  % (N)  % (N) % (N) % (N) % (N) % (N) % (N) 
          - diameter <20 mm 6 (59) 13 (22) 6 (49) 7 (22) 4 (60) 13 (124) 4 (84) 
 20-24 mm 64 (641) 70 (123) 69 (557) 34 (105) 42 (666) 67 (619) 47 (940) 
 >=25 mm 20 (200) 13 (23) 22 (175) 7 (22) 49 (770) 16 (149) 45 (904) 
          - length  <16 mm 14 (144) 9 (15) 10 (81) 8 (24) 16 (248) 8 (78) 20 (388) 
 16-30 mm 53 (526) 38 (66) 55 (446) 66 (202) 53 (834) 57 (526) 51 (1016) 
 >=30 mm 27 (272) 20 (36) 30 (243) 19 (59) 26 (418) 29 (273) 25 (502) 
          - presence of angulation 19 (194) 21 (37) 27 (216) 14 (42) 21 (329) 23 (214) 23 (458) 
Aneurysm         
          - diameter   <50 mm 23 (225) 15 (27) 20 (160) 28 (86) 12 (189) 23 (210) 13 (252) 
 50-59 mm 43 (427) 47 (83) 48 (384) 39 (121) 42 (667) 44 (406) 43 (845) 
 >=60 mm 32 (318) 36 (63) 31 (248) 28 (87) 43 (684) 33 (303) 43 (849) 
          - presence of angulation 9 (86) 11 (20) 12 (96) 3 (8) 11 (169) 12 (114) 11 (227) 
Right iliac artery         
          - diameter   <11 mm 11 (109) 20 (36) 13 (106) 28 (85) 7 (109) 32 (297) 7 (139) 
 11-15 mm 45 (445) 32 (57) 33 (270) 41 (125) 31 (495) 48 (444) 23 (459) 
 >=16 mm 15 (145) 6 (10) 12 (99) 6 (18) 20 (312) 12 (111) 22 (444) 
          - presence of angulation 28 (277) 23 (41) 33 (270) 13 (41) 32 (501) 38 (353) 33 (661) 
Left iliac artery         
          - diameter   <11 mm 13 (131) 19 (34) 15 (121) 30 (92) 7 (113) 33 (309) 6 (126) 
 11-15 mm 45 (445) 32 (56) 33 (266) 38 (118) 33 (521) 50 (463) 27 (533) 
 >=16 mm 11 (113) 5 (9) 9 (71) 6 (18) 17 (275) 8 (78) 18 (359) 
          - presence of angulation 33 (330) 29 (51) 37 (300) 15 (46) 37 (582) 44 (411) 39 (767) 
Aneurysm classification        
 aorta 62 (615) 47 (83) 75 (606) 34 (106) 65 (1021) 69 (644) 63 (1253) 
 aorto-iliac 28 (278) 12 (21) 23 (185) 23 (70) 32 (513) 28 (264) 36 (710) 
Device configureuration        
 bifurcated 92 (919) 70 (124) 96 (772) 90 (276) 85 (1344) 96 (890) 89 (1761) 
 other 8 (80) 30 (52) 4 (36) 10 (32) 15 (235) 4 (39) 11 (227) 
Hospital experience        
 <60 proc. 61 (613) 70 (123) 58 (467) 78 (239) 69 (1093) 75 (701) 47 (932) 
 >=60 proc. 39 (386) 30 (53) 42 (341) 22 (69) 31 (486) 25 (228) 53 (1056) 
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Patients were grouped according to the endograft model. 
Comparisons performed using Cox proportional hazards modelling are 
reported as hazard ratios (HR) and 95% confidence intervals. To allow 
direct comparison between two different stent-grafts models, risks of the 
different complications were calculated comparing each model of stent-
graft against each other model. Thereafter, the risk quantification of 
complications was adjusted for differences in baseline characteristics 
because these factors could potentially influence the observed association. 
Adjustments were made in models with the group of patients who received 
a Vanguard device as a control. In each consecutive model, one more 
group of the following factors were added to the prior model: (1) year of 
operation; (2) age at operation, gender, and smoking status; (3) “high risk” 
for operation and general anaesthesia, a history of previous laparotomy, 
and obesity; (4) preoperative aneurysm morphological characteristics, 
including maximum diameter, aneurysm length, aortic neck angulation, 
neck diameter, etc.; and finally (5) stent-graft configureuration and 
experience of the operating team. This stepwise modelling enabled 
determination of any influence of the individual or grouped baseline 
characteristics on the risk. Dummy variables were added to the models to 
account for missing values. Comparisons achieving p<0.05 (2-tailed) were 
considered to be statistically significant. All statistical analyses were 
performed using SAS software (version 8.0; SAS Institute Inc., Cary, NC, 
USA) 
 
RESULTS 
Endoleaks 
Device-related endoleaks were observed at 1 month in 10% 
(n=673) of the 6787 patients, within an at-risk period of 10,868 person-
years. Overall, the annual incidence rate was 6.2%. It was highest (IRann: 
9.6%) in patients with a Stentor and lowest (IRann: 4.1%) in patients with a 
Zenith device (Table 3). Statistically significant differences in the risk of 
device-related endoleak (types I and III) were found for Zenith compared 
to any other stent-graft except Excluder and for AneuRx, Excluder, and 
Talent versus EVT/Ancure and Stentor (Table 4). Compared to Vanguard 
(Table 5), the risk of these endoleaks was reduced 35%, 46%, 26%, and 
55% in patients with, respectively, an AneuRx (HR: 0.65, p<0.001), 
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Excluder (HR: 0.54, p<0.001), Talent (HR: 0.74, p=0.01), or Zenith (HR: 
0.45, p<0.001) stent-grafts, while it was increased by 1.45 times in 
patients with a Stentor device (p=0.003). However, after adjustment for 
baseline characteristics, statistical significance remained only for patients 
with an AneuRx (HR: 0.72, p=0.02) or a Zenith (HR: 0.49, p<0.001) 
device compared to those with a Vanguard device. The association 
between Excluder (p=0.05) and Vanguard (p=0.07) was of borderline 
significance in the fully adjusted model.  
 
Table 3: Annual incidence rates of complications according to stent-graft 
model 
Stent-graft  AneuRx EVT/Ancure Excluder Stentor Talent Vanguard Zenith Total 
 IRann N IRann N IRann N IRann N IRann N IRann N IRann N IRann N 
Device 
related 
endoleak  
0.052 (95) 0.086 (31) 0.050 (45) 0.096 (102) 0.066 (127) 0.072 (177) 0.041 (96) 0.062 (673) 
Type 2 
endoleak 
0.045 (84) 0.050 (19) 0.105 (89) 0.003 (4) 0.046 (90) 0.037 (95) 0.070 (161) 0.048 (542) 
Growth  0.027 (50) 0.022 (9) 0.042 (37) 0.027 (33) 0.043 (84) 0.027 (72) 0.040 (93) 0.033 (378) 
Shrinkage 0.203 (311) 0.264 (74) 0.209 (163) 0.066 (71) 0.300 (440) 0.171 (336) 0.350 (636) 0.227 (2031) 
Kinking 0.011 (21) 0.022 (9) 0.006 (6) 0.039 (46) 0.010 (20) 0.050 (125) 0.012 (30) 0.023 (257) 
Migration 0.043 (81) 0.005 (2) 0.011 (10) 0.031 (38) 0.024 (48) 0.050 (128) 0.007 (16) 0.028 (323) 
Occlusion 0.019 (37) 0.033 (13) 0.011 (10) 0.037 (44) 0.023 (46) 0.053 (133) 0.035 (84) 0.032 (367) 
Conversion 0.019 (38) 0.054 (23) 0.009 (8) 0.033 (43) 0.021 (44) 0.022 (63) 0.006 (15) 0.020 (234) 
Secondary 
intervention 
0.063 (113) 0.096 (34) 0.035 (32) 0.094 (98) 0.066 (127) 0.107 (245) 0.053 (122) 0.073 (771) 
Rupture 0.004 (7) 0.000 (0) 0.001 (1) 0.008 (11) 0.005 (10) 0.008 (23) 0.002 (4) 0.005 (56) 
Death 0.067 (132) 0.047 (20) 0.048 (45) 0.058 (75) 0.071 (146) 0.075 (212) 0.075 (185) 0.068 (815) 
 
Isolated type II endoleaks occurred in 8% (n=542) of patients 
within an at-risk period of 11,203 person-years. The annual incidence rate 
was 4.8% overall, ranging from 0.3% in patients with a Stentor to 10.5% 
in patients with an Excluder device (Table 3). The risk of isolated type II 
endoleak (Table 4) differed significantly for Excluder compared to any 
other label except EVT/Ancure, for Stentor versus any other label, and for 
Talent compared to Zenith. The risk was 88% lower in patients with a 
Stentor (HR: 0.12, p<0.001), and 1.54 times increased in patients with an 
Excluder (p=0.004) compared to Vanguard (Table 5). However, these 
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associations were due to differences in baseline characteristics. 
Statistically significant reductions in isolated type II endoleaks appeared 
in patients with an AneuRx (HR: 0.71, p=0.045), a Talent (HR: 0.45, 
p<0.001), or a Zenith (HR: 0.59, p=0.007) device versus Vanguard after 
correction for year of operation and persisted in the fully adjusted model. 
 
Table 4: Statistically different unadjusted hazard ratios for outcome events 
according to stent-graft model 
 Type I/III 
Endoleak 
Type II 
Endoleak 
Growth Shrinkage Migration Kinking Occlusion Conversio
n 
Secondary 
Interventi
ons 
Rupture Death 
AneuRx            
  vs. 
EVT/Ancure 
0.58 
(0.4–0.9) 
- - 0.72 
(0.6–0.9) 
9.41 
(2.3–38.3) 
- - 0.36 
(0.2–0.6) 
0.63 
(0.4–0.9) 
- - 
  vs. 
Excluder 
- 0.61 
(0.5–0.8) 
- - 3.59 
(1.9–6.9) 
- 2.23 
(1.1–4.5) 
2.62 
(1.2–5.6) 
2.10 
(1.4–3.1) 
- 1.64 
(1.2–2.3) 
  vs. Stentor 0.45 
(0.3–0.6) 
8.16 
(3.0–22.3) 
- 2.10 
(1.6–2.7) 
1.53 
(1.0–2.3) 
0.25 
(0.1–0.4) 
0.41 
(0.3–0.6) 
0.56 
(0.4–0.9) 
0.57 
(0.4–0.7) 
- - 
  vs. Talent - - 0.68 
(0.5–1.0) 
0.75 
(0.6–0.9) 
1.71 
(1.2–2.4) 
- - - - - - 
  vs. Zenith 1.44 
(1.1–1.9) 
- - 0.66 
(0.6–0.8) 
6.18 
(3.6–10.6) 
- 0.65 
(0.4–1.0) 
3.60 
(2.0–6.6) 
1.37 
(1.1–1.8) 
- - 
EVT/Ancure            
  vs. 
Excluder 
2.10 
(1.3–3.3) 
- - 1.52 
(1.2–2.0) 
- 3.77 
(1.3–10.6) 
4.10 
(1.8–9.4) 
7.36 
(3.3–16.5) 
3.34 
(2.1–5.4) 
- - 
  vs. Stentor - 10.41 
(3.5–30.6) 
- 2.90 
(2.1–4.0) 
0.16 
(0.0–0.7) 
- - - - -  
  vs. Talent 1.52 
(1.0–2.3) 
- - - 0.18 
(0.0–0.7) 
2.39 
(1.1–5.2) 
- 2.90 
(1.7–4.8) 
1.70 
(1.2–2.5) 
 - 
  vs. Zenith 2.49 
(1.7–3.7) 
- - - - - - 10.13 
(5.3–19.5) 
2.18 
(1.5–3.2) 
- - 
Excluder            
  vs. Stentor 0.37 
(0.3–0.5) 
13.39 
(4.9–36.6) 
- 1.91 
(1.4–2.5) 
0.42 
(0.2–0.9) 
0.14 
(0.1–0.3) 
0.18 
(0.1–0.4) 
0.22 
(0.1–0.5) 
0.27 
(0.2–0.4) 
- 0.58 
(0.4–0.8) 
  vs. Talent - 1.98 
(1.5–2.6) 
- 0.68 
(0.6–0.8) 
0.48 
(0.2–0.9) 
- 0.44 
(0.2–0.9) 
0.39 
(0.2–0.8) 
0.51 
(0.3–0.7) 
- 0.64 
(0.5–0.9) 
  vs. Zenith - 1.37 
(1.1–1.8) 
- 0.60 
(0.5–0.7) 
- - 0.29 
(0.2–0.6) 
- 0.65 
(0.4–1.0) 
- 0.62 
(0.4–0.9) 
Stentor            
  vs. Talent 1.96 
(1.5–2.6) 
0.15 
(0.1–0.4) 
- 0.36 
(0.3–0.5) 
- 4.57 
(2.7–7.8) 
2.37 
(1.5–3.6) 
1.82 
(1.2–2.8) 
1.89 
(1.4–2.5) 
- - 
  vs. Zenith 3.21 (2.4–
4.3) 
0.10 
(0.0–0.3) 
- 0.32 
(0.2–0.4) 
4.05 
(2.2–7.4) 
3.70 
(2.3–5.9) 
1.60 
(1.1–2.3) 
6.38 
(3.5–11.7) 
2.42 
(1.8–3.2) 
3.56 
(1.1–11.8) 
- 
Talent            
  vs. Zenith 1.64 
(1.3–2.1) 
0.70 
(0.5–0.9) 
- 0.88 (0.8–1.0) 
3.61 
(2.1–6.4) 
- 
0.67 
(0.5–1.0) 
3.50 
(1.9–6.3) 
1.29 
(1.0–1.6) 
- - 
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Change in Aneurysm Diameter 8 mm 
Aneurysm diameter increase occurred in 6% (n=378) of the 
patients within an at-risk period of 11,332 person-years. Overall, the 
annual incidence rate was 3.3%, ranging from 2.2% in patients with an 
EVT/Ancure to 4.3% in patients with a Talent device (Table 3). Aneurysm 
growth was found to be statistically different only between patients with 
an AneuRx (HR: 0.68, p=0.03) stent-graft compared to patients with a 
Talent device (Table 4). This remained unchanged after adjusted analysis 
with Talent as control (data not shown). None of the stent-grafts differed 
from Vanguard regarding growth of the aneurysm (Table 5).  
Shrinkage of the aneurysm diameter occurred in 5 times as many 
patients (30%, n=2031) within a much shorter at-risk period (8931 person-
years). The overall annual incidence rate was 22.7%. Shrinkage was 
observed most often (IRann: 35.0%) in patients with a Zenith and least 
often (IRann: 6.6%) in patients with a Stentor device (Table 3). Statistically 
significant differences in the hazard ratio of shrinkage were found between 
almost all stent-graft labels except AneuRx and Excluder, both versus 
Vanguard and each other, and for Talent and Zenith compared to EVT/ 
Ancure (Table 4). In the unadjusted comparison to Vanguard (Table 5), 
the aneurysm shrank least often in patients with a Stentor (HR: 0.49, 
p<0.001) and more frequently in patients with EVT/Ancure (HR: 1.41, 
p=0.008), Talent (HR: 1.36, p<0.001), or Zenith (HR: 1.54, p<0.001) 
devices. After adjustment for baseline characteristics, the associations of 
EVT/ Ancure, Talent, and Zenith were unchanged. 
 
Migration 
Graft migration was observed in 5% (n=323) of the patients in an 
at-risk period of 11,459 person-years. The annual incidence rate, which 
was 2.8% overall, ranged from 0.5% in patients with an EVT/Ancure to 
5.0% in patients with a Vanguard stent-graft (Table 3). Higher risk of graft 
migration was found between AneuRx and Vanguard devices compared to 
the other stent-grafts and between Stentor and Talent versus EVT/Ancure, 
Excluder, and Zenith (Tables 4 and 5). In the adjusted model compared to 
Vanguard (Table 5), the significance of the decreased risks of migration 
remained, except in patients with a Stentor or AneuRx device.  
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Table 5: Unadjusted and adjusted hazard ratios of outcome events compared 
to vanguard stent-graft 
  Hazard ratio (95% CI) 
  AneuRx EVT/Ancure Excluder Stentor Talent Zenith 
Type I/III 
endoleak       
 unadjusted 0.65 (0.5-0.8) 1.12 (0.8-1.6) 0.54 (0.4-0.7) 1.45 (1.1-1.9) 0.74 (0.6-0.9) 0.45 (0.4-0.6) 
 adjusted 0.72 (0.5-1.0) 1.21 (0.7-2.0) 0.67 (0.4-1.0) # 5 0.81 (0.4-1.6) # 1 0.75 (0.5-1.0) # 1 0.49 (0.3-0.7) 
Type II-endo       
 unadjusted 0.94 (0.7-1.3) 1.20 (0.7-2.0) 1.54 (1.2-2.1) 0.12 (0.0-0.3) 0.78 (0.6-1.0) 1.12 (0.9-1.4) 
 adjusted 0.71 (0.5-1.0) # 1 1.03 (0.6-1.9) 0.86 (0.6-1.3) # 1 0.40 (0.1-2.3) # 1 0.45 (0.3-0.7) 0.59 (0.4-0.9) # 1 
Growth       
 unadjusted 0.88 (0.6-1.3) 0.78 (0.4-1.6) 1.20 (0.8-1.8) 1.03 (0.7-1.6) 1.30 (0.9-1.8) 1.19 (0.9-1.6) 
 adjusted 0.91 (0.6-1.4) 0.96 (0.4-2.1) 1.03 (0.6-1.7) 1.08 (0.4-2.9) 1.35 (0.9-2.0) 1.01 (0.6-1.6) 
Shrinkage       
 unadjusted 1.02 (0.9-1.2) 1.41 (1.1-1.8) 0.93 (0.8-1.1) 0.49 (0.4-0.6) 1.36 (1.2-1.6) 1.54 (1.3-1.8) 
 adjusted 1.03 (0.9-1.2) 1.52 (1.1-2.1) 0.84 (0.7-1.1) (# 1,4) 0.78 (0.5-1.3) # 1 1.29 (1.1-1.6) (# 1,3) 1.42 (1.2-1.7) 
Kinking       
 unadjusted 0.21 (0.1-0.3) 0.44 (0.2-0.9) 0.12 (0.1-0.3) 0.85 (0.6-1.2) 0.19 (0.1-0.3) 0.23 (0.2-0.3) 
 adjusted 0.25 (0.1-0.4) 0.34 (0.1-0.9) 0.17 (0.1-0.4) 0.86 (0.4-2.0) 0.25 (0.1-0.4) 0.36 (0.2-0.7) 
Migration       
 unadjusted 0.91 (0.7-1.2) 0.10 (0.0-0.4) 0.25 (0.1-0.5) 0.60 (0.4-0.9) 0.53 (0.4-0.7) 0.15 (0.1-0.2) 
 adjusted 0.92 (0.7-1.3) 0.18 (0.0-0.8) 0.27 (0.1-0.6) 0.61 (0.2-1.5) # 1 0.47 (0.3-0.7) 0.13 (0.1-0.2) 
Occlusion       
 unadjusted 0.32 (0.2-0.5) 0.59 (0.3-1.0) 0.14 (0.1-0.3) 0.78 (0.6-1.1) 0.33 (0.2-0.5) 0.49 (0.4-0.6) 
 adjusted 0.39 (0.3-0.6) 0.70 (0.3-1.4) 0.18 (0.1-0.4) 0.49 (0.2-1.1) 0.34 (0.2-0.5) 0.53 (0.3-0.9) 
Conversion       
 unadjusted 0.83 (0.6-1.2) 2.34 (1.5-3.8) 0.32 (0.2-0.7) 1.47 (1.0-2.2) 0.81 (0.5-1.2) 0.23 (0.1-0.4) 
 adjusted 1.15 (0.7-1.8) 2.32 (1.2-4.6) 0.69 (0.3-1.6) # 1 0.59 (0.3-1.3) 1.08 (0.7-1.8) 0.38 (0.2-0.8) 
Secondary 
intervention       
 unadjusted 0.54 (0.4-0.7) 0.86 (0.6-1.2) 0.26 (0.2-0.4) 0.96 (0.8-1.2) 0.51 (0.4-0.6) 0.40 (0.3-0.5) 
 adjusted 0.57 (0.4-0.7) 0.90 (0.6-1.4) 0.29 (0.2-0.5) 0.67 (0.4-1.2) 0.51 (0.4-0.7) 0.40 (0.3-0.5) 
Rupture       
 unadjusted 0.50 (0.2-1.2) - 0.17 (0.0-1.3) 0.91 (0.4-1.9) 0.72 (0.3-1.5) 0.26 (0.1-0.8) 
 adjusted 0.32 (0.1-0.9) # 4 - 0.13 (0.0-1.2) 0.34 (0.0-2.7) 0.44 (0.2-1.2) 0.10 (0.0-0.4) 
Death       
 unadjusted 0.80 (0.6-1.0) 0.60 (0.4-0.9) 0.49 (0.4-0.7) 0.84 (0.6-1.1) 0.75 (0.6-0.9) 0.78 (0.6-1.0) 
 adjusted 0.94 (0.7-1.2) # 1 0.67 (0.4-1.2) # 1 0.62 (0.4-0.9) 0.73 (0.4-1.4) 0.79 (0.6-1.0) # 1 0.86 (0.6-1.2) # 1 
Adjusted results include correction for 1. year of operation, 2. demographics, 3. clinical 
characteristics, 4. vascular morphology, and 5. stent-graft related factors. 
# Correction level changing the significance of the association
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Kinking 
Stent-graft kinking occurred in 4% (n=257) of the patients during 
an at-risk period of 11,387 person-years. Overall, the annual incidence rate 
of kinking was 2.3%. It was highest (IRann: 5.0%) for patients with a 
Vanguard and lowest (IRann: 0.6%) for patients with an Excluder stent-
graft (Table 3). The risk of graft kinking differed significantly between 
third-generation models (AneuRx, Excluder, Talent, and Zenith) compared 
to the early models (EVT/Ancure, Stentor, and Vanguard; Tables 4 and 5). 
The risk of kinking in any stent-graft but Stentor versus Vanguard (Table 
5) remained significantly lower after adjustment for the differences in 
baseline characteristics (Table 5).  
 
Occlusion 
Stent-graft occlusion was also reported in 5% (n=367) of the 
patients, though in a shorter at-risk period (11,316 person-years). The 
overall annual incidence rate was 3.2% (range 1.1% for Excluder to 5.3% 
for Vanguard; Table 3). The risk of graft (limb) occlusion was reduced in 
patients with an Excluder compared to any other stent-graft and in patients 
with an AneuRx or Talent compared to Zenith. All of these in turn had a 
lower risk of limb occlusion than Stentor or Vanguard (Tables 4 and 5). 
Significance of any of the associations compared to Vanguard (Table 5) 
remained after adjustments for baseline characteristics.  
 
Reinterventions 
Conversion to open repair was performed in 3% (n=234) of all 
patients. Of these, 76 conversions were performed within 30 days of the 
initial operation. The annual incidence rate for conversion was 2.0% 
overall. It was highest in patients with an EVT/Ancure (5.4%) and lowest 
for patients with a Zenith stent-graft (0.6%; Table 3). Comparison of stent-
grafts showed a significantly lower conversion risk in patients with an 
Excluder or Zenith compared to any other device and for AneuRx or 
Talent compared to EVT/Ancure and Stentor (Table 4). After adjustments, 
the risk of conversion to open repair was 2.32 times higher in patients with 
an EVT/Ancure (p=0.02) and 62% lower in patients with a Zenith device 
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(p=0.008) compared to Vanguard (Table 5), but this risk was no longer 
significantly different between Vanguard and Excluder.  
One or more secondary interventions were necessary in 11% 
(n=771) of the patients; these were transfemoral, transabdominal, and 
extra-anatomic, respectively, in 625, 59, and 162 patients. The annual 
incidence rate was 7.3% (range from 3.5% for Excluder to 10.7% for 
Vanguard; Table 3). The risk of these reinterventions was significantly 
reduced for Excluder compared to any other stent-graft, for Zenith versus 
any other brand except Excluder, and for AneuRx or Talent compared to 
the early devices (EVT, Stentor, and Vanguard; Table 4). The reduced risk 
of reintervention with a third-generation device (AneuRx, Excluder, 
Talent, and Zenith) compared to Vanguard (Table 5) remained after 
adjustments for baseline characteristics. 
 
Rupture 
Rupture of the treated aneurysm was documented in 56 (0.8%) of 
the 6787 patients within an at-risk period of 11,946 person-years, giving 
an overall annual incidence of rupture of 0.5%. So far, no ruptures have 
been reported in patients with an EVT/Ancure device. The aneurysm 
rupture rate was highest (IRann: 0.8%) in patients with a Stentor or 
Vanguard device (Table 3). Due to the small numbers of ruptures, 
statistically significant differences were found only for Zenith compared 
to Stentor (HR: 0.28, p=0.04) and Vanguard (HR: 0.26, p=0.01; Tables 4 
and 5). The association between Zenith and Vanguard persisted after 
adjustments. Additionally, a statistically significant reduced risk of rupture 
appeared for the AneuRx (HR: 0.32, p=0.04) device versus Vanguard 
(Table 5) after adjustment for vascular morphology.  
 
Mortality 
A total of 815 (12%) patients died during an at-risk period of 
11,953 person-years. One hundred and sixty-eight (2.5%) patients died 
within 30 days, of which 15 underwent conversion to open repair. Of the 
647 late deaths, 23 (4%) followed a conversion. Overall, the (all-cause) 
annual mortality rate was 6.8% and was highest (IRann: 7.5%) in patients 
with a Zenith and lowest (IRann: 4.7%) in patients with an EVT/Ancure 
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stent-graft (Table 3). The risk of (all-cause) mortality was statistically 
significantly lower for Excluder versus any other label except 
EVT/Ancure (Table 4). Compared to Vanguard (Table 5), mortality risk 
was decreased for all labels except Stentor. However, significantly 
reduced mortality compared to Vanguard remained only in patients with 
an Excluder (38%) device after adjustment for baseline characteristics. 
The same was found when analyzing the combined risk of rupture and 
death or that of rupture, conversion, and death (data not shown).  
 
DISCUSSION 
Although there are several articles reporting long-term results of 
endovascular repair with individual makes of stent-grafts,7,9,19–25 only a few 
compared different endograft models.11– 16,26 Based upon small numbers, 
these studies identified several factors that potentially influence outcome. 
Patient-related risk factors, such as age and comorbidities, mainly 
influence short-term results.19,27 Factors related to arterial morphology 
influence short-term success as well as long-term outcome. For example, 
adverse anatomical features, such as an unfavourable aneurysm neck or 
narrow iliac arteries, may lead to technical failure at the initial repair. 
Progressive changes in arterial anatomy during follow-up, such as neck 
dilatation or aneurysmal transformation of iliac landing zones, may 
compromise stent-graft function later on.14,15,24,28–30 Physician-related 
factors, such as diagnostic insight, judgment of suitability for treatment, 
and operating experience, also influence outcome.31 All of these factors 
have been constantly changing as endovascular repair has evolved, 
creating a potential confounding effect upon comparative analyses. The 
present study hypothesized that (independent) differences exist between 
different makes of stent-grafts, which suggests that there are endograft-
related factors that influence outcome. Therefore, the statistical methods 
included staged correction for these potentially confounding factors. The 
results support a conclusion that stent-graft– related factors do 
significantly impact outcome independent of all the other factors. 
Adjustment steps for demographic and clinical characteristics 
brought out only minor changes for the outcome events studied. On the 
other hand, correction for differences in year of operation or factors of 
vascular morphology resulted in considerable shifts in the risks of 
complications and in the significance of their associations. Occasionally 
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this was profound, with a reversal of the direction of association. This 
study confirms the findings of others, as described above, and underlines 
the importance of risk adjustment in such analyses. Unadjusted risk 
estimations (e.g., Kaplan-Meier analyses) do not always provide a reliable 
estimation of risks and might therefore give an unfair comparison between 
stent-graft models. 
This study also confirms the influence of device-specific factors 
upon almost all early and late complications.10,13–15,19,26,27 The analysis 
reproduced the widely recognized differences in the incidence of type II 
endoleak with different stent-graft models.13,26 Additionally, differences 
were also observed in relation to device-related endoleaks between 
different endografts, some persisting after risk adjustment. Lower 
incidences of device-related endoleak reflect a combination of maintaining 
proximal and distal seal and fixation and also better modular stability. 
Changes in aneurysm diameter remain an important marker of aneurysm 
exclusion, and device-specific differences have been reported.13,26,28,29 
Certain stent-graft makes (e.g., Zenith) are associated with shrinkage more 
than others. The persistence of differences after risk adjustment (e.g., for 
endoleak) in this study might suggest an additional role for device 
components, such as fabric, in influencing postoperative changes in 
aneurysm size. It is also reassuring to note that most of the newer stent-
grafts fare better in this respect compared to earlier generation devices. 
Kink resistance and fixation depend upon structural aspects of a 
device, and differences in performance can be expected among stent-
grafts. The value of hooks and barbs in improving fixation has been 
recognized,10 which is reflected in this study by the lower risk of migration 
with devices that incorporate these appendages. Devices without hooks or 
barbs depend upon columnar strength for fixation. However, a risk of 
cephalad migration (with or without endoleak) exists if the aneurysm 
decreases in size. Partially supported devices, such as EVT/Ancure, have 
the potential to migrate downward only. Differences in applicability of 
stent-grafts exist due to different fixation methods, which are reflected by 
differences in patient characteristics (anatomical and general) among the 
stent-graft labels. Differences in outcome remain even after adjusting for 
these factors. 
Primarily unsupported devices (EVT/Ancure) might be expected to 
have the highest incidence of stent-graft limb occlusion13,16,28 because the 
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lack of device support predisposes to angulation and kinking, with 
resulting stenosis and thrombosis in the graft.32 In contrast, this analysis 
showed that they in fact fared slightly better than the other first-generation 
endografts. This could be due to the smaller number of patients with an 
Ancure stent-graft. However, this finding might also point to the fact that 
kink resistance may not be afforded by the mere presence of a stent-graft 
skeleton but is more a function of the construction of the skeleton. 
A high rate of conversion to open repair was found in patients with 
an EVT/Ancure device. This was primarily due to the large number of 
conversions for endoleak (including hook breakage) in the early 
experience with this stent-graft, and this observation is not applicable to 
the later Ancure device. Significantly fewer conversions were performed 
in patients with a Zenith device. Zenith also performed better regarding 
ruptures, as did the AneuRx device. No ruptures were reported with 
EVT/Ancure, but this might be due to the high number of conversions 
performed in this group. On the other hand, all-cause mortality, as well as 
the combined risk of rupture and death or rupture, conversion, and death, 
was significantly lower with the Excluder endograft. Although the 
EUROSTAR cohort remains one of the largest, with 56 reported ruptures, 
caution is necessary while drawing conclusions since the number of 
ruptures per device label remains small. Encouraging is the observation 
that 41 ruptures occurred with devices now regarded as obsolete (Stentor, 
Vanguard, and AneuRx). 
 
Study Limitations 
Despite the strengths of EUROSTAR analyses (i.e., large number 
of patients, multiple stent-graft makes, and extensive follow-up), there are 
some limitations to the study. Limited data monitoring and the absence of 
a core laboratory mean that it is not possible to ascertain adherence to the 
reporting standards by the large number of centers that contribute to the 
registry. The effect of this is quenched by regression to the mean. 
Incompleteness of data is considered inevitable in a voluntary registry; 
however, significant effort is made to remedy this situation. 
Incompleteness of follow-up is not expected to have significantly 
influenced this analysis since it was distributed over the different groups. 
At the inception, the registry was primed by retrospective registration of 
baseline information and early follow-up results for 13% of all currently 
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registered patients. From 1996 onward, when prospective patient 
registration and data collection was made mandatory, all information 
relating to these patients was collected prospectively. Retrospective data 
was mostly of patients with a Stentor device; the influence of this fact 
upon the analysis is not measurable but is considered negligible.  
Despite extensive risk adjustment, it was not possible to correct for 
every factor that changed during the study period. Manufacturers have 
incorporated modifications in device features to individual stent-graft 
labels. Suitability criteria for patients have changed. Also, reporting 
standards and diagnostic abilities for endoleaks and other complications 
have evolved. These factors could not be separately adjusted for in the 
analyses. A combined effect of these and possibly other factors is partly 
reflected by year of operation, explaining the considerable shifts in risks it 
brought about. However, these factors might still have had some influence 
on the results in a way that is not quantifiable 
Vanguard, the largest group of the first and second-generation 
devices, was taken as a control group to evaluate whether enhancements in 
design features of the other stent-graft labels indeed translated to 
improvement in outcome. The short and midterm results of the third-
generation stent-grafts appear better compared to the early (and now 
withdrawn) stent-grafts after accounting for the differences in the duration 
of follow-up. Nevertheless, third-generation stent-grafts are not immune to 
complications. A complete comparison will not be possible until even 
longer follow-up becomes available with the third-generation devices. 
 
Conclusions 
Stent-graft labels differ significantly in terms of applicability and 
individual complications during intermediate and long-term follow-up 
periods. The differences in outcome are persistent after adjustment for 
important factors, such as patient characteristics, vascular morphology, 
and operator experience. Although no single make of stent-graft emerges 
as the best, it is reassuring to note that the later models of stent-grafts 
perform better than the early versions. However, so far, reduced risk 
regarding the primary goal of the intervention—to prevent rupture and 
death—was observed only for patients with the Excluder device. Results 
of this comparative analysis should be used to pursue a single device that 
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combines all perceived improvements. Notably, patent protection of some 
of these design features might be regarded as conflicting with the best 
interests of our patients.  
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HYPOTHESIS: Little information about the long-term results of 
endovascular abdominal aortic aneurysm repair (EVAR) is available. This 
study was performed to evaluate long-term data of patients treated with 
the first generation commercially available stent-grafts.  
DESIGN: Multicenter registry 
SETTING: 62 European centres that participated in the European 
collaborators on stent-graft techniques for abdominal aortic aneurysm 
repair (EUROSTAR) registry. 
SUBJECTS: 1190 Patients with a follow-up time up to 8 years, who 
underwent EVAR with the Stentor® or Vanguard® stent-graft. 
INTERVENTION: Elective EVAR.  
MAIN OUTCOME MEASURES: Morbidity and mortality data of 
patients treated with the first generation stent-graft who enrolled in the 
EUROSTAR registry were analysed. Patient groups were stratified 
according to the size of the aneurysm, small aneurysms were defined by a 
diameter of 40-54mm and large aneurysm had a diameter of at least 
55mm. Incidence rates of complications were calculated to quantify 
annual risks. Life table analyses and log rank tests were used to compare 
outcome in the study groups. Moreover, multivariate Cox models were 
used to identify independent predictors of adverse outcome measures with 
adjustment for potential confounders. 
RESULTS: Conversion to open repair, aneurysm rupture, all-cause death 
and aneurysm-related death occurred respectively in 7.1%, 2.4%, 19.9% 
and 3.0% of the patients. The cumulative percentage of the combined 
outcome event: conversion-free and rupture-free-survival after 8 years was 
48.0%. Procedure related complications that frequently occurred were 
endoleak (13.0 cases per 100 patient years), stenosis/ thrombosis (4.6 
cases per 100 patient years) and stent migration (4.3 cases per 100 patient 
years). Secondary interventions were required at an incidence of 11.6 
cases per 100 patient years. Patients with large aneurysms (≥55mm) had 
more frequently a complication during follow-up and a higher mortality 
rate (4.9 vs. 9.7 cases per 100 patient years) in comparison to patients with 
smaller aneurysms (40 to 55mm).  
CONCLUSIONS: Patients treated with the first generation stent-grafts 
will need life-long surveillance because a considerable risk of late 
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complications. This risk is particularly high in patients with large 
aneurysms at the time of the initial intervention. . How these findings 
translate to the outcome of newer generation stent-grafts is unknown. For 
this reason vigilant surveillance remains indicated in all patients who 
received EVAR.  
 
INTRODUCTION 
The prevalence of abdominal aortic aneurysms (AAA) is 
increasing rapidly during the last decade, and at present aneurysmal 
rupture constitutes the 13th commonest cause of death in the Western 
world.1 Traditionally non-ruptured aneurysms are treated by open surgical 
repair. This involves exposure of the abdominal aorta, aortic and iliac 
clamping, and replacement of the aneurysmal segment by a prosthetic 
graft. However, during the recent years endovascular repair of abdominal 
aortic aneurysms (EVAR) is increasingly used in patients with suitable 
aorto-iliac anatomy. With this technique an endoprothesis is used, which is 
delivered through the femoral or iliac artery at the infrarenal position to 
exclude the aneurysmal sac from the arterial circulation. Endovascular 
repair has several advantages over conventional surgery. In the first place 
it is a minimal invasive technique, which is of major importance in 
patients with comorbid factors, who are at high risk for conventional 
surgery. Operative trauma, blood loss and significant disturbances of 
hemodynamics, and ventilatory condition associated with endovascular 
repair is minimal compared to the open procedure. Moreover, hospital stay 
and reconvalesence time have been reduced significantly since 
introduction of EVAR, approximately from ten to three days for hospital 
stay and from six weeks to eleven days for recovery time.2-4 
The technical feasibility and the short-term effectiveness to 
exclude an AAA from the circulation has been reported in several 
studies.5,6 Recently, the results from two randomised clinical trails 
demonstrated that endovascular repair with regard to initial outcome may 
be preferable to open repair because of a reduced aneurysm related 
mortality.7,8 Although, endovascular treatment of abdominal aortic 
aneurysms now appears an acceptable alternative for conventional surgery 
on the short term, one must be aware of the fact that the long-term safety 
of endografts is still untested. Concern remains about the durability of the 
endovascular approach in preventing aneurysm rupture. For this reason 
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one must be cautious in advising patients which treatment option will be 
best.  
This report documents data obtained from a large a multicenter 
registry, organised by the EUROSTAR collaborators’ group. The 
objective of the present assessment was to report the long term outcome of 
EVAR obtained by the first-generation endovascular devices.  
 
PATIENTS AND METHODS 
Data collection  
The EUROSTAR project was launched in July 1996 with the 
objective of collecting and analysing information prospectively on the 
results of endovascular treatment of abdominal aortic aneurysms. Patient 
characteristics, aneurysm morphology, operative data, postoperative 
outcome and clinical and imaging data at follow-up visits were collected 
on standardised Case Record Forms.9 The American Society of 
Anaesthesiology (ASA) risk classification and the Society of Vascular 
Surgery-International Society of Cardio-vascular Surgery (SVS-ISCVS) 
risk score were used to represent the patients risk profile.10,11 Follow-up 
examinations were performed at 1, 3, 6, 12, 18, 24 months and yearly 
thereafter.9 Reminders for overdue follow-up data were regularly sent to 
the participating institutions. Outcome reporting adhered to the guidelines 
from the Society for Vascular Surgery/American Association for Vascular 
Surgery (SVS/AAVS).12 Deaths were classified as aneurysm-related or all-
cause deaths.13 The latter included death related to co-morbidity and 
conditions unrelated to the aneurysm. Aneurysm-related deaths included 
30-day deaths and deaths that occurred as a result of aneurysm rupture, 
endograft infection or within one month after a secondary surgical 
procedure for late complications of the aneurysm.  
Other outcome events observed during follow-up included 
endoleak, migration, device kinking, stenosis/thrombosis and suture or 
stent breakage. Endoleaks were classified into type I, II, and III as 
described in previous reports.14,15 An endoleak is defined as a persistence 
of blood flow outside the lumen of the endograft but within the 
aneurysmal sac. Inadequate seal at the proximal or distal extremity of the 
stent-graft causes type I endoleak, whereas flow in the sac from side 
branch represents type II endoleak. Type III endoleak is midgraft 
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endoleakage originating either from fabric holes or inadequate seal 
between endograft components. In many analyses type I and III endoleak 
are considered combined, as these represent device-related endoleaks 
associated with an increased risk of AAA-rupture. In contrast, type II 
endoleaks are considered low-risk for rupture and do not pose an 
indication for urgent treatment. Surgical grafts are sutured in place 
proximally and distally, however stent-grafts are held in place by a 
combination of radial force (from the stent), hooks or barbs, and 
longitudinal support (stiffness).16 Failure of the fixation mechanisms may 
result in upward or downward migration of the stent-graft. Only 
migrations that were considered clinically significant by the physician 
were reported. The durability of endografts is determined by the 
occurrence of mechanical failure, which depends on both the structural 
properties of the device and the forces to which it is subjected. Possible 
complications of device failure include: angulation of the stent-graft 
(kinking), suture line, fabric tears, and stent breakage. Finally, occlusive 
problems, of the stent-graft limb or (rarely) the entire device have been 
reported, caused by stent-graft thrombosis or stenosis.  
 
Devices 
In this study data of patients treated for AAA by endovascular 
technique with the first generation stent-grafts (Stentor® and Vanguard®) 
between 1994 and 1999 in 62 European centres, who enrolled in the 
EUROSTAR registry, were analysed. The Stentor (Minimally Invasive 
Technologies, Mintec, La Ciotat, France) and the Vanguard stent-graft 
(Boston Scientific, Natick, MA, USA) were modular devices constructed 
from an externally placed, thin-walled dacron (polyester) graft covering a 
flexible self-expanding nitinol stent (Figure 1). The proximal end of the 
stent-graft was uncovered. It should be noted that this bare stent segment 
was much shorter than in modern stent-grafts, in which this part routinely 
provides suprarenal fixation. Fixation and sealing of the stent-graft was 
accomplished by a number of mechanisms, including compression fit, i.e. 
radial forces, exerted by the self-expanding stent, hooks and barbs.5,17,18 
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Data analysis 
Data were recorded on a computerised database. At the start of the 
study patients with maximal aneurysmal diameters of 40mm and larger 
were treated by endovascular surgery. However, the results from the UK 
Small Aneurysm Trial and the US Aneurysm Detection and Management 
Veterans Affairs Cooperative Study suggest that the risk of rupture in 
AAAs of less than 55mm does not justify surgery.19-21 Surgical repair 
should be withheld until the aneurysm reaches a diameter of at least 55mm 
or expands rapidly or develop symptoms For a better comparison with the 
outcome in series of more recently treated patients in whom large 
aneurysms were for more frequent, we have analysed the data in two 
groups stratified according to aneurysm size. The first group had an 
aneurysm between 40 to 55mm (small aneurysms) and the second group 
an aneurysmal diameter above 55mm (large aneurysms). The threshold of 
55mm was measured at the minor radius at the largest section of the 
aneurysm.  
 
Statistical analysis 
Incidence rates with 95% confidence intervals were determined to 
quantify the annual risk for developing a major complication. Life table 
analyses and log rank tests were used to compare outcome in the two 
study groups. Multivariate Cox models were used to determine whether 
Figure 1:  
Photograph of the Stentor bifurcated endograft. 
Note the longitudinal seam in the polyester fabric 
covering. The relative short segment of the bare 
stent at the top end was usually deployed distally 
of the level of the renal arteries. 
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aneurysm size was an independent risk factor for adverse outcome during 
follow-up, after adjustment for differences in patient-related and 
morphologic characteristics. Statistical significance was reached when the 
p-value was less than 0.05. The analysis of data was performed with SAS 
statistical software (version 8.00; SAS Institutes, Cary, NC, USA). 
Figure2: Event-free survival curves 
Log-rank p-value <0.0001 
Interval  Overall Small aneurysms Large aneurysms 
months N at risk 
Proportion 
free of 
events 
N 
at risk 
Proportion free 
of events 
N 
at risk 
Proportion free 
of events 
0 1190 0.961 581 0.979 609 0.944 
1 1144 0.961 569 0.979 575 0.944 
3 1114 0.953 559 0.971 555 0.936 
6 1103 0.913 554 0.934 549 0.893 
12 1049 0.892 528 0.917 521 0.869 
18 964 0.868 490 0.901 474 0.835 
24 886 0.824 463 0.872 423 0.775 
36 799 0.750 424 0.816 375 0.684 
48 639 0.681 348 0.749 291 0.614 
60 466 0.629 256 0.718 210 0.542 
72 329 0.576 186 0.663 143 0.488 
84 182 0.533 109 0.620 73 0.445 
96 88 0.480 57 0.561 31 0.396 
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RESULTS 
Study population and devices 
A total of 1190 patients, of which 1077 male, underwent EVAR 
with the first generation stent-grafts. The Stentor® device was used in 283 
patients, and 907 were treated with a Vanguard® stent-graft. The mean age 
was 71 years and over half of the patients (57%) were considered unfit for 
open surgery (Table 1). The mean aortic aneurysmal diameter was 56.2 
millimeter. 581 Patients had an aneurysm with diameter between 40 and 
55 millimeter.  In 609 patients the aneurysm was larger as 55millimeter. 
Patients with large aortic aneurysm (≥55millimeter) were older (mean 68.8 
vs. 72.3 years), had more frequently an ASA-class III or IV (48.5 vs. 
65.7%), diabetes (6.9 vs. 11.2 %), cardiac (47.3vs. 58.5%), carotid (13.3 
vs. 17.6%) and pulmonary (29.4 vs. 38.6%) diseases. Regarding the 
existing anatomic dimensions patients with large aneurysms had a higher 
incidence of significant angulation of the infra-renal neck (15.5 vs. 27.4%) 
and the iliac artery (33.0 vs. 37.7%). In addition the infra-renal neck was 
wider (mean 21.0 vs. 22.3 millimeter) and shorter (mean 28.8 vs. 27.2 
millimeter), and the distance between the lower renal artery and the iliac 
bifurcation was longer (mean 116.0 vs. 124.1 millimeter) in the large 
aneurysm group.  
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Interval  Overall Small aneurysms Large aneurysms 
Months N 
at risk 
Proportion free 
of AAA-death 
N 
at risk 
Months N 
at risk 
Proportion free 
of AAA-death 
0 1190 0.971 581 0 1190 0.971 
1 1155 0.971 573 1 1155 0.971 
3 1114 0.970 559 3 1114 0.970 
6 1112 0.964 559 6 1112 0.964 
12 1089 0.962 547 12 1089 0.962 
18 983 0.958 498 18 983 0.958 
24 908 0.955 469 24 908 0.955 
36 839 0.947 438 36 839 0.947 
48 696 0.928 369 48 696 0.928 
60 502 0.923 276 60 502 0.923 
72 354 0.923 194 72 354 0.923 
84 199 0.913 118 84 199 0.913 
96 94 0.883 60 96 94 0.883 
*Log-rank p-value <0.0001 
 
Figure 3: Freedom from aneurysm-related mortality 
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Table 1: Patient characteristics 
* Significant difference between patient with large (≥55mm) versus small aneurysms 
 
Early outcomes and complications 
The first-month mortality in the entire cohort was 2.9% (35 
patients). Significantly more patients died in the group with large 
aneurysms compared to small aneurysms (4.5% vs. 1.4%) (Table 2). 
 Study population 
Gender  
     Male 1077 (90.50%) 
     Female 113 (9.50%) 
Age (years) 70.55 ±  7.85 (43-93)* 
ASA >= 3 682 (57.31%)* 
SVS - ISCVS  
     Diabetes 108 (9.08%)* 
     Smoking 282 (23.70%) 
     Hypertension 612 (51.43%) 
     Hyperlipemia 405 (34.03%) 
     Cardiac status 631 (53.03%)* 
     Carotid disease 184 (15.46%)* 
     Renal status 169 (14.20%) 
     Pulmonary status 1406 (34.12%)* 
Obesity 256 (21.51%) 
Significant angulation (°)  
    Aortic neck 257 (21.60%)* 
    Aneurysm 122 (10.25%) 
    R Iliac 389 (32.69%) 
    L iliac 453 (38.07%)* 
Measurements (mm)  
D2 (neck diameter) 22.13 ± 2.66 (12-32)* 
D3 (AAA diameter) 56.25 ± 10.18 (40-110)* 
H1 (neck length) 27.97 ± 11.14 (7-100)* 
H3 (Length between renal artery and iliac bifurcation) 120.28 ± 18.15 (45-265)* 
Adjunct procedures 318 (26.72%)* 
Duration of Procedure (minutes) 155.03 ± 75.23 (28-785)* 
Follow-up (months) 38.53 ± 26.06 (0-96)* 
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Patients with a large aneurysm also underwent more often a conversion to 
open repair (2.3% vs. 0.7%). Intraoperatively device related complications 
including inability to deploy the device and device migration occurred in 
9.3% of the patients and arterial problems in 3.5%. These complications 
occurred significantly more in patients with aneurysm larger than 55mm. 
In 24 patients (2.0%) there was a failure to complete the endovascular 
procedure, i.e. conversion to open surgery, abandoning the procedure, or 
unplanned extra-anatomic bypass. This complication had no significant 
difference associated with aneurysm size. 
From operation to discharge systemic complications (cardiac, 
cerebral, pulmonary, renal, hepatobiliary, bowel and sepsis) were observed 
in 12.9% of the patients. Patients with large aneurysms suffered more 
frequently from these complications (15.9% vs. 9.8%). Minor 
complications, i.e. from the access sites and lower limb arteries occurred 
in 8.7% of the cases and were independent of the aneurysm size. 
Table 2 : Early (30-day) complications 
 Small aneurysms 
(N=581) 
Large aneurysms 
(N=609) 
P-value 
Final Completion angiogram    
     Endoleak 77 (13.25%) 101 (16.58%) NS 
           Type 1/3 endoleak 40 (6.88%) 65 (10.67%) .021 
           Type 2 endoleak 36 (6.20%) 31 (5.09%) NS 
Complications intraoperatively    
     Device related complications 43 (7.40%) 68 (11.17%) .026 
     Failure to complete procedure 8 (1.38%) 16 (2.63%) NS 
     Arterial complications 10 (1.72%) 32 (5.25%) .001 
Complications from operation to discharge    
     Systemic complications 57 (9.81%) 97 (15.93%) .002 
     Procedure & device related 14 (2.41%) 16 (2.63%) NS 
     Access site & lower limb complications 44 (7.57%) 59 (9.69%) NS 
Hospital Stay (days) 6.46±5.23 
(0-65) 
7.41±10.17 
(1-163) 
.045 
Early Death 8 (1.38%) 27 (4.43%) .002 
Early Conversion 4 (0.69%) 14 (2.30%) .023 
Early rupture - - - 
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Late outcomes and complications during follow-up 
The 1190 patients attributed to 3820 person-years of follow-up. 
Approximately in 20% of the patients, one of the annual follow up forms 
was not submitted. Late all-cause death, aneurysm-related death, 
conversion to open surgical repair, and aneurysm rupture occurred in 237 
(19.9%), 36 (3.0%), 84 (7.1%), and 29 (2.4%) of the patients, respectively. 
The annual incidence rate of all-cause death, aneurysm-related death, 
conversion and AAA-rupture per 100 patient years were 7.1 cases (CI: 5.7 
– 8.5), 1.9 cases (CI: 1.4 – 2.6), 1.6 cases (CI: 0.9 – 1.2) and 0.8 cases (CI: 
0.3 – 1.2), respectively. The complications with the highest incidence rate 
per 100 patient-years were endoleak (13.0 cases), stenosis/thrombosis (4.6 
cases), migration (4.3 cases) and suture breakage (4.0 cases). Secondary 
interventions were required with an annual incidence of 11.6 cases per 100 
patient years. Complications were treated most frequently by transfemoral 
reinterventions (8.7 cases per 100 patient years).  
Patients with large aneurysms had a significantly higher incidence 
rate per 100 patient years for all-cause death (0.097 vs. 0.049 cases; 
P<.0001), aneurysm-related death (0.028 vs. 0.010 cases: <.0001), 
conversion (0.034 vs. 0.020 cases; P=.007) and aneurysm rupture (0.012 
vs. 0.004 cases; P=.003), (Table III-IV). Endoleaks (14.9 vs. 11.3 cases 
per 100 patient-years; P=.020) and stenosis/thrombosis (5.7 vs. 3.7 cases 
per 100 patient-years; P=.013) occurred more frequently in patients with 
large aneurysms. This corresponded with a higher incidence of secondary 
interventions (13.4 vs. 10.1 cases per 100 patient-years; P=.007) in this 
study population. 
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Table 3: Annual incidence risk rates of the major complications for small 
aneurysms 
Major complication N 
Patient-years 
of  follow-up 
Annual 
incidence 
rate 
95% 
Confidence 
Interval 
Death    
     Overall 99 2029 0.049* 0.037 - 0.061 
     Procedure related 20 2029 0.010* 0.004 - 0.015 
Conversion  41 2029 0.020* 0.012 - 0.028 
AAA-rupture 8 2029 0.004* 0.000 - 0.007 
Endoleak 181 1598.92 0.113* 0.096 - 0.131 
     Type 1-3 endoleak 129 1883.42 0.068 0.054 - 0.083 
     Type 2 endoleak 72 1829.25 0.039 0.029 - 0.050 
Kinking stent-graft 63 1875.75 0.034 0.024 - 0.044 
Stenosis/Thrombosis 69 1881.92 0.037* 0.026 - 0.047 
Graft migration 74 1888.50 0.039 0.028 - 0.050 
Suture breakage 71 1874.75 0.038 0.027 - 0.048 
Stent breakage 12 2001.00 0.006 0.002 - 0.010 
Severe angulation 63 1908.50 0.033 0.023 - 0.043 
Secondary Intervention 170 1685.92 0.101* 0.084 - 0.118 
     Transfemoral intervention 132 1720.83 0.077* 0.062 - 0.091 
     Transabdominal intervention 39 2021.75 0.019 0.012 - 0.027 
     Extra-anatomic intervention 28 1969.83 0.014 0.008 - 0.021 
*Significant difference with large aneurysms after adjustment of differences in patient risk profile 
and morphologic characteristics. 
 
Analysis with a Cox proportional hazards model revealed that both 
age at operation and aneurysmal diameter were risk factors independently 
associated with an increased mortality and rupture rate during follow-up, 
while conversion to open repair was related with the aneurysmal diameter. 
The cumulative percentage of the combined outcome event conversion-
free-and-rupture-free-survival after 8 years follow up was 48.0% (56.1% 
in patients with small and 39.6% in large aneurysms, P<.0001), (Figure 2). 
The cumulative survival rate after 8 years was 63.1% (74.5% in the small 
and 49.6% in large aneurysm group, p<.0001). Freedom from aneurysm-
related death rate was 88.3% after 96 months (94.3% in small and 78.8% 
in patients with large aneurysms, P<.0001), (Figure 3). 
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Figure. 4c: Example of separation of the 
proximal bare stenting from a 
Vanguard endograft (black arrow). 
Note the buckling of the iliac limb 
(white arrow) caused by downward 
migration of the device body and 
upward migration of the iliac limb. 
Figure. 4 b: Illustration of the 
mechanism of fabric tearing. 
The apex of one of the internal 
stent zigs has perforated the 
polyester covering 
Figure. 4a: Explanted Vanguard device 
because of a type III endoleak caused 
by fabric tears 
Figure. 4 d: Arteriogram of a 
migrated proximal extremity of a 
Vanguard endograft (arrow 
indicated position after migration). 
Note the distorted course if the 
stent-graft. In this instance no 
endoleak could be identified. 
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Table 4: Annual incidence risk rates of the major complications for large 
aneurysms 
Major complication N Patient-years 
of  follow-up 
Annual incidence 
rate 
95% 
Confidence 
Interval 
Death     
     Overall 173 1791.58 0.097* 0.080 - 0.113 
     Procedure related 51 1791.58 0.028* 0.019 - 0.038 
Conversion  61 1791.58 0.034* 0.024 - 0.044 
AAA-rupture 21 1791.58  0.012* 0.006 - 0.018 
Endoleak 202 1351.50 0.149* 0.130 - 0.169 
     Type 1-3 endoleak 129 1593.08 0.081 0.066 - 0.096 
     Type 2 endoleak 81 1619.83 0.050 0.038 - 0.062 
Kinking stent-graft 70 1643.75 0.043 0.031 - 0.054 
Stenosis/Thrombosis 91 1603.50 0.057* 0.044 - 0.070 
Graft migration 79 1648.42 0.048 0.036 - 0.060 
Suture breakage 72 1676.92 0.043 0.032 - 0.054 
Stent breakage 15 1777.08 0.008 0.003 - 0.014 
Severe angulation 51 1711.08 0.030 0.020 - 0.039 
Secondary Intervention 194 1452.42 0.134* 0.115 - 0.152 
     Transfemoral 
intervention 149 1495.17 0.100* 0.083 - 0.116 
     Transabdominal 
intervention 46 1778.58 0.026 0.017 - 0.035 
Extra-anatomic 
intervention 37 1715.17 0.022 0.014 - 0.030 
*Significant difference with small aneurysms after adjustment of differences in patient risk profile 
and morphologic characteristics. 
 
DISCUSSION 
 A few studies have reported on the long-term follow-up of 
endografts for AAA. Following the era of prototypes the first industry-
produced endograft was manufactured by a company named Endovascular 
Technologies and marketed as the EVT®-graft. This company was 
subsequently acquired by Guidant. EVT®-grafts were of uni-piece 
configureuration with fixating stents, only at the top and the bottom ends. 
The EUROSTAR Registry did not include any prototype or self-
constructed devices, and the subgroup of EVT® was too small for a 
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meaningful analysis. The present report represents the long-term 
evaluation of results obtained from the collective experience of 62 
European centers with the first generation of modular, fully stent-
supported commercially available devices. Stentor®, produced by the 
company Minimally Invasive Technologies (MinTec; Freeport, Grand 
Bahama, Bahamas), was the first of this device configureuration, which 
formed the basis of all currently used stent-grafts. The “Mialhe Stentor-
B(ifurcated)”, as it was formally indicated, was designed by Claude 
Mialhe from Draguignan, France.22 Reports of postoperative “leaks” 
indicated by contrast filling of the aneurysm on CT-examination or 
angiography were reported from 1997.18,23 Defects in the thin polyester 
covering, were increasingly identified as causes of endoleaks in the 
Stentor®. The fabric was hand-sewed and had a seam in it (Figure 1). 
Suture line disruption and fabric tears because of impingement of a stent 
apex to the polyester, were recognised causes of device failure. The 
successor of the Stentor® was marketed by Boston Scientific (Natick, 
Massachusetts, USA) as the Vanguard® endograft. Although the fabric 
was changed into a more densely woven seamless polyester device 
deterioration continued to occur and ultimately resulted in the withdrawal 
of this device.  
Structural failure of the endovascular device constitutes an 
important cause of delayed failure of EVAR. The different failure modes 
can be discriminated into: (1) fabric tears and suture line disruption, (2) 
stent fractures caused by metal fatigueness leading to the break-down of 
the mechanical components, (3) disintegration of the stent frame, because 
of break-down of the polypropylene sutures connecting the different stent 
rows, (4) type I and III, graft-related, endoleaks are caused by insufficient 
fixation at the graft extremities or at the device modules. Too short 
overlapzones and insufficient oversizing, sometimes due to a limited range 
of available diameters, may add to these complications. In Figure 4 some 
of these complications are illustrated (fabric tears, stent row dislocation, 
iliac limb dislocation, iliac limb withdrawal). A detailed account of the 
failure modes of the Vanguard was provided in the literature.24,25 Many of 
the mechanisms of device failure have been recognised and responded to 
by the manufacturers. Improvement in corrosion resistance, one of the 
main causes of metal fatigueness, was achieved by a number of processes 
including electro-polishing and chemical etching of the metal surface.26 
Stronger fabrics are also being used and mechanisms have been found to 
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eliminate or reduce friction between components constructed of different 
materials. Therefore, there is optimism that this type of problem will be 
much less frequent in the current generation devices.34 
 The risk of adverse events in patients treated with the early 
generation of endografts is considerably higher than with modern devices. 
In the long-term over half of these patients will either die, experience a 
rupture of their aneurysm, or have a conversion to open repair. There was 
a distinct difference between patients with large and small aneurysms. 
Unfavourable anatomic characteristics were more frequently wider, 
shorter and severely angulated infra-renal necks. These findings result in 
unsuitability of many patients with an aneurysm of 55 millimeter or larger 
for endograft repair, compared to smaller aneurysms.27,28 With current 
stent-grafts, sealing and fixation can be achieved in aneurysms, which 
previously would be considered unsuitable for EVAR.29,30 The correlation 
of aneurysm size, applicability of EVAR and an increased operative risk 
has been documented previously.31,32  Intraoperative and early 
postoperative complications including systemic events, endoleak, primary 
conversion and first-month mortality rates all occurred significantly more 
frequently in the large aneurysm category. However, it is of note that the 
4.4% early mortality rate in the large-aneurysm group still compares 
favourably with the rate of 5 to 6%, associated with open surgery reported 
in many previous studies in which good and poor risk patients were 
combined.19,33,34 
 The most frequent complications reported during follow-up 
included endoleak, stenosis/thrombosis, endograft migration, and suture 
breakage, all of which occurred at a higher incidence in the large-
aneurysm group. This higher incidence is most likely due to a generally 
unfavourable anatomic condition in the large size category.35,36 The higher 
annual complication rate was also reflected in a higher incidence of 
secondary interventions. In a study of patients treated by current 
generation of stent-grafts aneurysm size was also identified as an 
independent predictor for secondary interventions.37 Secondary 
interventions in general, despite the fact that most are by transfemoral 
route, have a negative impact upon the quality-of-life of patients and the 
cost-effectiveness of EVAR. In a recent EUROSTAR-analysis the annual 
risk of secondary interventions in currently used stent-grafts was 3.7% in 
the entire cohort and 4.0% in the patients with large aneurysms, which 
compared favourably with the incidences in the present analysis.38 
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 The rates of mortality, conversion and AAA-rupture in the present 
study were significantly higher in patents with large aneurysms, and 
patients with advanced age. These findings were irrespective the brand of 
the device. In the AneuRx clinical trial, Zarins, et al. observed aneurysm 
rupture in 0.8%, aneurysm-related death in 0.7% and late conversion in 
3.2% of the patients during the follow-up period of six years.39 The lower 
mortality rate in Zarins’ study probably is the result of AneuRx belonging 
to the current device generation. Nevertheless, the conversion and the 
rupture rates were similar in the AneuRx and in the presently assessed 
cohort with first commercially available stent-graft generation.  
 Significant differences in major complications including aneurysm-
related death were observed between large and small aneurysm groups. 
After 8 years of follow-up the cumulative rate of the combined outcome 
event: conversion-free and rupture-free survival was 56.1% and 39.6% in 
patients with small and large aneurysms respectively. Freedom-from-
aneurysm-related death was observed in 94.3% and 78.8% in patients with 
small and large aneurysms. The long-term aneurysm-related mortality 
after open repair has not been assessed in a comparable way as after 
EVAR. However, Hallett et al. reported an overall survival rate of 72% 
after open surgery for AAA, of which only 2.6% of survivors of the 
operation died from graft-related operative complications.40 The 
cumulative survival after 8 years was 74 in the small-aneurysm group 
compared to 50% in patients with large aneurysms. A worse initial 
physiologic and morphologic status in this category likely caused this 
difference. Although, the potential advantage of EVAR seems to be 
smaller in patients with large aneurysms and more co-morbid factors, 
prevention from rupture in this category with an unfavourable natural 
history and a higher risk for open surgery, may still pose an excellent 
indication for EVAR.31,41 Finally, newer generation stent-grafts were also 
associated with similar high complication rates in patients with large 
aneurysms.35 
 Our study bears relevance also for patients with a small aneurysm. 
The 74%-survival rate in this category compared favourably with the long-
term outcomes in the UK Small Aneurysm Trial, in which this rate was 
59% in the early surgery group, and 51% in the surveillance group after 8 
years of follow-up.20 Recently, Zarins et al. considered on the basis of 
available literature data that EVAR in small aneurysms reduced the risk of 
rupture and aneurysm-related death and improved patient survival 
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compared to an initially conservative policy.42  Our long-term follow-up 
findings are in agreement with the conclusions of Zarins, and also support 
the recent initiatives for two trials (the PIVOTAL and the CAESAR trial) 
that will compare EVAR and an initially conservative approach in patients 
with small aneurysms.43,44 
 There are a number of disadvantages of a voluntary multicenter 
registry. The possibilities to collect a large amount of patient data in a 
relatively short period of time, to address upcoming questions and to 
evaluate long-term effectiveness are unique for a registry. Drawbacks 
include a larger interobserver variation, a lower accuracy and an 
incomplete dataset. Nevertheless, the patient population in a registry 
represents well the common day clinical practice. The EUROSTAR-
database constitutes the largest study group available at present with long-
term follow-up results. One-third of all Stentor® and one-sixth of all 
Vanguard®-devices ever placed in the world were included in this report. 
Despite the fact that the investigated endografts are no longer available, 
the long-term outcomes are highly relevant. In the first place, a large 
number of patients had operations with these devices in the past and need 
accurate aftercare. Second, the high annual incidents rate of complications 
after EVAR seem generalisable to some extent to the present situation.  
 In conclusion: patients treated with the first generation of stent-
grafts will need life-long surveillance, because of the risk of 
complications. This risk is particularly high in patients with large 
aneurysms at operation. Long-term effectiveness of endografts in current 
use has not been demonstrated yet.45 Vigilant surveillance is indicated in 
all patients after EVAR.   
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AIM: The purpose of this study was to evaluate the effect of the 
preoperative diameter of abdominal aortic aneurysms (AAA) upon the 
midterm outcome obtained by endovascular AAA repair, using a third-
generation endovascular device, the Excluder bifurcated endoprosthesis 
(W. L. Gore & Associates, Inc. Sunnyvale, CA, USA).  
METHODS: The data of 676 patients, who had undergone endovascular 
aneurysm repair (EVAR) were analysed. Patients were enrolled over a 6-
year period to April 2004 in the EUROSTAR database. Outcomes were 
compared between 2 groups defined by the preoperative diameter of the 
aneurysm: group A (n=300), smaller than 5.5 cm; group B (n=376), 5.5 
cm or larger. Patient characteristics, details of aorto-iliac anatomy, opera-
tive procedure and postoperative complications in the 2 patient groups 
were compared. Outcome events included aneurysm-related death, overall 
death, conversion, and late rupture of the aneurysm. Life table analyses 
and log rank tests were used to compare outcome in the study groups. 
Multivariate Cox models were used to determine whether baseline and 
follow-up variables were independently associated with adverse outcomes.  
RESULTS: Patients in group B were significantly older than patients in 
group A (73 years vs 71, years respectively; p=0.006), and more 
frequently were at higher operative risk (ASA-classification >3; 44% vs 
59%; p<0.0001). Anatomic differences included a higher incidence of 
aorto-iliac angulation, a wider and shorter infrarenal neck in group B. Risk 
factors that were more frequently observed in group B included 
hypertension, carotid disease and pulmonary disorders. Additional 
operative events including device migration occurred more frequently in 
group B (0% vs 2%; p=0.03). Device-related (type I and III combined) 
endoleaks were more frequently observed at completion arteriography in 
group B compared to group A (2% vs 4%; p=n.s.). Thirty-day mortality 
was comparable between the 2 study groups. However, the overall death 
rate after 3 years of follow-up was significantly higher in patients with 
larger aneurysms, group B (4% vs 14%; p=0.0025). Similarly, aneurysm-
related death was significantly higher in group B (after 3 years 0.3% vs 
3%; p=0.02). Aneurysm growth after EVAR was modestly low in both 
study groups (after 2 years 6% vs 8%; non-significant). There was no 
correlation between growth of the sac and aneurysm-related death.  
CONCLUSION: The midterm outcome after endovascular repair by 
Excluder devices was satisfactory in patients with small and large AAAs. 
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A higher rate in all-cause deaths and aneurysm-related deaths in patients 
with larger aneurysms was observed. Post-EVAR aneurysm growth was 
observed in a small percentage of patients but this did not contribute to 
aneurysm-related death.  
 
INTRODUCTION 
Endovascular repair represents a major innovation in the treatment 
of abdominal aortic aneurysms (AAA). Although the results of 
randomised trials are awaited, there is compelling evidence from case-
controlled and observational studies that endovascular repair is associated 
with shorter hospital stay, intensive care use and a lower incidence of 
major morbidity and mortality in the postoperative period compared to 
conventional surgery.
1-4 
In a recent EUROSTAR study 
5 
a comparison of 
outcomes of endovascular aneurysm repair (EVAR) was made between 
patients with small and large AAAs with 5.5 cm diameter as a threshold. 
This analysis demonstrated distinct differences in outcome in different 
size categories, with higher incidences of adverse events including 
aneurysm-related death in the large aneurysm category.
5 
However, 
protection from rupture by EVAR was still over 96% in large aneurysms. 
A second most surprising observation in this study was that EVAR in 
aneurysms smaller than 5.5 cm also appeared associated with a distinct 
protection-from-rupture. This conclusion was drawn from a comparison of 
the late outcome from EVAR and observed risk of rupture within a period 
of 6 years in initially conservatively treated patients.
6 
This favourable 
comparison for EVAR related to a very low mortality and morbidity in 
patients with small aneurysms. Thus, outcome of EVAR in small and large 
aneurysms are likely to be associated with significant improvements 
compared to a non-intervention policy. The objective of the present 
assessment is to report the outcome of EVAR in different size categories 
obtained by a third-generation endovascular device (the Excluder 
bifurcated endoprosthesis manufactured by W. L. Gore & Associates, Inc., 
Sunnyvale, CA, USA). Stratified outcome in patient groups with small and 
large aneurysms will be reported.  
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MATERIALS AND METHODS  
This report summarises the experience collated in the 
EUROSTAR-database with the Excluder bifurcated endoprosthesis (W. L. 
Gore & Associates, Inc., Sunnyvale, CA, USA). The data of 676 patients 
operated over a 6-year period until April 2004 constituted the basis of this 
analysis. The experience was obtained in 65 centers in Europe, the 
contributors to this series are listed in the front page. An account of the 
organisation of the EUROSTAR Registry and reports on various aspects 
after EVAR have been published previously.
7-9 
All patients had a minimal 
follow-up of 1 month. Patients with an aneurysm smaller than 4 cm in 
diameter, including those with large iliac aneurysms, were excluded from 
this study cohort.  
The use of the Excluder bifurcated endograft has been previously 
described in detail.
10 
Briefly, the Excluder endograft is a modular 
endovascular system composed of one trunk-ipsilateral piece and one 
contralateral leg piece (Figure 1). Additional aortic and iliac artery 
extension cuffs are available in similar sizes as the aortic and iliac 
endograft components, respectively. Each stent-graft is made of an 
expanded polytetrafluoroethylene (ePTFE) graft material bonded to the 
inside of a nitinol exoskeleton with ePTFE film. Each device comes in a 
delivery catheter which may be introduced over a 0.035 inch guidewire 
through an 18 French (for the major endograft component) and a 12 
French (for the contralateral iliac leg) sheath. Placement is guided by 
fluoroscopy and the identification of radio-opaque markers. Deployment 
of the device follows after pulling a deployment line, allowing rapid self-
expansion of the stent-graft. To assess the influence of aneurysm size on 
the early and mid-term outcome after EVAR the study cohort was 
subdivided according to the preoperative aneurysm diameter: group A 
with aneurysms smaller than 5.5 cm and group B with aneurysms of 5.5 
cm and larger. Inclusion criteria, as defined in the EUROSTAR registry 
protocol, comprised elective treatment for AAA and a vascular anatomy 
suitable for the implantation of a stent-graft. Baseline data, including co-
morbidity, estimate of unfitness for open repair,
11 
anatomic aspects and 
operative details were recorded by the participating institutions on case 
record forms and submitted for inclusion to the Data Registry Center. 
Findings at follow-up visits, which involved clinical examination, CT-
assessment or (in 5% of the visits) angiographic, MRI or ultrasound 
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follow-up studies were recorded in data forms and returned at regular 
intervals to the Data Registry Center for processing and analysis. There 
was no outside monitoring of centers or involvement of a core laboratory 
for the evaluation of CT-scanning or other imaging studies. Follow-up 
visits according to the protocol were scheduled at 1, 6, 12, 18 and 24 
months and annually thereafter. Reminders for overdue follow-up data 
were regularly sent to the participating institutions. Outcome reporting 
adhered to the guidelines from the Society for Vascular Surgery/American 
Association for Vascular Surgery (SVS/AAVS).
12 
Deaths were classified 
as aneurysm-related or overall deaths.
13 
The latter included death related to 
co-morbidity and conditions unrelated to the aneurysm. Aneurysm-related 
deaths included 30-day deaths and deaths that occurred as a result of 
aneurysm rupture, endograft infection or within 1 month after a secondary 
surgical procedure for late complications of the aneurysm.  
Other outcome events observed during follow-up included 
endoleaks, migration, severe device kinking, occlusion and aneurysmal 
growth. Only endoleaks that were identified at 1 month and thereafter 
were included in the analysis, while endoleaks at the completion 
angiography were not considered. Endoleaks were classified into type I, II, 
and III as previously described.
14 
In cases in which different types of 
endoleaks were observed at different follow-up periods, types I and III 
were considered above type II for the analysis. The interval between the 
date of surgery and the date on which the endoleak was identified for the 
first time, was used for the lifetable analysis.  
Aneurysmal growth was determined on the recording of an 
increase of the aneurysm diameter measured at its largest section from 
outer wall to outer wall across the minor diameter on the axial CT-slice. 
Aneurysmal enlargement was defined as a diameter increase of at least 8 
mm relative to the preoperative measurements on CT. The maximum 
recorded aneurysm diameter during follow-up was taken for this analysis.  
Results were reported as means, ranges and percentages of patients 
with discrete variables unless other wise specified. Preoperative patient 
characteristics, co-morbid factors, aneurysmal morphology at the time of 
the initial procedure and details regarding the procedure and devices were 
correlated with the defined study groups by univariate analysis. 
Differences in findings between study groups were assessed by χ
2 
tests for 
discrete variables and by Mann-Whitney tests for continuous variables. All 
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variables with a significant correlation with an adverse outcome event and 
variables appearing clinically related, including size classification, were 
entered in a multivariate Cox analysis to assess independent associations. 
A p-value <0.05 was considered to represent a significant difference. 
Cumulative rates of freedom-from-aneurysm-related deaths, overall 
deaths, aneurysm rupture, conversion to open repair, endoleaks and 
aneurysm growth were assessed by lifetable analysis. Significant 
differences between study groups were assessed by log-rank testing. All 
statistical analyses were performed with SAS Statistical Software (version 
8.00, SAS Institute, Inc., Cary, NC, USA).  
 
RESULTS 
The 676 patients, 626 male and 50 female, ranged in age from 43 
to 96 years. Average diameter of the aneurysm sac was 5.67 cm (4-10 cm) 
in minor dimension. Group A consisted of patients with aneurysm 
diameter of 4.87 cm (4-5.4 cm) (the 300 patients) and group B 6.32 cm 
(5.5-10 cm) (376 patients). Patients in group B were in average 1.6 years 
older, had more frequently an ASA-class III or IV, and had more 
frequently hypertension or carotid disease than in group A (Table 1). The 
difference in incidence on pulmonary co-morbidity did just not achieve the 
level of statistical significance. Regarding existing anatomy patients in 
group B had a higher incidence of significant angulation in the neck, the 
aneurysm, and the iliac arteries and in average a 0.5 mm wider infrarenal 
neck. In addition, the infrarenal neck was 2.5 mm shorter and the distance 
between the lower renal artery and the aortic bifurcation was 9.5 mm 
longer in group B.  
Operative time was 109 minutes in group A compared to 125 
minutes in group B (p<0.0001), (Table 2). Oversizing of the device by 
more than 20% at the level of the infrarenal neck was applied in 75 
patients (25%) in group A and in 102 (27%) in group B (n.s.). Device 
migration during the procedure as observed on the intraoperative 
angiogram, occurred in 6 patients (1.6%) in group B and in none of the 
patients in group A (p=0.03). No differences were observed with regard to 
the hospital length of stay, prevalence of endoleak and the incidence of 
primary conversion (Table 2). The 1
st 
month mortality in the entire cohort 
was 0.9% (6 patients). There was no significant difference in 1
st
-month 
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death rate in the 2 study groups. There were no significant differences 
with regard to systemic complications (cardiac, cerebral, pulmonary, renal, 
hepatobiliary, bowel and sepsis) in the 2 study groups. Minor 
complications from the access sites and lower limb arteries were similar in 
group A and group B (4% and 7.4%, respectively; n.s.). Arterial 
thrombosis occurred slightly more frequently in group B (1.4% vs 0%; 
p=0.04).  
 
Table 1: Demographic characteristics, co-morbidity and details of aorto-iliac 
anatomy in 676 patients 
 Aneurysm diameter 
Group A 
< 5.5 cm 
300 pts 
Group B 
> 5.5 cm 
376 pts 
p-value 
Age of patient (yrs) (range)  71.2 (43–92) 72.8 (49–96) 0.006 
Male  280 (93.3) 346 (92) n.s. 
ASA-class > III  132 (44.0) 223 (59.3) < 0.0001 
Unfit for surgery or 
anaesthesia (combin)  73 (24.3) 111 (29.5) n.s. 
Hypertension  185 (61.7) 259 (68.9) 0.049 
Carotid disease  41 (13.7) 97 (21.0) 0.01 
Pulmonary symptoms  125 (41.7 184 (48.9) 0.06 
       
Diameter of infrarenal neck  22.3 (12–30) 22.8 (18–34) 0.005 
Length of infrarenal neck  30.0 (8–130) 27.5 (10–75) 0.02 
Maximum diameter of 
aneurysm  48.7 (40–54) 63.2 (55–100) < 0.0001 
Length of lower renal 
artery to bifurcation  110.2 (40–210) 119.7 (50–190) < 0.0001 
Significant angulation of       
− Infrarenal neck  44 (14.7) 145 (38.6) < 0.0001 
− Aneurysma  22 (7.3) 61 (16.2) 0.0005 
− iliac artery right  83 (27.7) 155 (41.2) 0.0002 
− iliac artery left  97 (32.3) 166 (44.1) 0.002 
Figures indicate number of patients between parenthesis the % of size group is indicated, unless 
indicated otherwise. 
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Table 2: Procedural details and early complications in 676 patients 
 Aneurysm 
diameter 
Group A 
< 5.5 cm 
300 pts 
Group B 
> 5.5 cm 
376 pts 
p-value 
Anaesthesia       
− local  43 14.3 35  9.3 n.s. 
− regional  85 28.3 122 32.5 n.s. 
− general  172 57.3 219 58.2 n.s. 
Duration of procedure (min.)  109 (35–344) 125  (37–405) < 0.0001 
Hospital length of stay (days)  4.0 (0–52) 4.2 (0–22) n.s. 
Endoleak at completion 
arteriogram  
 24 (8.0) 41 (10.9) n.s. 
Device migration 
intraoperatively 
 0 (0) 6 (1.6) 0.03 
Primary (operative) 
conversion  
 1 (0.3) 1 (0.3) n.s. 
30-day Mortality   1 (0.3) 5 (1.3) n.s. 
Figures indicate number of patients. Between parentheses the % of size group is indicated, unless 
indicated otherwise. 
 
Mean duration of follow-up was 13.5 months (1 to 60 months), 
with 14.2 (1 to 60), and 19.9 (1 to 60) months of follow-up in groups A 
and B, respectively. The difference in follow-up period was not 
significant. The percentage of patients lost-to-follow-up after 3 years was 
considerable. In the entire cohort it was 42.5%, and in groups A and B 
40.2% and 44.5%, respectively (n.s.). Patient cumulative survival 
(freedom from all cause death) was 90.3% at 3 years. Group B had a 
significantly lower overall survival compared to group A at 3 years (86% 
vs 96%; p=0.0025). Multivariate analysis of risk factors for all-cause death 
demonstrated independent influence of large size aneurysm, advanced age 
and unfitness for open repair (Table 3).  
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Aneurysm-related death  
The freedom-from-aneurysm-related death in the entire study 
cohort was 98.2% crude rate at 3 years. Aneurysm-related death occurred 
in 1 patient in group A and 9 patients in group B, for a freedom-from-
aneurysm-related death at 3 years of 99.7% and 97% in these groups, 
respectively (p=0.024, Figure 2).  
A multivariate analysis of risk factors for aneurysm-related death 
was performed and included the following factors: large aneurysm, age of 
the patient, Follow-up (months) renal insufficiency, pulmonary 
insufficiency, unfitness for open repair, proximal/midgraft/distal 
(combined type I and III) endoleak, growth of the aneurysm. None of 
these variables had an independent association with aneurysm-related 
death (Table 3).  
 
Table 3: All-cause death. Outcome of multivariate analysis 
 Hazard 
ratio 
95% confidence 
intervals 
Aneurysm size, group B 2.9 1.2 – 6.7 
Age 1.05 1.0 – 1.1 
Unfitness for surgical aneurysm repair 2.6 1.2 – 5.6 
 
Aneurysm-related complications  
Rupture post-EVAR occurred in only 1 patient in this entire study 
cohort. This regarded a patient in group B. Late conversions were 
observed in 2 patients in group A and in 3 in group B (crude rates 0.7 and 
0.8; n.s.). Combined type I and III endoleaks (crude incidence in entire 
cohort 6%) had a higher incidence in group B (86.8% freedom-from-
endoleak at 3 years) compared to group A (89.3%, p=n.s.). When 
endoleaks were separated into type I proximal, distal and type III 
endoleaks patient numbers became too small for analysis of any 
differences. Dilatation of the infrarenal neck ≥4 mm (crude incidence in 
the entire cohort 13%) occurred at comparable cumulative rates at 2 years 
from EVAR in group A (35%) and group B (40%). Migration of the 
device at assessment during follow-up (crude rate 1%) had a cumulative 
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incidence of patients free-of-migration at 3 years of 85.7% in group A and 
95.1% in group B (p=n.s.). A shorter neck length constituted an 
independent risk factor for migration (HR 0.8, 95% CI 0.75-0.96), while 
aneurysm size, neck diameter, device oversizing >20% and neck dilatation 
during follow-up ≥4 mm were not associated.  
  
 
Growth of the aneurysm after EVAR was comparable in group A and 
group B with a cumulative incidence at 2 years of 6.4% and 8.2%, 
respectively (n.s., Figure 3). No risk factors for aneurysm growth during 
follow-up were identified among the following variables: larger size of the 
aneurysm, hypertension, smoking, any type of endoleak and migration of 
the device. 
 
Figure 2: Cumulative freedom-from-aneurysm-related death.   
Figure 1: Components of excluder bifurcated 
endograft. Main component, controlateral leg, 
aortic extender, and iliac extender 
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Figure 3: Cumulative proportion of patients with aneurysm growth after evar 
 
DISCUSSION AND CONCLUSIONS 
Short term benefits of EVAR compared to conventional open 
aneurysm surgery include a reduced blood loss at operation, shorter 
intensive care and hospital length of stay.
1-3, 15 
The advantages of EVAR 
are also well-documented in the present study in which over 40% of 
patients had their procedure performed under local or regional anaesthesia, 
over half had an ASA-class III or IV and the mean admission time was 
only 4 days. These outcomes re-emphasize that refinements in stent-graft 
design and technology, as are represented in the third endograft generation 
that was used in this study population, further diminishes the likelihood of 
early complications. For instance, an initial rate of 9% of endoleak, less 
than 1% device migration, and 0.3% primary conversion into open repair 
compare favourably with findings reported previously on patient cohorts 
including earlier device generations.
8 
 
Recently the size of the aneurysm has been indicated as a variable 
with strong influence on a variety of early and late outcome events.
5, 16, 17 
A threshold value of 5.5 cm as measured at the minor radius at the largest 
section of the aneurysm is considered the threshold discriminating small 
and large aneurysms. A similar study assessing the influence of aneurysm 
size was performed on the present patient cohort treated by a single last 
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generation stent-graft model. A typical pattern characterised by a higher 
incidence of co-morbidity and unfavourable anatomic characteristics in the 
large size category was observed in the present study as it was in the 
previous report. Systemic and device-related complications including 
endoleak, primary conversion and first month mortality did not differ 
between the size categories. However, intraoperative migration of the 
device was slightly more frequent in large aneurysms, illustrating the 
greater technical challenge of the associated more complex anatomy, 
which was associated with the large aneurysm category.  
Endoleak development during follow-up is to some extent device 
specific as observed in a previous EUROSTAR report.
9 
However, 
Excluder devices did not demonstrate more endoleaks than other currently 
used devices in this earlier study. In the present cohort, a crude incidence 
of type I and III endoleak of 6% compared favourably with a 12% 
incidence of endoleak in the previous EUROSTAR report including older 
and last generation models.  
We also found that late device migration was not influenced by the 
size category of the aneurysm. This had also been observed by 
Peppelenbosch et al.5 in a series including a variety of endografts. In 
addition endograft migration had no correlation with significant late 
dilatation of the infrarenal neck and oversizing of the endograft in excess 
of 20%. Other reports had suggested that these factors may be the cause of 
loss of fixation and seal of the endograft.
18, 19 
However, these findings 
could not be confirmed in the present study. The propensity for severe 
adverse events, such as proximal migration, may be device dependent, 
although this is speculative. Excluder devices differ from other stent-grafts 
in that they do not use suprarenal fixation. The correlation of different 
models with different proximal fixation systems was subject of an 
unpublished EUROSTAR study (J Buth. Is neck dilatation cause or result 
of stent-graft migration? Presented at the 8
th 
international symposium on 
critical issues in endovascular grafting. Malmø, Sweden, 11-12 May-
2004). No significant differences were observed between any of the 
currently or recently used endografts and the incidence of migration (1% 
in Excluder cohort as compared to 0.9% to 5.8% in other endografts, crude 
rates).  
Aneurysm shrinkage is generally considered an indicator of 
successful exclusion, while growth may be associated with insufficient 
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depressurisation of the aneurysm sac. A diameter change of 5 mm is 
considered significant, although in the EUROSTAR a threshold of 8 mm 
is used because of multiple readers of CT-studies.
5 
While endoleaks are a 
common cause of aneurysm growth, the concept of endotension, defined 
by most investigators as diameter increase without identified endoleak, is 
important as well.
20 
Excluder endografts may be associated with a lower 
incidence of aneurysm regression than some other types of endograft 
according to a recent study.
21 
In the present study we focussed on the 
observation of aneurysm expansion as it appears a more relevant measure 
than regression. Aneurysm growth may be a cause for concern, while 
unchanged or decreased diameters, which are present in the vast majority 
of patients after EVAR, are considered to represent the “normal” course.  
Aneurysm growth was not directly compared between different 
models of endografts in the present study. However, a previous assessment 
of growth in the overall EUROSTAR-population demonstrated a similar 
pattern compared to the Excluder specific growth profile. No difference 
was found in the proportion of patients with growth in small and large 
aneurysm categories. The overall cumulative proportion with growth 
demonstrated a modest difference between Excluder and the overall 
EUROSTAR cohort with an increase from 8% to 19% in the Excluder 
group at 3 years, compared to an increase from 12% to 19% in the 4
th 
year 
in the overall EUROSTAR group. The clinical significance of this finding 
is unclear at this time.  
The all-cause mortality in the present study was significantly 
higher in category B with as independent risk factors a large diameter 
aneurysm, the patient’s age and unfitness for open aneurysm repair. The 
latter variables are clearly related to pre-existent co-morbidities. With 
regard to aneurysm-related death no clinical or anatomic factors were 
found in the multivariate regression model to correlate with this event. A 
similar analysis in the overall EUROSTAR cohort demonstrated a variety 
of variables including the presence of proximal type I endoleak and 
aneurysm growth, to correlate with aneurysm-related death. The absence 
of a similar observation in the present analysis is reassuring with regard to 
the clinical significance of aneurysm growth in a proportion of patients. 
Intra-sac pressure measurement which can now be performed by remote 
technique, seems an interesting tool to further study this phenomenon. 
However, at this time a standard schedule including regular CT-scanning 
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and plain abdominal X-ray studies seem sufficient for patient and 
aneurysm surveillance.  
The need for secondary interventions was not addressed in the 
present study of patient treated by Excluder endografts. In a previous 
published multicenter study the incidence of reinterventions was 7% in the 
1
st 
and 7% in the 2
nd 
year of follow-up.
4 
This compared favourably with 
18% secondary intervention with the first 14 months of follow-up which 
was observed in a previous EUROSTAR assessment of older and last 
generation devices combined.
22 
Finally, as a weakness of the present study 
a loss to data registration of approximately 40% of the patients after 3 
years of follow-up was disturbing. However, standard errors by lifetables 
were still below 10% indicating a robust data set.  
In conclusion, in this device-specific assessment a higher rate of 
all-cause death and aneurysm-related death was observed in patients with 
larger aneurysms. Post-EVAR growth was observed in a small percentage 
of patients, but this did not seem to contribute to aneurysm-related death.  
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BACKGROUND: The objective of this study was to assess the 
prevalence of and the correlation between dilatation of the infrarenal neck 
and proximal device migration after endovascular abdominal aortic 
aneurysm repair (EVAR). The analysis made use of the EUROSTAR 
registry. 
 
METHODS: Between 1994 and 2004, 4,233 patients with an abdominal 
aortic aneurysm larger then 4 cm underwent EVAR. Only patients with 
available follow-up data regarding neck size and device position were 
included in this assessment. Chi-square and t-tests or Wilcoxon rank sun 
tests were used for comparison of discrete and continuous variables, 
respectively. Time-dependent variables were evaluated by log-rank tests. 
In addition, multivariate analysis was performed to determine anatomic 
and operative variables with an independent correlation with neck growth 
and device migration, respectively. In addition, the association with 
proximal endoleak was assessed.  
 
RESULTS: Neck dilatation and proximal migration were found in 1,342 
(32%) and 192 (4.5%) of the 4,233 patients, respectively. One hundred 
twelve patients (2.5%) had neck dilatation and migration of the proximal 
device extremity. The correlation between proximal migration and neck 
dilatation was statistically significant (p < .0001). Other independent 
variables for migration were a wider neck and aneurysmal diameter, 
shorter necks, proximal endoleak, and absence of suprarenal fixation. 
Neck dilatation was predicted by narrow necks, use of devices with 
suprarenal fixation, and larger device diameters. Proximal endoleak 
occurred in 136 (3.2%) patients and was significantly associated with 
shorter, angulated necks and proximal migration.  
 
CONCLUSION: The present study documented that migration may be 
caused by neck dilatation. However, neck dilatation was not significantly 
promoted by proximal migration. Other factors, such as dimensions of the 
neck, the device fixation system, and perhaps progressive wall 
degeneration, are also likely to play a role in the pathogenesis of neck 
dilatation. To obtain good results from EVAR, accepted criteria of neck 
dimensions should be adhered to.  
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INTRODUCTION 
It is now understood that the configureuration of the aortoiliac 
vascular anatomy may change significantly after endovascular abdominal 
aortic aneurysm repair (EVAR). One of the morphologic changes concerns 
an increase in the diameter of the infrarenal neck. Late neck dilatation may 
be caused by a number of mechanisms, including continued aneurysmal 
degeneration of segments adjacent to the aneurysm, shortening of the neck 
in case of incomplete aneurysm exclusion with expansion of the sac, and 
radial force exerted by the proximal fixation stent.  
The position of the implanted endograft may also be subject to 
changes during follow-up. This may either be in response to progressive 
enlargement of the aneurysm neck or independently of this. Migration of 
the proximal stent-graft, because of destabilized fixation, is an important 
complication of EVAR, with recognized associations with late aneurysm 
rupture, proximal endoleak, graft kinking, and graft limb thrombosis.1,2  
Movement of the endograft occurs when the displacement forces 
on the endograft exceed the strength of fixation at the proximal attachment 
zones (Figure 1A). With early generations of endografts, migration was a 
frequent event, the incidence of which increased progressively with time. 
The cumulative rate of migration in these older series was a high as 75% 
after 7 years of follow-up.3,4  
The present report is based on an assessment of the EUROSTAR 
database (European Stent-graft Treatment of Abdominal Aortic 
Aneurysms Registry) and has the objective of studying the prevalence of 
aneurysmal dilatation, proximal migration of the stent-graft, and the 
correlation between these two phenomena. In addition, the occurrence and 
associations with proximal endoleak at follow-up are assessed. The 
implications of these findings for postEVAR surveillance are discussed 
(Figure 1B).  
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Figure 1: A, stent-graft migration (black arrow). B, example of neck dilatation 
with proximal endoleak (white arrow).   
 
METHODS 
This report summarizes the experience collated in the EUROSTAR 
database with the data of 4,233 patients operated on over a 10-year period 
between 1994 and 2004, constituting the basis of this analysis. The 
experience was obtained in 147 centers in Europe. Patients with an 
aneurysm with a diameter smaller than 4 cm at baseline were excluded 
from this study cohort (including those in whom a large iliac aneurysm 
presented the primary indication for the stent-graft procedure). In addition, 
patients whose neck diameters on less than two occasions were measured 
or who were without data on whether the device had migrated were 
excluded from analysis. Only migration of the proximal stent-graft was 
considered for this analysis. This selection involved checking the free text 
fields of case record forms with recorded migration to distinguish 
proximal from distal extremity stent-graft migration and component 
dislocation. 
Methods of data collection and analysis by EUROSTAR have been 
described.2,5–7 Baseline data, including comorbidity, an estimate of 
unfitness for open repair, anatomic aspects, and operative details, were 
recorded by the participating institutions on case record forms and 
submitted for inclusion to the data registry center. The influence of 
differences in stent-graft fixation modes was analyzed as follows. Two 
 
A B 
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main categories were distinguished: devices with suprarenal fixation or 
hooks (Talent  (AVE/Medtronic, Santa Rosa, Calif, USA), Zenith 
(William Cook Europe, Bjaeverskov, Denmark, Lifepath (Edwards, Irvine, 
CA, USA), EVT/Ancure (Guidant Endovascular Technologies, Menlo 
park, CA, USA), and others) and devices without suprarenal fixation or 
hooks (Vanguard (Boston Scientific, Natick, MA, USA), Stentor (MinTec, 
La Ciotat, France), AneuRx (AVE/Medtronic, Santa Rosa, Calif, USA), 
and Excluder (W.L. Gore, Flagstaff, AZ, USA)). In this latter category, 
Vanguard and Stentor devices were included because their proximal bare 
stent portion was short compared with those in modern systems. In 
addition, at the time in which the Stentor and Vanguard devices, as first 
early-generation devices, were in use, the bare stent portions were most 
frequently deployed distal to the renal artery orifices.  
The findings at follow-up visits, which involved clinical 
examination, computed tomography (CT), or (in 5% of the visits) 
angiographic, magnetic resonance imaging (MRI), or ultrasound follow-up 
studies, were recorded on data forms and returned at regular intervals to 
the data registry center for processing and analysis. In addition, plain 
abdominal radiograph studies were performed at 1 month, at 1 year, and 
annually thereafter. No outside monitoring by a core laboratory was used 
of CT, angiographic, MRI, or plain abdominal radiograph studies. Since 
2002, all data transmission has been by the Internet (KIKA Medical 
Communications, Nancy, France).  
Growth of the infrarenal aneurysm neck was determined on the 
recording of an increase in the diameter measured 3 mm distally from the 
lower renal artery. The measurement was performed from the outer wall to 
the outer wall across the minor diameter on the axial CT slice. Growth of 
the aneurysm neck was defined as a diameter increase of at least 4 mm 
relative to the preoperative measurements on CT. The maximum recorded 
neck diameter during follow-up was taken to identify neck expansion. 
Patients who experienced neck dilatation at the first- or third-month 
follow-up visit were excluded from this analysis because this early 
enlargement might have been due to immediate postoperative deployment. 
Since the preoperative and early postoperative neck diameters were 
comparable (23.4 ± 3.0 mm vs 23.7 ± 2.9 mm), the preoperative 
measurement was considered to provide an accurate representation of neck 
behaviour during follow-up. The diagnosis of migration was based entirely 
on the judgment of the management team of individual patients. Although, 
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in the majority of cases, details regarding the site of the migration were 
provided on the follow-up form, the extent of the migration could not be 
included in the analyses because this was rarely quantified in millimeter 
device displacement. The majority of centers have used regular CT 
examination to determine whether migration occurred. In 42% of the 
patients, the clinical significant migration was confirmed by radiography.  
Standard statistical methods were used as in previous EUROSTAR 
studies.5–7 Chi-square tests were used for comparison of discrete variables, 
t-test, or Wilcoxon rank sum test for continuous variables. Multivariate 
Cox proportional hazard model was used to determine anatomic and 
operative variables, with an independent correlation with neck growth and 
device migration, respectively, as the outcome event.  
 
RESULTS 
The 4,233 patients, 3,967 (93.7%) male and 266 (6.3%) female, 
ranged in age from 37 to 101 years. The average diameter of the aneurysm 
sac was 5.8 cm (4–11 cm) in minor dimension. Patient subgroups 
categorized according to general or systemic factors, morphologic factors, 
and procedural or device-related factors are represented in Table 1.  
Of the entire patient cohort, 2,804 patients had neither neck 
dilatation nor device migration. Neck dilatation without migration was 
observed in 1,237 patients. Of the 1,342 patients with neck dilatation, 105 
(7.8%) had a migration, whereas in the 2,891 patients without neck 
dilatation, device migration occurred in only 87 (3.0%) cases. The 
correlation between migration and dilatation of the neck was statistically 
significant (p < 0.0001). To further examine the relationship between these 
two phenomena in the study, the relationship in time was assessed in the 
105 patients who had dilatation and migration (Figure 2). The proportion 
in which neck dilatation preceded the migration was 38%, migration was 
identified first in 23%, and dilatation and migration were felt at the same 
follow-up visit in 39%. All migrations of the proximal stent-graft 
extremity were downward, and no upward migration with the fabric of the 
stent-graft covering the renal arteries was reported. 
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Table1: Demographic characteristics and morphologic and procedural details 
in 4,233 patients 
 Characteristics Number of Patients (%) 
General and systemic factors   
 Gender 3,967 (93.7) 
 Hypertension 2,634 (62.2) 
 Smoking 983 (23.2) 
Morphologic factors   
 Neck length, mm (mean ± SD (range)) 27.6 ± 12.7 (5–130) 
 Neck diameter, mm (mean ± SD (range)) 23.4 ± 3.0 (12–40) 
 Significant neck angulation 969 (22.9) 
 Aneurysm diameter, mm (mean ± SD (range))  57.6 ± 10.5 (40–110) 
 Device to neck diameter ratio ≥ 1.20 1,072* (28.6) 
Procedure and device-related factors   
 Use of aortic extension cuff 134 (3.2) 
 Absence of proximal bare stent fixation  1,787 (42.2) 
 Intraoperative proximal endoleak 119 (2.8) 
* N=3753 
 
To examine the independent influence of clinical variables, a 
number of general clinical, morphologic, and procedural or device-related 
factors were entered into the multivariate Cox model (Table 2). Neck 
dilatation had a positive correlation (occurred more frequently) when the 
proximal oversizing was 20% or greater and with increasing device main 
diameter. A negative correlation (less frequent neck dilatation) was 
observed with a larger baseline neck size and a device category that had 
no suprarenal bare stent or hook fixation (see also the first footnote to 
Table 5). Most importantly, migration, when entered as a variable in the 
model, had no statistical influence on the occurrence of neck dilatation.  
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Figure 2: Findings regarding neck dilatation and device migration in 4,233 
patients. Relationship with time of identification of these findings. 
 
Similarly, a multivariate analysis with device migration as an 
outcome event using the same variables demonstrated a weak but negative 
influence of hypertension and a positive association of neck diameter, 
aneurysm diameter, proximal endoleak, and absence of a suprarenal 
fixation system (Table 3). A shorter neck length was associated with an 
increased tendency to migration. Finally and most importantly, neck 
dilatation had an independent statistically significant promoting effect on 
the occurrence of device migration.  
 
 
Only neck dilat.
1237 patients
Only migration
87 patients
Dilatation
& Migration
105 patients
Dilatation & Migrat
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First migration
24 patients
First neck dilatation
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Table 2:  Risk factors of dilatation (n = 1,342), multivariate cox analysis of 
4,233 patients 
Risk Factors Hazard 95% Confidence p-value 
Hypertension 0.95 0.85–1.07 .43 
Smoking 1.10 0.96–1.25 .19 
Neck diameter 0.84 0.81–0.86 < .0001 
Aneurysm diameter 1.00 0.99–1.01 .41 
Neck length 0.99 0.99–1.00 .08 
Neck angulation 1.03 0.90–1.18 .64 
Device to neck diameter ratio ≥ 1.20 1.34 1.17–1.54 < .0001  
Device main diameter 1.12 1.09–1.16 < .0001 
Use of aortic extension cuff 1.24 0.85–1.80 .27 
Intraoperative proximal endoleak 0.82 0.54–1.26 .37 
No suprarenal fixation system or hooks 0.58 0.51–0.66 < .0001 
Proximal endoleak 1.04 0.75–1.44 .81 
Device migration  0.90 0.72–1.11 .3 
All indicated variables were entered into the multivariate model. Hazard ratio, confidence interval, 
and p- value are presented only for variables with a significant correlation. 
 
Table 3: Risk factors of migration (n = 192), multivariate cox analysis of 4,233 
patients 
Risk Factors Hazard 95% Confidence p-value 
Hypertension 0.73 0.55–0.98 .03 
Smoking 1.24 0.90–1.72 .19 
Neck diameter 1.10 1.04–1.16 .001 
Aneurysm diameter 1.005 1.001–1.009 .02 
Neck length 0.98 0.97–0.99 .004 
Neck angulation 0.96 0.68–1.36 .83 
Device to neck diameter ratio ≥ 1.20 1.29 0.80–2.08 .30 
Device main diameter 1.09 0.98–1.22 .13 
Use of aortic extension cuff 0.38 0.09–1.53 .17 
Intraoperative proximal endoleak 1.64 0.80–3.36 .17 
No suprarenal fixation system or hooks 2.12 1.51–2,97 < .0001 
Proximal endoleak 3.66 2.26–5.93 < .0001 
Infrarenal neck dilatation 1.49 1.09–2.03 .01 
All indicated variables were entered into the multivariate model. Hazard ratio, confidence interval, 
and p-value are presented only for variables with a significant correlation. 
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Proximal endoleaks were observed at one or more follow-ups visits 
(endoleaks within the first month were not counted) in 136 patients. In a 
multivariate model with the same variables indicated in Tables 2 and 3, an 
independent correlation with proximal endoleak was observed for device 
migration, neck angulation (both variables had a positive correlation), and 
neck length (negative association) (Table 4).   
The various endograft types and devices categorized according to 
the presence of suprarenal fixation or anchoring hooks were compared in a 
univariate analysis with the frequency of the three outcome events (Table 
5). From this table, it can be noticed that suprarenal fixation does not 
protect better from dilatation of the neck or proximal endoleak (see also 
the first footnote to Table 5) but does provide better protection against 
device migration than no suprarenal fixation. Moreover, from the lower 
frequencies of adverse findings, it appears that the Excluder device 
performs as well as devices with suprarenal fixation.  
 
Table 4: Risk factors of proximal endoleak (n = 136), multivariate cox analysis 
of 4,233 patients 
Risk Factors Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
Hypertension 1.25 0.83–1.87 .28 
Smoking 0.96 0.61–1.52 .87 
Neck diameter 1.04 0.90–1.19 .63 
Aneurysm diameter 1.00 0.99–1.01 .66 
Neck length 0.97 0.95–0.99 .0043 
Neck angulation 2.02 1.37–2.99 .0004 
Device to neck diameter ratio ≥ 1.20 0.97 0.48–1.56 .63 
Device main diameter 1.01 0.89–1.14 .93 
Use of aortic extension cuff 0.91 0.28–2.88 .87 
No suprarenal fixation system or hooks 0.75 0.48–1.15 .18 
    
Infrarenal neck dilatation 0.85 0.55–1.31 .45 
Migration 3.11 1.83–5.30 < .0001 
All indicated variables were entered into the multivariate model. Hazard ratio, confidence interval, 
and p-value are presented only for variables with a significant correlation. 
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Table 5:  Comparison of different device brands with neck dilatation, device 
migration, and proximal endoleak at follow-up in 4,233 patients  
 Device Brands Number of 
Patients 
% with 
Dilatation 
% with Proximal 
Migration 
% with 
Proximal 
Endoleak 
With suprarenal fixation or 
hooks 
2,446 30* 2.5† 3.4‡ 
 Talent 892 31 3.9 3.7 
 Zenith 1,185 33 0.9 2.0 
 Lifepath  63 21 4.8 4.7 
 EVT/Ancure 142 16 1.4 9.1 
 Others§ 
 
164 23 6.0 6.1 
Without suprarenal fixation 
or hooks 
1,787 34* 7.3† 2.9‡ 
 Vanguard/Stentor 646 42 10 3.7 
 AneuRx 672 36 8.3 3.1 
 Excluder 469 20 1.7 1.7 
*Chi-square p = .02; hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.51 to 0.66, adjusted p 
< .0001 The predictive value of the absence of suprarenal fixations in relation to the three 
outcome events was calculated in terms of HR. Adjustment occurred for SVS-ISCVS  (Society for 
Vascular Surgery-International Society for CardioVascular Surgery) risk scores and anatomic and 
device measurements. Note a “reversal” in the relationship between suprarenal fixation and 
dilatation when correction occurs for follow-up time. In the table above (representing crude 
incidences), the absence of suprarenal fixation and hooks is associated with more frequent neck 
dilatation. However, when adjusted for other variables, an association with a lower incidence of 
dilation was observed. This is due to the fact that devices without suprarenal fixation have a 
longer follow-up time. 
†Chi-square p < .0001, HR 2.12, 95% CI 1.51 to 2.97, adjusted p < .0001. 
‡Chi-square p = not significant, HR 0.75, 95% CI 0.48 to 1.15, adjusted p = not significant. 
§Including Fortron, Anaconda, Endologix, and homemade devices. For 16 patients, the device 
brand was unknown.  
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DISCUSSION 
Neck dilatation has been described as a continuous process by 
several investigators.8–10 In a provoking article, May and colleagues 
presented evidence to suggest that endografts positioned correctly 
immediately below the renal arteries may protect the infrarenal aortic 
segment from further dilatation in a manner that does not occur after open 
repair of AAA.11 In the present study, the association of several factors 
with proximal neck dilatation after EVAR has been assessed, including 
smoking, an initially wide-size neck, large stent-graft diameters, and the 
absence of suprarenal or hook fixation. The influence of smoking could 
not be established in our study. In addition, large-diameter aneurysms and 
aneurysm sac expansion have been linked to shortening of the infrarenal 
neck. Cao and colleagues found significant dilatation of the infrarenal 
neck in 20% of patients with a positive correlation with wide preoperative 
necks, mural thrombus in the neck, and large-diameter aneurysm.12 It is 
difficult to explain why we found the opposite association with narrower 
necks correlating with dilatation during follow-up. No correlation with 
neck dilatation in their and our analysis was found with regard to neck 
angulation, neck length, and early endoleak. Nevertheless, in Cao and 
colleagues’ experience, significant proximal neck dilatation was a 
harbinger of risk because 20% either had a proximal extension cuff or a 
conversion and 13.8% demonstrated device migration. This compared 
unfavourably with the 2.0% of nondilators who had a cuff or conversion 
and 0.8% who had a migration. 
Mohan and colleagues indicated increased systolic blood pressure, 
reversed conical infrarenal necks (increase in diameter from proximal to 
distal), and significant angulation of iliac arteries as significant downward 
displacement forces.13 Although, in our analysis, neck dilatation was a 
predictor of device migration, a large proportion demonstrates no adverse 
consequences from widening of the neck. This may be due to 
improvements in graft design and technology, including increased radial 
force provided by self-expanding stents, hooks, barbs, and, most 
importantly, suprarenal fixation. Another factor that has impacted 
favourably on the issue of proximal migration is the tendency of 
interventionalists to oversize the stent-graft relative to the proximal neck 
by 15 to 20% than the rather 5 to 10% advocated originally. When 
commercial devices became available, the incidence of migration of the 
proximal stent (defined as 5 mm of distal movement) decreased to 3.0%, 
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and in a recent study relating to a second-generation endograft, evidence 
of clinically significant migration was observed in just 1.0% of cases at 2 
years after operation.13,14 
Opinions about the mechanisms of late migration vary. Some 
authorities have reported progressive enlargement of the aneurysm neck 
and claim that this may destabilize fixation. We also found a positive 
correlation between proximal migration and neck dilatation. Patients with 
larger aneurysms appear to be at a significantly higher risk from neck 
dilatation.12,15 However, this observation was not confirmed in the 
multivariate analysis in the present study, suggesting interaction from 
other factors, such as progressive wall degeneration. There is agreement 
that careful patient selection excluding patients with necks that are 
excessively angulated or too short and accurate placement of the graft 
adjacent to the renal arteries help minimize the risk of distal 
migration.11,15,16 As a general principle, maximal overlapping of all 
healthy tissue until the anatomic boundaries of the renal arteries 
proximally should be the aim.  
The increased incidence of proximal migration with some of the 
older-generation endografts, such as the Stentor, Vanguard, and AneuRx 
devices, emphasizes the importance of a strong proximal fixation system. 
This observation should not be understood as a plea for the use of too wide 
proximal endografts because excessive endograft oversizing (> 20% 
diameter) may accelerate the process of neck dilatation and thereby 
perhaps migration according to Sternbergh and colleagues.17 The same 
investigators found that angulation did not correlate with migration, which 
was similar to our observation. 
There are reasons to suspect that migration can lead to a sudden 
loss of “seal,” with immediately disastrous consequences. Therefore, it is 
advised that secondary intervention, usually by placement of an extension 
cuff, should be undertaken sooner rather than later, when migration has 
been identified. The observed correlation of migration and proximal 
endoleak development was expected. Endograft-related endoleak is a 
significant predictor of aneurysmal rupture and conversion.18 Thus, 
vigorous endograft surveillance may prevent aneurysm-related death by 
identifying endograft migration.19 Vigorous surveillance, including CT 
scanning and plain abdominal radiography according to a standardized 
protocol, are proven methods to detect migration.20,21  
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Weaknesses of this study include the following. The CT technique 
used for assessing whether device migration had occurred was not uniform 
between centers. For instance, the interval between CT slices was not 
recorded and may have differed between institutions. For this reason, the 
extent of the migration was not quantified in this assessment. We consider 
this simplification of the recorded data set inherent in the methods used in 
large-scale registries and essential to retain user compliance. The outcome 
of these databases relies on large cohorts rather than very uniform 
measurements, such as in institutional series. In this regard, migration in 
this report must be interpreted as “clinically significant device migration” 
instead of a fixed threshold displacement distance. The early postoperative 
diameter has been recommended as a reference measurement,16 although 
the preoperative neck width continued to be used in some reports.22 We 
chose to use the preoperative value as a baseline measurement because 
this was measured in all patients, whereas early postoperative diameter in 
a proportion was measured at variable time intervals from the procedure. 
To avoid a disturbing effect of an initial postoperative dilatation of the 
neck, perhaps caused by the stent-graft procedure, patients with early 
dilatation ≥ 4 mm were deleted from the database. This resulted in a 
comparable mean diameter of the neck pre- and early postoperatively in 
the study cohort, whereas the measured dilatation of the neck most likely 
occurred during the follow-up period. In the present study, findings in the 
plain abdominal radiograph study did support CT-based findings of 
migration relative to the level of the renal arteries. However, using bony 
landmarks, plain abdominal radiograph studies can be used only as 
reliable indicators of proximal stent-graft migration when they are 
performed in a rigorously standardized way, which is not routine in most 
institutions.23 For this reason, the CT findings were used as the prime 
indicator of migration. 
In conclusion, the present study documented that migration may be 
caused by neck dilatation. However, other factors, most notably neck size, 
length, and the device fixation system, perhaps together with progressive 
wall degeneration, are also likely to play a role. To obtain acceptable 
results with EVAR, accepted criteria of neck dimensions should be 
adhered to.  
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OBJECTIVE: To evaluate the influence of the infra-renal neck length on 
clinical outcome after endovascular abdominal aortic aneurysm repair 
(EVAR). 
 
SUMMARY BACKGROUND DATA: An important variable 
determining whether a patient can successfully undergo EVAR is the 
infra-renal neck length. In the initial period of EVAR, it was generally 
considered that at least 15 mm of non-aneurysmal vessel proximal to the 
aneurysm was needed for secure graft fixation. More recently, the 
threshold has been relieved to a minimum of 10 mm by some device 
companies. 
 
METHODS: Data from patients enrolled in the EUROSTAR registry 
between January 1999 and April 2005, with detailed morphologic data 
recorded, were analyzed. The study cohort was divided into three groups 
according to infra-renal neck length: >15 mm (group A, reference), 11-15 
mm (group B), and ≤10 mm (group C). Uni- and multivariate analyses 
were performed to evaluate differences in clinical outcome between the 
study groups. 
 
RESULTS: Of the 3897 enrolled patients, 3164, 525 and 208 individuals 
were categorized into group A, B and C, respectively. After correction for 
confounders, proximal type I endoleak at completion of the angiogram 
occurred in 10.6% of group C compared to 2.4% of group A (Odds Ratio C 
vs. A=4.50, 95% Confidence Interval=2.67–7.57). Within 48 months of 
follow-up, the incidence of proximal endoleaks was higher in groups B 
(8.5%) and C (10.3%) compared to group A (3.2%) (Hazard Ratio B vs. 
A=1.83, 95% Confidence Interval=1.08–3.11 and Hazard Ratio C vs. A=2.16, 
95% Confidence Interval=1.09–4.26).  
 
CONCLUSIONS: Our study indicates that endovascular treatment of 
abdominal aortic aneurysms with infra-renal neck length shorter than 15 
mm is associated with significantly increased risk of short- and long-term 
proximal endoleaks after EVAR. The greater risk of proximal endoleaks 
should be weighed against the risks of alternative treatment modalities. 
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INTRODUCTION 
 Abdominal Aortic aneurysm (AAA) is a serious vascular disorder 
in which the abdominal aorta becomes permanently dilatated to at least 1.5 
times its normal diameter. The normal size of the abdominal aorta is about 
20 mm. The prevalence of AAA has increased rapidly during the last 
decade, and aneurysmal rupture is now the 13th most common cause of 
death in the Western world.1 Risk factors for AAAs are advanced age, 
male gender, family history, atherosclerosis, smoking, hypertension, 
diabetes and previous vascular surgery.2 
 Traditionally, aneurysms are treated by open surgical repair. This 
involves exposure of the abdominal aorta, aortic and iliac clamping, and 
replacement of the aneurysmal segment with a prosthetic graft. 
Endovascular treatment of abdominal aortic aneurysms introduced at the 
beginning of the 1990s was a significant step in vascular surgery. This 
technique uses an endoprothesis, which is delivered through the femoral or 
iliac artery to exclude the aneurysm from the circulation. Endovascular 
repair has significant advantages over conventional surgery. First, it is a 
much less invasive technique than the traditional operation; this is of 
major importance for patients with coexistent diseases, who would be at 
high risk with conventional surgery. Second, with endovascular treatment 
operative trauma, blood loss and disturbance of hemodynamics and 
ventilation is minimal. And third, since the introduction of this 
endovascular technique, length of hospital stay and recovery have been 
reduced significantly, from approximately ten to three days for hospital 
stay and from six weeks to eleven days for recovery time.3-5 Following the 
initial successful application of stent-graft treatment by Parodi et al. in 
1991, the technical feasibility and the short-term effectiveness to exclude 
AAA from the circulation have been reported in several studies.6-10 
The applicability of endovascular abdominal aortic aneurysm 
repair (EVAR) depends on aorto-iliac morphology.11 Adverse anatomy of 
the iliac arteries usually can be overcome by an adjunctive procedure. An 
important variable determining whether a patient can successfully undergo 
endovascular treatment of an AAA is aneurysm neck anatomy, including 
infra-renal neck length. The infra-renal aortic neck extends from the most 
caudal main renal artery to the onset of the aneurysm (Figure 1).12-17 In the 
initial period of EVAR, it was generally considered that at least 15 mm of 
non-aneurysmal vessel proximal to the aneurysm was needed for secure 
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graft fixation. However, as new improved endovascular devices became 
available and the experience increased, EVAR was applied to a broader 
spectrum of patients and selection of particular devices that best suit the 
anatomy of individual patients took place. More recently, the threshold of 
infra-renal neck length has been relieved to a minimum of 10 mm by some 
device companies. Nevertheless, failure to connect a particular part of the 
device to the aortic wall may result in inferior outcome.18 Problems 
encountered with short infra-renal neck length include type I endoleak, 
graft migration, thrombosis of the renal arteries, renal or distal 
embolization, and hemorrhage from excessive manipulation or 
overdilation.18,19  
The EUROSTAR registry was launched with the objective to 
include a large number of patients with EVAR within a limited time span. 
It was expected that this registry might provide rapid answers on clinical 
questions, while at the same time reflecting existent practice patterns. The 
large number of patients included in this registry provides the possibility 
to analyze infrequently occurring events that occurred as a consequence of 
breached or evolved accepted guidelines, or due to the non-vigorous 
selection of patients and institutions.  
  The purpose of the present study was to determine the relation 
between infra-renal neck length and short and long-term outcomes after 
EVAR with third generation stent-grafts (Talent and Zenith).  
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Figure 1: Kaplan meier curves of the absence of proximal endoleak during 
follow-up for the three study groups stratified by the infra-renal neck length. 
Group A: infra-renal neck length >15 mm, group B: between 11 and 15 mm, 
group C: ≤ 10mm 
Number of patients at risk for each time interval 
Time Period (months) 1 3 6 12 18 24 36 48 
N at risk group A 3164 2462 2250 2072 1627 1183 921 493 
N at risk group B 525 408 372 347 261 187 137 67 
N at risk group C 208 156 149 136 111 86 75 40 
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METHODS 
Study design 
The EUROpean collaborators on Stent-graft Techniques for 
Abdominal aortic aneurysm Repair (EUROSTAR) registry was launched 
in 1996. In this voluntary multi-centre registry, patients with a non-
ruptured asymptomatic AAA planned for elective endovascular surgery 
were prospectively enrolled.20 The study population represented patients 
from 165 European institutions (Appendix 1).  
Enrolment forms were submitted to the data registry before the 
operation to prevent selective patient inclusion. For every patient, 
collaborators completed a case record form (CRF) which was submitted to 
the data registry center. In the CRF, the patient risk profile, anatomic 
characteristics, operative details, intraoperative complications, and 
complications from operation until discharge were recorded. Regular 
follow-up data were recorded at 1, 3, 6, 12, 18 and 24 months and 
annually thereafter. Adverse events reported during the follow-up period 
were endoleaks, migration, kinking, occlusion, aneurysmal rupture, 
conversion and death. Outcome reporting adhered to the guidelines of the 
Society for Vascular Surgery/American Association for Vascular Surgery 
(SVS/AAVS).21 Team experience was defined as at least 30 EVAR cases 
per year. Since September 2003 the registry database was available online 
(www.eurostar-online.org, KIKA Medical, Nancy, France), and patient 
data could be entered online by each participating physician. Reminders 
for overdue follow-up data were regularly sent to the participating 
institutions. Eventually, complete follow-up data was obtained in 71% of 
patients.  
 
Study population 
In this study, patients with an aneurysm diameter larger than 40 
mm, treated with Talent (Medtronic Vascular, Santa Rosa, CA, USA) or 
Zenith (Cook, Indianapolis, IN, USA) endoprotheses were included. Only 
the Talent and Zenith stent-grafts were selected because they both use 
transrenal fixation and gradual deployment. Excluded devices for this 
analysis were the Excluder (W. L. Gore & Associates, Inc. Sunnyvale, 
CA, USA) and AneuRx (Medtronic Vascular, Santa Rosa, CA, USA) 
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because they differ in fixation and deployment modes. By this selection 
confounding by device type was avoided.  
Patients were categorized into three groups according to the infra-
renal neck length: patients with an infra-renal neck length >15 mm (group 
A), an aneurysm neck length between 11 and 15 mm (group B), and with a 
proximal neck length of ≤10 mm (group C).  
 
Statistical analysis 
 Comparison of patient, morphologic, and center-related 
characteristics between the three infra-renal neck length groups was 
performed using Chi-square tests and Wilcoxon’s rank sum tests for 
categorical and continuous variables, respectively. As a conservative 
approach, all variables which differed significantly between the three 
groups according to these univariate analyses were considered potential 
confounders, and therefore included as covariates in multivariate outcome 
analysis. Logistic multivariate regression analysis was performed for early 
complication (i.e. occurring within 30 days) and odds ratios (OR) with 
corresponding 95% confidence intervals (CI) were calculated. For late 
outcome measures (1-48 months), multivariate Cox proportional hazard 
models were fitted, and hazard ratios (HR) with corresponding 95% CI 
were presented. P-values less than 0.05 were considered statistically 
significant. All statistical analyses were performed using SAS software 
(version 8.0, SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Study population  
Of 3897 enrolled patients, 3164 patients had an infra-renal neck 
length >15mm (group A), 525 patients between 11 and 15 mm (group B), 
and 208 patients 10 mm or less (group C). Univariate analysis of baseline 
variables (Table 1) revealed significant differences in patient risk profile, 
anatomic and center-related characteristics between the three groups. 
Significant differences in risk profile between groups A, B and C were 
observed for: ASA-class ≥ 3, hypertension, hyperlipedemia, renal and 
pulmonary impairment, and unfitness for open surgery or general 
anaesthesia. Anatomic characteristics that were unequally distributed 
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between the groups were infra-renal neck diameter, aneurysmal diameter 
and severe angulation of the aortic neck. Team experience also differed 
between the groups. 
 
Table 1: Patient, morphologic and center-specific characteristics 
 Group A 
N (%) 
Group B 
N (%) 
Group C 
N (%) 
P-value 
Age (mean (SD)) 72.8  (7.8) 73.4 (7.3) 72.1 (7.4) NS 
Male Gender 2969 (93.8) 495 (94.3) 200 (96.1) NS 
ASA-class ≥ 3 1523 (48.1) 290 (55.2) 127 (61.1) <.0001 
Diabetes 429 (13.6) 67 (12.8) 36 (17.3) NS 
Smoking 750 (23.7) 135 (25.7) 52 (25.0) NS 
Hypertension 2079 (65.7) 350 (66.7) 159 (76.4) .006 
Hyperlipidemia 1469 (46.4) 208 (39.6) 89 (42.8) .011 
Cardiac impairment 1977 (62.5) 323 (61.5) 141 (67.8) NS 
Carotid disease 611 (19.3) 91 (17.3) 40 (19.2) NS 
Renal impairment 629 (19.9) 133 (25.3) 55 (26.4) .002 
Pulmonary impairment  1351 (42.7) 251 (47.8) 112 (53.8) .0003 
Previous Laparotomy 817 (26.0) 146 (28.2) 53 (25.6) NS 
Unfit for open surgery or 
general anesthesia 
922 (29.1) 164 (31.2) 86 (41.3) .0001 
Anatomic Measurements     
     Infra-renal neck diameter 
(mean (SD)) 
24.5 (3.3) 24.8 (3.3) 25.5 (3.6) <.0001 
     Aneurysm diameter (mean 
(SD)) 
59.5 (11.3) 60.9 (11.8) 61.6 (11.5) .002 
Severe angulation     
     Aortic neck 680 (21.5) 141 (26.9) 56 (26.9) .007 
     Aneurysm 365 (11.5) 46 (8.8) 20 (9.6) NS 
Iliac aneurysm (comm. or int.) 407 (12.9) 59 (11.2) 16 (7.7) NS  
Team experience 
(>30cases/year) 
1359 (43.0) 250 (47.6) 114 (54.8) .0009 
Group A: infra-renal neck length >15 mm (N=3164), group B: between 11 and 15 mm (N=525), 
group C: ≤10 mm (N=208) 
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Early complications  
 The proportion of proximal endoleak at the completion of 
angiography or within the first 30 days after surgery was 10.6% in group 
C compared to 2.4% in group A (adjusted odds ratio (OR)=4.50, 95% 
confidence interval (CI)=2.67 – 7.57) (Table 2). Compared to group A, 
reinjection from sidebranches occurred less frequently in group C 
(adjusted OR=0.41, 95% CI=0.21 – 0.81). No significant difference in any 
endoleak rate was observed between group B and group A. Intraoperative 
complications and complications before discharge occurred in similar 
proportions in the three study groups, except for arterial complications 
which occurred in 7.2% of group C compared to 3.4% of group A 
(adjusted OR=2.02, 95% CI=1.14 – 3.57).  
 Conversion to open surgery was rarely needed in any of the three 
study groups (0.8, 0.6 and 1.0% in groups A, B, and C respectively). The 
30-day mortality rate was higher in groups B (4.8%) and C (4.3%) 
compared to group A (2.5%), although the difference between group C 
and A did not reach statistical significance (Table 2).  
 
Complications during follow-up  
 The follow-up duration in the three groups A, B and C was 
comparable (median 12 months). Proximal type I endoleak occurred 
significantly more frequently in patients with shorter necks (B, C) 
compared to group A (hazard ratio (HR) B vs. A=1.83, 95% CI=1.08 – 3.11) 
and HR C vs. A=2.16, 95% CI=1.09 – 4.26) (Table 3). At 48 months of 
follow-up, 91% of patients in group B and 90% in group C were free from 
proximal endoleaks, compared to 97% of patients in group A; the 
difference was statistically significant (Figure 1). Systemic complications 
occurred significantly more frequently in group C than in group A 
(HR=1.73, 95%CI=1.10 – 2.73). No other differences in outcome of 
device migration, kinking, stenosis, and secondary interventions were 
observed between the three groups.  
No differences between groups were observed with respect to the 
rates of late conversion to open repair or rupture rate. Only 1 patient 
(0.2%) had a post-EVAR rupture in group B and none in group C, 
compared to 12 (0.4%) of the patients in group A. After correction for 
potential confounders the occurrence of late death was similar in groups 
 160
A, B and C. Aneurysm-related death during follow-up also occurred in 
similar proportions in the three study groups; 0.5% in group A, 0.8%in 
group B, and none in group C.   
 
Table 2: Early complications (0-30 days) 
 Group A 
N (%) 
Group B 
N (%) 
Group C 
N (%) 
OR* 
(95%CI)Bvs.A 
OR* 
(95%CI)Cvs.A 
Complications 
intraoperatively 
     
     Device related      
complications 
135 (4.3) 26 (5.0) 13 (6.2) 1.12 
(0.72 – 1.73) 
1.35 
(0.74 – 2.44) 
     Failure to complete 
procedure 
51 (1.6) 8 (1.5) 5 (2.4) 0.99 
(0.28 – 3.45) 
1.87 
(0.42 – 8.39) 
     Arterial complications 106 (3.4) 18 (3.5) 15 (7.2) 0.96 
(0.57 – 1.60) 
2.02 
(1.14 – 3.57) 
Complications from 
operation to discharge 
     
     Systemic complications 346 
(11.0) 
76 (14.6) 32 (15.4) 1.28 
(0.97 – 1.68) 
1.32 
(0.89 – 1.97) 
     Procedure & device 
related 
101 (3.2) 9 (1.7) 7 (3.4) 0.50 
(0.25 – 1.01) 
0.91 
(0.42 – 2.01) 
     Access & lower limb 
complications 
196 (6.2) 30 (5.8) 17 (8.2) 0.89 
(0.59 – 1.32) 
1.13 
(0.66 – 1.93) 
Endoleak      
      Proximal 75 (2.4) 17 (3.2) 22 (10.6) 1.33 
(0.77 – 2.28) 
4.50 
(2.67 – 7.57) 
      Midgraft  64 (2.0) 6 (1.1) 3 (1.4) 0.56 
(0.24 – 1.29) 
0.70 
(0.22 – 2.27) 
      Distal 51 (1.6) 4 (0.8) 2 (1.0) 0.43 
(0.15 – 1.19) 
0.48 
(0.11 – 1.98) 
      Reinjection from 
sidebranches 
348 
(11.0) 
51 (9.7) 10 (4.8) 0.92 
(0.67 – 1.26) 
0.41 
(0.21 – 0.81) 
Conversion to open repair 25 (0.8) 3 (0.6) 2 (1.0) 0.62 
(0.19 – 2.09) 
1.13 
(0.26 – 4.87) 
Death 78 (2.5) 25 (4.8) 9 (4.3) 1.71 
(1.06 – 2.74) 
1.48 
(0.71 – 3.07) 
Group A: infra-renal neck length >15 mm (N=3164), group B: between 11 and 15 mm (N=525), 
group C: ≤10 mm (N=208) 
* Adjusted for ASA-class≥3, hypertension, renal and pulmonary impairment, unfitness for open 
surgery or anesthesia, maximal aneurysmal diameter, infra-renal neck diameter, angulation and 
team experience. 
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Table 3: Complications during follow-up (1-48months) 
 Group A Group B Group C   
 N Failure  
within 48 
months of 
follow-up 
N Failure  within 
48 months of 
follow-up 
N Failure  within 
48 months of 
follow-up 
HR* (95%CI) 
B vs. A 
HR* (95%CI) C 
vs. A 
Findings at 
assessment 
        
     Proximal 
endoleak 
59 3.2%  18 8.5% 10 10.3% 1.83 
(1.08 – 3.11) 
2.16 
(1.09 – 4.26) 
     Midgraft 
endoleak 
92 5.5% 12 3.4% 1 0.7% 0.81 
(0.44 – 1.47) 
0.15 
(0.02 – 1.11) 
     Distal 
endoleak 
64 3.8% 5 1.2% 6 6.5% 0.46 
(0.18 – 1.14) 
1.18 
(0.51 – 2.74) 
     Reinjection 
sidebranches 
302 15.2% 41 13.8% 14 12.0% 0.82 
(0.59 – 1.14) 
0.70 
(0.41 – 1.19) 
     Kinking 
stent-graft 
37 2.6% 2 3.6% 0 - 0.34 
(0.08 – 1.42) 
- 
     Stenosis 94 4.9% 13 3.4% 7 4.5% 0.82 
(0.46 – 1.47) 
1.02 
(0.47 – 2.22) 
     Graft 
migration 
27 2.5% 6 2.7% 2 1.9% 1.39 
(0.57 – 3.39) 
0.94 
(0.22 – 3.99) 
Systemic 
complication 
180 10.4% 37 14.4% 22 20.5% 1.29 
(0.90 – 1.84) 
1.73 
(1.10 – 2.73) 
Secondary 
intervention      
        
Transfemoral 103 6.5% 12 5.1% 8 11.0% 0.73 
(0.40 – 1.33) 
1.06 
(0.51 – 2.19) 
     Trans- 
abdominal 
21 1.9% 5 4.5% 1 0.7% 0.55 
(0.58 – 4.13) 
0.69 
(0.09 – 5.19) 
     Extra-
anatomic 
30 1.0% 7 2.3% 2 0.9% 1.32 
(0.58 – 3.02) 
0.86 
(0.20 – 3.64) 
AAA growth ≥ 
8 mm 
153 19.8% 24 18.8% 9 13.9% 1.11 
(0.72 – 1.72) 
0.77 
(0.39 – 1.52) 
Conversion to 
open repair 
20 2.5 4 2.4 1 5.3 1.39 
(0.47 – 4.11) 
0.70 
(0.09 – 5.25) 
Death  187  21.3 36 20.8 22 30.4 1.17 
(0.82 – 1.67) 
1.37 
(0.88 – 2.14) 
AAA-related 
death 
16 1.9 4 1.8 0 - 1.44 
(0.48 – 1.34) 
- 
Group A: infra-renal neck length >15 mm (N=3164), group B: between 11 and 15 mm (N=525), 
group C: ≤10 mm (N=208) 
* Adjusted for ASA-class≥3, hypertension, renal and pulmonary impairment, unfitness for open 
surgery or anesthesia, maximal aneurysmal diameter, infra-renal neck diameter, angulation and 
team experience. 
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DISCUSSION 
In the present study, patients with an infra-renal neck length of 10 
mm or less had 2.2 times more risk to develop a proximal endoleak within 
4 years of follow-up compared to patients with a neck length of more than 
15 mm.  
This finding is relevant because the proportion of patients with 
AAAs for whom treatment by EVAR is considered suitable has risen from 
a reported 20% in the early experience of this technique to 45% to 80%.22-
24 Adverse anatomy of the infrarenal neck of the aneurysm used to be the 
predominant reason for exclusion from EVAR candidacy. The generally 
accepted guideline was that an infra-renal neck length of at least 15 mm 
was needed for secure graft fixation. More recently, however, a threshold 
of 10 mm has been stipulated as sufficient to produce an adequate sealing 
zone for stent-graft positioning.  
Similar examples of guidelines that have been challenged over 
time are the treatment of selected patients with high-risk for open 
procedures, infra-renal necks wider than 30 mm and with some 
thrombus.25,26 Patients treated with these characteristics had similar 
outcomes after EVAR compared to patients where the guidelines were 
adhered to.  
In the present report we discuss post-operative outcome in patients 
with shorter necks than the recommended 15 or 10 mm treated with the 
third generation stent-graft. Results show that, after adjustment for 
potential confounders, the risk of type I proximal endoleak increased 
significantly with decreasing infra-renal neck length. The odds of 
suffering of a proximal endoleak at one month was 4.5 times higher when 
the neck length was 10 mm or less (group C), than in patients with neck 
length over 15 mm (group A). Reinjection from side branches within 30 
days post-surgery occurred less frequently in patients of group C 
compared to group A. A possible explanation for this difference is the 
decreased occurrence of iliac aneurysms and severe angulations in the iliac 
arteries in group C. The 30-day death rate was higher in patients with 
necks shorter than 15 mm (groups B and C combined) compared to group 
A. This supports the findings of Hovsepian et al.15 who found that a short 
proximal neck was a significant risk factor for more intra-, postoperative 
complications and death.  
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During long term follow-up (4 years), the hazard of suffering from 
a proximal endoleak was 1.8 and 2.2 times higher in group B (11-15 mm) 
and C (≤10 mm), respectively, than in A (>15mm). Stanley et al.12, who 
used the zenith endograft, found an increased risk of proximal endoleaks 
in patients with infra-renal neck length less than a threshold of 20mm. In 
the present study, patients in group C (≤10 mm) also suffered from 
systemic complications more frequently, presumably due to their worse 
physiologic status at baseline. 
Strengths of the present study are the large sample sizes and the 
long periods of follow-up. One possible limitation relates to the potential 
selective patient inclusion into the voluntary registry. To prevent such 
selective inclusion, enrolment forms were submitted 24h before operation 
to the EUROSTAR data registry center. Furthermore, data collected in a 
multicenter registry may suffer from relatively large inter-observer 
variation, and limited data monitoring. Theoretically, these factors could 
result in non-differential misclassification and lead to an underestimation 
of differences between the infra-renal neck length groups.  
In an ongoing effort to overcome some of the problems with an 
inadequate infra-renal neck, fenestrated stent-grafts have been suggested 
as an alternative treatment option for patients with neck lengths shorter 
than 15 mm. The incidence of endoleaks reported when using this 
technique is exceptionally low.27,28 However, also in this case, it will 
remain critical to follow the status of stented visceral vessels, and to 
establish the long-term efficacy of this type of repair. The most important 
adverse events associated with fenestrated endovascular grafts are renal 
problems.29 Furthermore, regular stent-graft use is simpler and less 
demanding for the high-risk patients who are included in the short neck 
category. Comparative studies between patients with short infrarenal 
necks treated with fenestrated endografts versus regular stent-grafts will 
be needed to shed more light on possible advantages and disadvantages of 
this new technique.  
In conclusion, our results indicate that endovascular treatment of 
abdominal aortic aneurysms with infra-renal neck length shorter than 15 
mm is associated with significantly increased risk of short- and long-term 
proximal endoleak development after EVAR. The greater risk of proximal 
endoleaks should be weighted against the risks of alternative treatment 
modalities.  
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What Determines and Are the 
Consequences of Surveillance Intensity 
after Endovascular Abdominal Aortic 
Aneurysm Repair? 
 
Lina J. Leurs, MSc, Robert J.F. Laheij, PhD, and Jaap Buth, MD. 
Ann Vasc Surg 2005; 19(6): 868-75. 
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BACKGROUND: Follow-up examinations are advised 1, 3, 6, 12, 18, 
and 24 months and yearly thereafter by the European Collaborating Group 
on Stent-Graft Techniques for Abdominal Aortic Aneurysm Repair 
(EUROSTAR).  
 
AIM: The aim of this study was to evaluate the determinants and 
consequences of surveillance completeness.  
 
METHODS: Patients who underwent endovascular abdominal aortic 
aneurysm repair between October 1996 and August 2004 and enrolled in 
the EUROSTAR registry were analyzed. Two groups were compared: 
patients who attended all scheduled visits (group A) and those who came 
infrequently (group B). Odds ratios and hazard rates (HRs) with 95% 
confidence intervals (CIs) were determined to detect which patient 
characteristics and complications were associated with follow-up intensity.  
 
RESULTS: Of the 4,433 patients, 1,538 (35%) attended all scheduled 
visits until the end of follow-up (group A). Analysis of patient 
characteristics demonstrated that intensive visitors were more often 
smokers, hyperlipemic, and considered unfit for open surgery or general 
anaesthesia. Complications during follow-up, including endoleaks (24% 
vs. 20%), kinking (3.5% vs. 2.5%), and migration (4.9% vs. 3.5%), 
appeared significantly more frequently in group A. Despite intensive 
follow-up of this category, still a greater proportion died (12% vs. 9%, 
adjusted HR = 1.5, 95% CI 1.2-1.8). After 84 months of follow-up, the 
cumulative survival rates in groups A and B were 71% and 74%, 
respectively (p < 0.0001).  
 
CONCLUSIONS: It seems that follow-up intensity was based on baseline 
patient characteristics. High-risk patients had, despite more intensive 
surveillance, still more complications after adjustment for patient, 
morphological, and center-specific characteristics. Further assessment is 
indicated to evaluate the effectiveness of different frequencies of 
surveillance visits. 
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INTRODUCTION 
Endovascular repair of abdominal aortic aneurysm (AAA) has 
become an accepted alternative to open surgery. The minimally invasive 
nature of this technique appears to be an advantage, especially for patients 
who have severe comorbidities.1,2 Follow-up examinations are generally 
recommended after the endovascular treatment of AAA to assess whether 
the aneurysm remains excluded from the circulatory system or late 
expansion and eventual rupture occurs. At surveillance visits, changes that 
may not cause clinical symptoms, such as endograft stenosis, endoleak, 
migration, and kinking, can be detected. On the basis of findings at 
surveillance, additional procedures may be indicated. 
Follow-up examinations are advised by the European 
Collaborating Group on Stent-Graft Techniques for Abdominal Aortic 
Aneurysm Repair (EUROSTAR) at 1, 3, 6, 12, 18, and 24 months and 
yearly thereafter.3 This follow-up intensity was arbitrarily chosen in 1996 
when the collaborative database started. Since the initial EUROSTAR 
protocol, computed tomographic angiography (CTA) has become the most 
frequently applied investigation for diameter assessments as well as for 
identifying endoleaks. Also often used as a preoperative examination is 
intra-arterial digital subtraction angiography (IA-DSA). Occasionally, 
magnetic resonance imaging (MRI) or intravascular ultrasound (IVUS) is 
used. Duplex ultrasound scanning (DUS) examination is considered by 
some to be a reliable method to replace CTA.4 Since complications can 
become manifest at any period of time after the treatment, regular 
surveillance is necessary.5-7 In the literature, different intensities of follow-
up visits can be observed between different studies or hospitals.7-9 The 
incidence of complications appears comparable between different 
surveillance schedules.7,9,10 Thus, little information exists about how often 
patients should be examined during follow-up and the impact of this 
intensity on patient outcomes. The aim of this study was to evaluate the 
effect of compliance to the follow-up protocol as recommended by 
EUROSTAR. 
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PATIENTS AND METHODS 
EUROSTAR is a multicenter observational study (registry), in 
which patients receiving stent-graft treatment with different types of 
commonly used device for AAA are recruited. The project was launched 
in July 1996 with the objective of collecting and analyzing data on 
endovascular repair of AAA (EVAR). Patient characteristics, risk factors, 
aneurysm morphology, operative technical and procedural details, 
incidence of complications and major events (death, rupture, and 
conversion to open repair), and follow-up information were collected by 
means of standardized EUROSTAR case record forms. Since 2002, all 
data transmission has occurred by internet connection (KIKA Medical 
Communications, Nancy, France). The study cohort represented patients 
from 155 European institutions (see Appendix 1). Patients were treated 
with commercially available, Communauté Européenne (CE)-approved 
devices from different companies such as Talent (AVE/Medtronic, Santa 
Rosa, CA), Excluder (W.L. Gore, Flagstaff, AZ), Zenith (William Cook 
Europe, Bjaeverskov, Denmark), AneuRx (AVE/Medtronic), Fortron 
(Cordis, Waterloo, Belgium), and Lifepath (Edwards, Irvine, CA). Follow-
up visits, which involved clinical examination, CT, angiogram, MRI, or 
DUS assessment, were prescribed at 1, 3, 6, 12, 18, and 24 months and 
annually thereafter.3 Reminders for overdue follow-up data were regularly 
sent to the institutions participating in the project. 
Complications during the follow-up period included endoleaks, 
kinking, migration, stenosis, and thrombosis of the stent-graft; secondary 
interventions; conversion; AAA rupture; and death. The diagnosis of 
complications was based on the judgment of the management team for 
individual patients. No outside monitoring by a core laboratory occurred. 
Outcome reporting adhered to the guidelines from the ad hoc Committee 
for Standardized Reporting Practises in Vascular Surgery of the Society 
for Vascular Surgery/American Association for Vascular Surgery 
(SVS/AAVS).11 
 
Data Analysis 
In this study, all patients surviving the operation who had a 
minimal follow-up of 1 year were included. Patients who attended every 
prescribed follow-up visit were categorized as regular visitors (group A). 
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Patients missing one or more follow-ups were classified in the irregular 
study group (group B). There were 1,214 patients registered in our 
database who did not have the necessary data to participate in either 
group. The remaining 4,433 patients were categorized in either group A or 
B. Univariate chi-squared tests and multivariate logistic regression 
analyses were performed to explore differences in patient and anatomical 
demographics. Kaplan-Meier analysis and Cox proportional hazards 
models were performed to assess differences in outcome during follow-up 
and mortality. Odds ratios (ORs) and hazard rates (HRs) with 95% 
confidence intervals (CIs) were determined. The HR was adjusted for 
patient (age, Society of Vascular Surgery/International Society of 
Cardiovascular Surgery (SVS/ISVS) risk factors, unfitness for open 
surgery or general anaesthesia, and follow-up time), morphological 
(diameter and length measurements of the aortoiliac segment), and center-
specific (team experience) characteristics. Statistical significance was 
reached when the p value was less than 0.05. Analysis of data was 
performed with SAS statistical software (version 8.0; SAS Institute, Cary, 
NC). 
 
RESULTS 
Study Population 
Between October 1996 and August 2004, 4,433 patients underwent 
EVAR in 163 European centers. Of these patients, 1,538 (35%) were 
present at all scheduled surveillance visits (group A). The other 2,895 
(65%) patients missed one or more control exanimation and were therefore 
categorized as group B. Attendance at scheduled visits of the two groups 
is represented in Figure 1. The majority of patients were male (93%), and 
the mean age at operation was about 71 years (range 37-101). Analysis of 
patient characteristics revealed that a greater proportion of group A was 
classified as current smoker (27% vs. 22%, p = 0.0005), hyperlipemic 
(21% vs. 14%, p < 0.0001), and unfit for conventional open surgery or 
general anaesthesia (22% vs. 19%, p = 0.0217). Significantly more 
intraoperative additional procedures (36% vs. 28%, p < 0.0001), including 
percutaneous transluminal angioplasty (PTA)/stent for stenosis and 
uncovered stent crossing the renal artery, were performed in this study 
cohort. Also, more extensions were used in group A versus group B (38% 
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vs. 31%, p = 0.0005), and a longer operation time was necessary (139 vs. 
130 min, p < 0.0001) (Table I).  
 
Table 1: Patient characteristics (total n = 4,433) 
Total N=4433 
Group A 
N=1538 
Group B 
N=2895 
P-value 
Gender    
     Male 1429 (93.03%) 2706 (93.47%)  NS 
     Female 109 (7.09%) 189 (6.53%) NS 
Age at operation 70.71 ± 7.74 (48-91) 71.04 ± 7.66 (37-101) NS 
SVS-ISCVS    
     Diabetes 160 (10.40%) 290 (10.02%) NS 
     Smoking 412 (26.79%) 640 (22.11%) 0.0005 
     Hypertension 877 (57.02%) 1725 (59.59%) NS 
     Hyperlipemia 316 (20.55%) 402 (13.89%) <0.0001 
     Cardiac status 427 (27.76%) 735 (25.39%) NS 
     Carotid disease 79 (5.14%) 158 (5.46%) NS 
     Renal status 223 (14.50%) 450 (15.54%) NS 
     Pulmonary status 274 (17.82%) 471 (16.27%) NS 
Indication for EVAR    
    Previous laparotomy 394 (25.70%) 769 (26.60%) NS 
     Obesity 398 (25.98%) 682 (23.61%) NS 
     Unfit for open surgery/anaesthesia 330 (21.46%) 538 (18.52%) .0217 
Aneurysm measurements    
     Neck diameter 23.18 ± 3.09 23.27 ± 2.99 NS 
     Aneurysm diameter 56.35 ± 10.33 (30-105) 56.47 ± 10.72 (30-110) NS 
     Neck length 28.44 ± 12.60 27.13 ± 11.80 .0008 
     Length renal a. to iliac bifurcation 119.77 ± 18.65  117.12 ± 21.42 .0001 
Significant angulation    
     Aortic neck 337 (21.91%) 648 (22.38%) NS 
     Aneurysm 151 (9.82%) 338 (11.68%) NS 
     Iliac artery 696 (45.25%) 1227 (42.38%) NS 
Additional procedures 548 (35.63%) 812 (28.05%) <.0001 
     PTA/stent for stenosis 237 (15.41%) 355 (12.26%) .0034 
     Endarectomy 28 (1.82%) 36 (1.24%) NS 
     Iliofemoral bypass for access 7 (0.46%) 19 (0.66%) NS 
     Crossover fem-fem bypass 54 (3.51%) 111 (3.83%) NS 
     Uncovered stent crossing renal art. 81 (5.27%) 89 (3.07%) .0003 
     Other 245 (15.93%) 363 (12.54%) .0018 
Number of extensions    
0 941 (61.83%) 1956 (68.51%) .0005 
1  305 (20.04%) 466 (16.32%)  
>1 276 (18.13%) 433 (15.17%)  
Duration of the procedure 139.36 ± 60.97  130.46 ± 53.52 <.0001 
Follow-up time 30.17 ± 19.04 (12-96) 31.88 ± 19.45 (12-96) NS 
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Diagnostic methods, CTA, and IA-DSA were used more frequently 
in group A (98% vs. 93% and 89% vs. 76%, respectively; both p < 
0.0001), while MRI and IVUS were used more frequently in group B 
(2.0% vs. 7.6%, p < 0.0001, and 1.2% vs. 2.2%, p = 0.0226, respectively) 
(Table 2). In both groups, the majority of patients (89%) were treated with 
a bifurcated stent-graft; in 4% an aorto-uni-iliac and in 3% a straight tube 
was used. The type of device was unknown in 4% of the study population. 
The most frequently used devices were Zenith (33% in both groups), 
followed by Talent (26% vs. 25% in A vs. B), AneuRx (17% vs. 24% in A 
vs. B), Excluder (16% vs. 12% in A vs. B), Lifepath (2% in both), and 
Fortron (1% in both). In 5% vs. 3% (A vs. B) of patients, other or 
unknown device types were reported.  
 
Figure 1: Percentage of expected attendance duing the surveillance period. 
 
The contributing centers were divided into three categories 
according to team experience. The first category consisted of large centers 
with a team experience greater than 30 cases, the second category operated 
between 10 and 30 cases, and the third category included smaller centers 
with an experience of fewer than 10 patients. Patients of group A were 
enrolled in the registry by large centers in 40%, middle centers in 30%, 
and small centers in 30% of cases. In group B, the distribution was 60%, 
23%, and 17%, respectively (p < 0.0001). 
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Table 2: Diagnostics 
 Group A  
Group B 
 P-value 
Baseline N=1538 N=2895  
     CT 1507 (97.98%) 2694 (93.06%) <.0001 
     IA DSA 1365 (88.75%) 2211 (76.37%) <.0001 
     MRI 31 (2.02%) 219 (7.56%) <.0001 
     IVUS 19 (1.24%) 64 (2.21%) .0226 
Follow-up N=9498 N=12213  
     CT 7497 (78.93%) 10180 (83.35%) <.0001 
     Angiogram 621 (6.54%) 410 (3.36%) <.0001 
     MRI 219 (2.31%) 207 (1.69%) .0013 
     Duplex 2791(29.39%) 2304 (18.87%) <.0001 
  
Outcomes during Follow-Up 
During the control visits, CTA was used as a diagnostic method in 
79% vs. 83% of cases in groups A and B, respectively (p < 0.0001). Other 
methods used to follow patients were angiogram in 6.5% vs. 3.3% (p < 
0.0001), MRI in 2.3% vs. 1.7 (p = 0.0013), and DUS in 29% vs. 19% (p < 
0.0001) in groups A and B, respectively (Table 2). Completeness of 
follow-up data was 83%. Complications during the follow-up period 
included endoleaks, kinking, migration, stenosis, and thrombosis of the 
stent-graft, which were manifested more frequently in group A. Endoleaks 
occurred in 24% vs. 20% (p = 0.0003) and migration in 4.9% vs. 3.5% 
(p = 0.023) in groups A and B, respectively. Also, significantly more 
transfemoral secondary interventions were performed in group A (7.2% 
vs. 5.4%, adjusted HR = 1.4, 95% CI 1.1-1.8; p = 0.016). During the 
follow-up period, 182 (11.8%) and 252 (8.7%) died in groups A and B, 
respectively (adjusted HR = 1.5, 95% CI 1.2-1.8; p = 0.0002) (Table 3). 
Kaplan-Meier analysis showed, after 84 months of follow-up, a 
cumulative survival rate of 71% and 74% in, respectively, groups A and B 
(log rank p < 0.0001) (Figure 2).  
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Figure 2: Kaplan-meier survival curves for patients of both study groups. 
 
 
Table 3: Complications during follow-up 
Major complication Group A 
N=1538 
Group B 
N=2895 
Adjusteda 
Hazard 
Rate 
95% 
Confidence 
Limits 
P-value 
Endoleak 370 (24.06%) 590 (20.38%) 1.28 1.12-1.46 .0003 
     Proximal 41 (2.67%) 69 (2.38%) 1.20 0.81-1.78 NS 
     Midgraft 65 (4.23%) 103 (3.56%) 1.27 0.92-1.70 NS 
     Distal 65 (4.23%) 110 (3.80%) 1.20 0.87-1.65 NS 
     Reinjection sidebranches 211 (13.72%) 311 (10.74%) 1.39 1.16-1.66 .0003 
Kinking stent-graft 53 (3.45%) 71 (2.45%) 1.44 0.99-2.08 NS 
Stenosis / Thrombosis 98 (6.37%) 147 (5.08%) 1.29 0.99-1.68 NS 
Graft migration 75 (4.88%) 102 (3.52%) 1.43 1.05-1.95 .023 
Secondary intervention 140 (9.10%) 226 (7.81%) 1.19 0.95-1.48 NS 
     Transfemoral intervention 111 (7.22%) 155 (5.35%) 1.37 1.06-1.76 .016 
     Transabdominal intervention 14 (0.91%) 37 (1.28%) 0.74 0.40-1.39 NS 
     Extra anatomic intervention 21 (1.37%) 42 (1.45%) 0.98 0.57-1.68 NS 
Death 182 (11.83%) 252 (8.70%) 1.45 1.20-1.77 .0002 
AAA related death 21 (1.37%) 26 (0.90%) 1.53 0.85-2.73 NS  
Conversion 55 (3.58%) 90 (3.11%) 1.19 0.84-1.67 NS 
AAA rupture 20 (1.30%) 29 (1.00%) 1.50 0.83-2.71 NS 
aAdjusted for follow-up time and patient, morphological, and center-specific characteristics. 
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DISCUSSION 
The EUROSTAR collaborators recommend follow-up 
examinations at 1, 3, 6, 12, 18, and 24 months and annually thereafter.3 
However, it is unclear if this policy meets the needs of all types of patient. 
How often patients should return for follow-up visits and the impact of 
this intensity on patient outcomes remain in dispute. The main objective of 
this study was to evaluate the determinants and consequences of 
surveillance intensity. 
Thirty-five percent of the patients enrolled in EUROSTAR pursue 
accurately the suggested surveillance protocol. Analyses of patients’ 
characteristics revealed that patients who were present at every scheduled 
follow-up visit suffered more often from comorbid factors, including 
current smoking, hyperlipemia, and unfitness for open surgery or general 
anaesthesia. The most frequently used diagnostic methods during 
preoperative scanning were CTA and IA-DSA. During follow-up, CTA 
and DUS dominate. Analyses of late outcomes after EVAR revealed that, 
despite intensive follow-up of high-risk patients, still more complications, 
secondary interventions, and deaths occurred in this category. 
The finding that patients considered unfit for open surgery have 
more complications over time is in agreement with previous reports.4,12-14 
Riambau et al.12 analyzed the association between comorbidity and 
mortality after EVAR in patients ineligible for elective open surgery and 
concluded that the survival curves in these patients were significantly 
worse than in patients with a good medical condition. However, the 
frequency of follow-up visits was not analyzed in their research. 
The intensity of follow-up appears to be confounded by indication, 
which means that the reason for a more intense follow-up negatively 
influences the results. Patients with a severe risk profile had a higher 
chance of receiving a more intensive follow-up policy, which may worsen 
the results in this study population. The more intensive the follow-up 
visits, the more complications were found and the more secondary 
interventions performed. The literature shows that reinterventions are 
necessary in 12-28% of cases, but whether they are disadvantageous for 
the patient or lead to an increased mortality rate remains in question.15-18 
Becquemin et al.15 claimed that secondary reinterventions were associated 
with more surgical conversions and a higher clinical failure rate but not 
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with increased mortality. However, the high incidence of secondary 
interventions remains a cause of concern.15-19 
Determining how intensive a follow-up policy should be to meet 
the needs of each patient is a difficult task. Follow-up examinations are 
necessary to detect complications and to decide if a secondary intervention 
is needed. In case of too few control visits, complications may not always 
be detected in time, which could result in a higher mortality rate. 
Increasing the number of control examinations would also raise costs and, 
furthermore, could cause an inconvenience for the patient. 
One of the major advantages of an organized collaboration is the 
ability to gather a large number of patients in a reduced time span. 
Furthermore, ongoing analysis of improved or new devices provides 
updated knowledge and the ability to address new questions arising from 
previous investigations. The goal of EUROSTAR is a commercially 
unbiased, scientifically reliable collation and analysis of current AAA 
endografts. Disadvantages include absence of randomization and double 
blinding, larger interobserver variation, and lower accuracy and 
completeness of data. Nevertheless, a registry’s patient population is 
considered a good reflection of everyday clinical practice. 
In conclusion, intensity of follow-up programs seems to be based 
on patient demographics. Patients with more comorbidity were controlled 
more intensively. However, despite more intensive surveillance, still more 
complications occurred in this patient category even after adjustment for 
patient, demographic, and center-specific characteristics. Further 
assessment is indicated to evaluate the effectiveness of different 
frequencies of surveillance visits. 
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Section 6 
 
General Discussion 
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Section 1: Introduction. 
Endovascular abdominal aortic aneurysms repair (EVAR) has been 
proven to be a feasible alternative for open surgery in selected patients. 
There are short-term benefits such as patient-friendliness, savings on 
hospital stay and reduction of severe perioperative complications and 
mortality.1,2 However, uncertainty remains with respect to eligibility 
criteria, long-term side-effects, durability of the endoprothesis, and the 
method and frequency of follow-up.3-5 Risk factors associated with 
complications after endovascular repair can be patient, morphologic, or 
device related. The aim of the present thesis was to adress the following 
research question: What is the influence of patient, device, anatomic, and 
surveillance related risk factors on outcome after EVAR? This 
assessment was made on the basis of data collated in the EUROSTAR 
registry.  
 
Section 2: What is the relationship of complications after EVAR and 
patient characteristics? (Chapter 2.1: diabetes mellitus, chapter 2.2: 
advanced age, and chapter 2.3: preoperative statin use) 
EVAR has become increasingly popular as treatment of abdominal 
aortic aneurysms (AAA). Recently, the early benefits compared to open 
surgery, including a lower 30-day morbidity/mortality and reduced 
hospital stay, were confirmed in two randomized clinical trials.1,2 Diabetes 
mellitus has not been widely assessed as a comorbid factor that might 
impact the risk or outcome of EVAR. Diabetes is associated with 
accelerated rates of mortality, particularly from cardiovascular causes, and 
several chronic diseases, such as renal and peripheral arterial occlusive 
diseases.6 These comorbidities do increase the risk of open aneurysm 
repair. Therefore it may be advantageous for diabetic patients with AAA 
to be treated by EVAR. Rayan et al.7 investigated diabetes as a risk factor 
for patients undergoing open AAA repair who enrolled in a Vascular 
Surgery Registry. The postoperative mortality rate was relatively higher in 
the diabetic population. However, long-term cumulative survival was 
similar in diabetic and nondiabetic patients, as we concluded from our 
comparison between diabetes and endovascular AAA repair. We noted a 
4% higher 30-day mortality rate in the diabetic group, which was caused 
primarily by cardiac disease. However, this higher early mortality rate still 
ranged from 0% to 7% as reported by other recent studies analyzing 
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EVAR.8-12 De Virgilio et al. compared cardiac morbidity and mortality 
between conventional and endovascular AAA repair, but in their study, 
diabetes was not a predictive factor for adverse cardiac events (p=0.07).  
In conclusion. After the initially higher 30-day mortality rate in 
patients with diabetes compared to patients without diabetes, long-term 
survival was similar in both study groups. Further assessment is needed to 
evaluate the effect of diabetes on adverse events after EVAR. 
  
Because more people live longer, the need of surgical therapy in 
the elderly becomes an increasing concern and calls for less-invasive 
surgical treatment. Life expectancy, risks of the procedure, and 
postoperative quality-of-life play an important role in the decisions about 
treatment of an AAA made by patients, surgeons, and anesthesiologists.14 
This concern is highlighted by the fact that overall there are currently at 
least 4 million octogenarians in the United States, a figure expected to 
grow to as high as 30 million by 2050.15 We observed a hospital mortality 
of 5% in a group of patients of over 80 years, which is on the lower end of 
the range that varied from 5% to 10.5% in series treated by open 
surgery.16-18 Dardik et al.19 demonstrated a significant increase in the first-
month mortality after elective AAA repair with advanced age. In this 
report the death rate ranged from 2.2% for patients in the sixth decade of 
life to 7.3% in octogenarians. The rate of complications (13%), in 
particular systemic events, although higher than in younger patients, 
appeared acceptable. Most of these systemic complications were cardiac, 
pulmonary, and renal. Although one may assume that these complications 
adversely influence the quality of life, objective assessments on this matter 
have not been performed in the elderly age group.  
In conclusion. EVAR might be considered feasible for the treatment 
of octogenarians, provided their aneurysms are anatomically suitable for 
the endovascular technique. A lower early mortality and a shorter time for 
physical recovery in this patient group may outweigh the risk for late 
complications compared to open repair. 
 
Several studies have reported reduced perioperative mortality with 
statin use in patients undergoing major non-cardiac vascular surgery.20-24 
No previous research had been performed on the effect of statin use on 
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adverse outcomes after EVAR. After conventional open abdominal aortic 
aneurysm surgery Kertai et al. reported perioperative mortality of 3.7 % in 
patients using statins versus 11.0 % in non-statin users.24 The difference in 
all-cause mortality after EVAR in our study was less then in the series of 
Kertai, but still significantly lower in the statin group, 6% versus 10% 
respectively. The current propensity to prescribe statin to younger patients, 
or persons with a history of cardiac disease, 23,24 was also confirmed by 
our series. Statin users were in average 2.5 years younger and a 10% 
greater proportion had cardiac impairment. Conform to Parker et al. we 
found a reduction in length-of-hospital stay for statin users.26 The 
favourable effect of statins on long-term survival after various other 
vascular surgical procedures has been reported in several recent 
publications.25,26 We also noticed a 30% reduction in overall mortality 
after EVAR with perioperative statin use. Recently, it has been reported 
that statins also decrease the serum concentrations of matrix 
metalloproteinase (MMP) type 3 and 9. MMP-3 and 9 are associated with 
AAA formation and expansion. These data suggest a potentionally 
effective pharmacological therapy to inhibit further expansion of an 
established AAA.27 We were not able to analyse if there was reduced level 
of MMP-3 and MMP-9 in patients who were treated with statins in our 
study because no information on blood values was included in this 
registry.  
In conclusion. Our results confirm that pre-operative statin 
prescription occurred more frequent in younger patients and resulted in 
shorter hospital stay. Statin use was associated with improved overall-
survival after EVAR, even after adjustment for differences in age and 
medical risk factors.   
 
Section 3: What is the influence of device-specific characteristics on 
outcomes after EVAR?  (Chapter 3.1: overview of devices, chapter 3.2: 
first generation commercially available endograft, chapter 3.3: third 
generation stent-graft) 
Although there are several articles reporting long-term results of 
endovascular repair with individual makes of stent-grafts,28-33 only a few 
compared different endograft models.34-36 The present study hypothesized 
that (independent) differences exist between different makes of stent-
grafts, and endograft-related factors may influence treatment outcome. 
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Therefore, the statistical methods included a staged correction for these 
potentially confounding factors. The results support a conclusion that 
stent-graft-related factors do significantly impact outcome independent of 
several other factors that were studied. Stent-graft labels differ 
significantly in terms of applicability and types of complications during 
intermediate and long-term follow-up periods. The differences in outcome 
were persistent after adjustment for other important factors, including 
various patient characteristics, vascular morphology, and operator 
experience.  
In conclusion. Although no single make of stent-graft emerges as 
the best, it was reassuring to find that the later models of stent-grafts 
perform better than the early versions. Results of this comparative 
analysis should be used to develop a single device that combines all 
perceived improvements.  
  
Chapter 3.2 represented the long-term evaluation of results 
obtained from the collective experience of 62 European centers with the 
first generation of modular, fully stent-supported commercially available 
devices (Stentor and Vanguard). Frequent device failure ultimately 
resulted in the withdrawal of this device. A detailed account of the failure 
modes of the first generation endografts was provided in the literature.37,38 
Many of the mechanisms of device failure have been recognised and 
responded to by the manufacturers. The risk of adverse events in patients 
treated with the early generation of endografts is considerably higher than 
with modern devices. In the long-term over half of these patients will 
either die, experience a rupture of their aneurysm, or have a conversion to 
open repair. There was a distinct difference between patients with large 
and small aneurysms. The correlation of aneurysm size, applicability of 
EVAR and an increased operative risk has been documented 
previously.39,40  The most frequent complications reported during follow-
up included endoleak, stenosis/thrombosis, endograft migration, and 
suture breakage, all of which occurred at a higher incidence in the large-
aneurysm group. This higher incidence is most likely due to relativelly 
unfavourable anatomic conditions in the large size category.41,42 Despite 
the fact that the investigated endografts are no longer available, the long-
term outcomes are quite relevant. In the first place, a large number of 
patients had operations with these devices in the past and need continued 
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adequate aftercare. Secondly, the annual incidence rate of complications 
after EVAR seems generalisable to some extent to the present situation.  
In conclusion. Because of the risk of complications during follow-
up, patients treated with the first generation of stent-grafts will need life-
long surveillance. This risk of complications was particularly high in 
patients with large aneurysms at operation. Because the long-term 
effectiveness of endografts in current use has not been demonstrated yet, 
vigilant surveillance is indicated in all patients after EVAR.   
  
The advantages of EVAR are well-documented in chapter 3.3. 
Over 40% of patients had their procedure performed under local or 
regional anaesthesia, over half had an ASA-class III or IV and the mean 
admission time was only 4 days. These outcomes emphasize that 
refinements in stent-graft design and technology in the Excluder device 
that was used in this study population, further reduced the likelihood of 
early complications. The initial rate of 9% of endoleak, less than 1% 
device migration, and 0.3% primary conversion into open repair compared 
favourably with previously reported findings in patient cohorts including 
earlier device generations.
9 
 
Recently the size of the aneurysm has been indicated as a variable 
with strong influence on a variety of early and late outcome events.
41,43,44
 
In our study intraoperative device migration occurred slightly more 
frequent in large aneurysms, illustrating the greater technical challenge of 
the associated more complex anatomy, which was associated with the 
large aneurysm category. Endoleak development during follow-up is to 
some extent device-specific as was observed in another EUROSTAR 
report.
45 
However, the Excluder device did not demonstrate more 
endoleaks than other currently used devices in this earlier study. In the 
present cohort, a crude incidence of type I and III endoleak of 6% 
compared favourably with a 12% incidence of endoleak in the previous 
EUROSTAR report including a combined cohort with older and last 
generation models.  
In conclusion. Similar as in a previously published overall registry 
study in this device-specific assessment of patients treated with Excluder 
devices a higher rate of all-cause death and aneurysm-related death was 
observed in patients with larger aneurysms.  
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Section 4: How do characteristics of the aortoiliac arterial segment 
influence results after EVAR? (Chapter 4.1: infra-renal neck dilatation, 
chapter 4.2: infra-renal neck length)  
In the first chapter, the association of several factors with proximal 
neck dilatation after EVAR was assessed. These factors included smoking, 
large dimater infra-renal neck at operation, large stent-graft diameter, and 
absence of suprarenal or hook fixation. Influence of smoking or neck 
dilatation could not be demonstrated in this study. Large-diameter 
aneurysm and aneurysm sac expansion have been linked to shortening of 
the infrarenal neck. Cao and colleagues found significant dilatation of the 
infrarenal neck in 20% of patients with a positive correlation with wide 
infra-renal necks at the time of the procedure, mural thrombus in the neck, 
and large-diameter aneurysm.46 We found an opposite association with 
narrower necks correlating with dilatation during follow-up which is 
difficult to explain. No correlation with neck dilatation in their and our 
analysis was found with regard to neck angulation, neck length, and early 
endoleak. Older-generation endografts, such as the Stentor, Vanguard, and 
AneuRx devices had an increased incidence of proximal migration. This 
finding emphasizes the importance of an effective proximal fixation 
system. This observation should not lead to the conclusion to use too wide 
proximal endografts because other groups have observed that excessive 
endograft oversizing (> 20% diameter) may accelerate the process of neck 
dilatation and thereby perhaps migration.47 The same investigators found 
that angulation did not correlate with migration, which was similar to our 
observation.  
In conclusion. Our study suggested that migration is caused by 
neck dilatation. However, also other factors may play a role, such as the 
initial infra-renal neck size, length, device fixation system, and 
progressive wall degeneration. It is advisable to adhere to accepted 
criteria of neck dimensions to obtain acceptable results with EVAR.  
  
In the second chapter we have focused on the influence of the 
infra-renal neck length. This study revealed that the odds of suffering of a 
proximal endoleak at one month was 4.5 times higher when the neck 
length was 10 mm or less, than in patients with neck length over 15 mm. 
The 30-day death rate was higher in patients with necks shorter than 15 
mm compared to patients with an infra-renal neck length shorter than 10 
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mm. This supports the findings of Hovsepian et al.48 who found that a 
short proximal neck was a significant risk factor for intra-, postoperative 
complications and death. Also, during long term follow-up (4 years), the 
hazard of suffering from a proximal endoleak was 1.8 and 2.2 times higher 
in patients with an infra-renal neck length between 11 and 15 mm and 10 
mm or less, respectively, than in patients with an infra-renal neck length 
longer than 15 mm. Stanley et al.49, who used the Zenith endograft, found 
an increased risk of proximal endoleaks in patients with infra-renal neck 
length less than 20 mm. To overcome avoid the problems of too short 
infra-renal neck, fenestrated stent-grafts have received much attention as 
an alternative treatment option for patients with neck lengths shorter than 
15 mm. Indeed the incidence of endoleaks reported when using fenestrated 
endografts is reported quite low.50,51 However, it remains critical to follow 
the status of stented visceral vessels to establish the long-term efficacy of 
this type of repair. Important adverse events that were reported after 
fenestrated endovascular grafting involved renal problems.52 In this 
respect, regular stent-graft use is simpler and less demanding in high-risk 
patients who typically constitute a relatively large proportion of the short 
infra-renal neck category. Comparative studies between patients with short 
infrarenal necks treated with fenestrated endografts versus regular stent-
grafts will be needed to shed more light on possible advantages and 
disadvantages of this new technique.  
In conclusion. In our series EVAR with infra-renal neck length 
shorter than 15 mm was associated with significantly increased risk of 
short- and long-term proximal endoleak. The greater risk of proximal 
endoleaks should be weighted against the risks of alternative treatment 
modalities.  
 
Section 5: Chapter 5.1: What determines and are the consequences of 
surveillance intensity after endovascular abdominal aortic aneurysm 
repair?  
The EUROSTAR collaborators recommend follow-up 
examinations at 1, 3, 6, 12, 18, and 24 months and annually thereafter.53 
However, it is unclear if this policy meets the needs of all types of 
patients. How often patients should return for follow-up visits and the 
impact of this intensity on patient outcomes remains open to debate. 
Determining how frequent a follow-up schedule should be to meet the 
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needs of each patient is a difficult task. Follow-up examinations are 
necessary to detect complications and to decide whether a secondary 
intervention is required. In case of too few control visits complications 
may not always be detected in time, which may result in a higher mortality 
rate. Increasing the number of control examinations would raise costs of 
health care and adds to the burden of exposure to medical management for 
the patient. In our database, the intensity of follow-up appeared to be 
confounded by indication, which means that the reason for a more intense 
follow-up negatively influences the results. Patients with a severe risk 
profile had a higher chance of receiving a more intensive follow-up policy, 
which at the same time may worsen the results of treatment in this study 
group.  
In conclusion. Despite more intensive surveillance of patients with 
greater comorbidity, still more complications occurred in this patient 
category even after adjustment for patient, demographic, and center-
specific characteristics. Further assessment is indicated to evaluate the 
effectiveness of different frequencies of surveillance visits. 
 
Data quality, advantages and weaknesses of the EUROSTAR registry. 
Data quality can be described in different dimensions including 
relevance, accuracy, accessibility, comparability and completeness.  
Relevance. The EUROSTAR registry was launched with the 
objective to include a large number of patients in a reduced time span. It 
was expected to provide quick answers on clinical questions, while at the 
same time reflecting existing practice patterns. Furthermore, ongoing 
analysis of improved or new generation devices provided a constantly 
updated knowledge. This enabled us as investigators to perform analyses 
on questions that arised from previous investigations. The multicenter 
EUROSTAR registry included patients with a large variety of coexisting 
illnesses and a wide spectrum of disease severities. This makes the 
registry’s patient population a proper reflection of every day clinical 
practice. Additional advantages included the possibility to analyse 
infrequent events, for instance events caused by a breach from accepted 
indications, anatomic criteria or technique. Due to the large number of 
included patients, analysis provides greater statistical power. Moreover, 
assessment of small subgroups, which usually would be too small for a 
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meaningful analysis can still be performed because of the small 
confidence intervals. 
 Accuracy. To prevent selective inclusion into the EUROSTAR-
registry, enrolment forms were to be submitted 24h before operation to the 
data registry center. Inevitably, data collected in a multicenter registry 
have a relatively large interobserver variation, lower accuracy, and limited 
data monitoring compared to studies with fewer participants. This 
situation of non-differential misclassification may lead to an 
underestimation of differences of variables between comparator 
categories. At regularly intervals data controls were performed to detect 
double entry, not-plausible values, and to check on correct data 
chronology.  
Accessibility.  Since September 2003 the website ‘www.eurostar-
online.org’ (build and maintained by KIKA Medical, Nancy, France) is 
used for online access to the registry database. Patient data can be entered 
onlinebasic statistics, such as a comparison of institutional data with the 
overall database can be performed by each participating physician. 
Comparability. In statistical analysis correction for potential 
confounders can be made. It is important to adjust for differences in risk 
profile, anatomic and center-related characteristics between study groups, 
to allow valid comparisons between these stratefied groups and identify 
independent correlations with the outcome variables.  
Completeness. The mean completeness of follow-up data was 
70%. Incompleteness of data may distract from generalisability of 
observed results. Analysis of risk profile, morphologic and center-related 
characteristics between patients with complete follow-up and patients lost 
at some period during follow-up revealed that the missing values occurred 
more frequently in high-risk patients. Patients lost-to-follow-up are more 
frequently high risk patient reflected by higher incidence of ASA-class ≥ 
3, hypertension, hyperlipidemia, cardiac, renal and pulmonary impairment. 
Anatomic and center-specific characteristics were similar between 
patients-lost-to-follow-up and the rest of the study population. Differences 
in risk profile could lead to an underestimation of complications during 
the follow-up period. Correction for differences in follow-up time, risk 
profile, anatomic, device, and center-specific characteristics can be 
achieved by multivariate Cox proportional hazard models.  
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Conclusions 
From this thesis we may conclude that different aspects can 
influence the outcomes after EVAR. Patient-specific, anatomic, device-
related and surveillance characteristics have impact on outcomes. These 
findings emphasize the importance of proper patient selection i.e. patients 
that meet the accepted clinical and aortoiliac morphology criteria. Most 
benefit from endovascular aneurysm repair can be obtained in 
appropriately selected patients. The development of a prognostic model 
based on preoperative collected measurements is likely to be useful for 
therapeutically decision making, patient selection for clinical trials, and 
informing patients and families on the risks and outcome of EVAR.  
Proper patient selection, combined with the improved durability of 
stent-grafts, may also lead to a reduction of costs because of less 
secondary interventions and in the future perhaps a reduced surveillance 
schedule after EVAR. These goals are paramount since recent trials 
suggested that EVAR might not be cost effective compared to open 
surgery. These assessments were made in patients with an aneurysm larger 
than 5 cm who were also considered fit for open surgery. The clinical and 
economic outcomes of EVAR in patients with small aneurysms (<5 cm) 
are currently assessed in the PIVOTAL and CAESAR trials.54,55 
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An Abdominal Aortic Aneurysm (AAA) is a vascular disorder in 
which the abdominal aorta becomes permanently dilatated to at least 1.5 
times its normal diameter. The prevalence of AAA has increased rapidly 
during the last decade, and aneurysmal rupture is now the 13th most 
common cause of death in the Western world. Risk factors for AAAs are 
advanced age, male gender, a positive family history of AAA, 
atherosclerosis, smoking, hypertension, diabetes and previous vascular 
surgery. 
 April 8th 1955, Albert Einstein died from a ruptured AAA. A few 
years before his dead, he suffered regularly from pain in the abdominal 
region. This is not typical because mostly an AAA does not cause any 
disturbance before it ruptures.  A swelling the size of a grapefruit was 
established and an aneurysm was diagnosed. The aneurysm was intact and 
the vascular wall firm. Therefore it was decided not to treat the AAA. In 
general rupture of a large aneurysm can occur suddenly at any moment. 
When this occurs the person’s life is difficult to save by an operation. In 
Einstein’s case six years after the detection of the AAA, it ruptured, and 
he died.  The day after his dead the New York Times described his cause 
of death as follows: '… a big blister on the aorta, which broke finally like 
a worn-out inner tube.' Also the French mathematician Jean Fourier and 
the American comedienne Lucille Ball died from ruptured aneurysms. 
Traditionally, aneurysms are treated by open surgical repair. This 
involves exposure of the abdominal aorta, aortic and iliac clamping, and 
replacement of the aneurysmal segment by a prosthetic graft. 
Endovascular treatment of abdominal aortic aneurysms, introduced at the 
beginning of the 1990s, by Juan Parodi, an Argentine vascular surgeon, 
was a significant accomplishment in vascular surgery. This technique uses 
an endoprothesis, which is delivered through the femoral or iliac artery to 
exclude the aneurysm from the circulation. Endovascular repair has 
significant advantages over conventional surgery. First, it is a much less 
invasive technique than the traditional operation. This is of major 
importance for patients with coexistent diseases, who would be at high 
risk with conventional surgery. Secondly, with endovascular treatment 
operative trauma, blood loss and disturbance of hemodynamics and 
ventilation is minimal. And thirdly, since the introduction of this 
endovascular technique, length of hospital stay, and recovery have been 
reduced significantly, approximately from ten to three days for hospital 
stay and from two months to eleven days for recovery time. 
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The applicability and short and long-term efficacy of endovascular 
abdominal aortic aneurysm repair (EVAR) depends on patient-related 
characteristics (section 2), device properties (section 3), aorto-iliac 
morphology (section 4), and follow-up strategy (section 5).  
 
In section 2 we have analysed the effect of three patient related risk 
factors: diabetes mellitus (chapter 2.1), advanced age (>80years) (chapter 
2.2), and preoperative statin use (chapter 2.3). Our study revealed that 
patients with diabetes mellitus had a significantly higher 30-day mortality 
rate compared to patients without diabetes. After the lower initial success 
rate, long-term survival was similar in both study groups. However, more 
assessment is needed to evaluate the effect of diabetes on outcomes after 
EVAR.  
Our analysis of octogenarians supported the proposition that 
EVAR may be considered when treating elderly patients who have a 
limited life expectancy, provided their aneurysms are anatomically suited 
for the endovascular technique. The risk for late complications compared 
with open repair may be outweighed by a lower early mortality and a 
shorter time for physical recovery.  
We confirmed that pre-operative statin prescription occurred more 
frequently in younger patients and was associated in shorter hospital stay. 
After adjustment for differences in age and medical risk factors we found 
that statin use was still independently associated with improved overall-
survival after EVAR.  
 
Influence of stent-graft generation and different brands was 
discussed in section 3. In chapter 3.1 we present an overview of the 
different stent-graft labels collected in the EUROSTAR registry. We can 
conclude that stent-graft labels differ significantly in terms of applicability 
and individual complications during intermediate and long-term follow-up 
periods. The differences in outcome are persistent after adjustment for 
important factors, such as patient characteristics, vascular morphology, 
and operator experience. Although no single make of stent-graft emerges 
as the best, it is reassuring to note that the later models of stent-grafts 
perform better than the early versions.  
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When focussing on the first generation commercially available 
stent-grafts (chapter 3.2) we noticed that patients treated with these first 
endografts needed life-long surveillance, because of the continued risk of 
complications. This risk is particularly high in patients with large 
aneurysms at operation. Long-term effectiveness of endografts in current 
use has not been demonstrated yet. Vigilant surveillance is indicated in all 
patients after EVAR.   
In this device-specific assessment of the Excluder (chapter 3.3) a 
higher rate of all-cause death and aneurysm-related death was observed in 
patients with larger aneurysms. Post-EVAR growth was observed in a 
small percentage of patients, but this did not seem to contribute to 
aneurysm-related death.  
 
In section 4 the influence of the infra-renal neck anatomy was 
evaluated. In chapter 4.1 we looked at the infra-renal neck dilatation. We 
concluded that migration may be caused by neck dilatation. However, 
other factors, most notably infra-renal neck diameter, length, and the 
device fixation system, perhaps together with progressive wall 
degeneration, are also likely to play a role. To obtain acceptable results 
with EVAR, accepted criteria of neck dimensions should be adhered to.  
With regard to the infra-renal neck length (chapter 4.2), our results 
indicate that endovascular treatment of abdominal aortic aneurysms with 
an infra-renal neck length shorter than 15 mm was associated with 
significantly increased risk of short- and long-term proximal endoleak 
development after EVAR. The greater risk of proximal endoleaks should 
be weighted against the risks of alternative treatment modalities.  
 
In section 5, chapter 5.1 we noticed that the frequency of follow-
up schedule was related to patient demographics. Patients with more 
comorbidity were controlled more intensively. However, despite more 
intensive surveillance, still more complications occurred even after 
adjustment for patient, demographic, and center-specific characteristics. 
Further assessment is indicated to evaluate the effectiveness of different 
frequencies of surveillance visits.  
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In conclusion, adequate patient selection for endovascular 
treatment is of great importance. Identification of patients at high risk for 
death after EVAR by means of a range of preoperative measurements 
should get more attention. The development for an accurate prediction 
score may lead to a better selection of patients who would benefit most 
from EVAR.  
 
 
 204
 
 205
 
Section 8 
 
Nederlandse Samenvatting 
 
 206
Een Abdominaal Aorta Aneurysma (AAA) is een ernstige 
vasculaire aandoening waarbij de vaatwand plaatselijk verwijd is tot 
minstens anderhalve keer zijn normale diameter. Het aantal AAA’s neemt 
enorm toe de laatste tien jaar, en een gebarsten AAA is momenteel de 
dertiende meest voorkomende doodsoorzaak in de westerse wereld. 
Risicofactoren voor het krijgen van een aneurysma zijn: hoge leeftijd (> 
60 jaar), mannelijk geslacht, erfelijkheid, atherosclerosis, roken, hoge 
bloeddruk, diabetes en het hebben ondergaan van een eerdere vasculair 
chirurgische ingreep aan de aorta.  
Op 8 april 1955 overleed Albert Einstein aan de gevolgen van een 
gebarsten abdominaal aneurysma. Tijdens de laatste jaren van zijn leven 
had Einstein regelmatig last van pijnaanvallen bovenin de onderbuik 
(meestal veroorzaakt een AAA echter geen pijnklachten). Er werd een 
gezwel ter grootte van een pompelmoes vastgesteld, het was een 
aneurysma van de abdominale aorta. Het aneurysma was intact en de 
vaatwand was stevig, en daarom besloot men om het niet te behandelen. 
Maar iemand met een aneurysma in de aorta leeft verder met een tijdbom 
in de buik. Deze belangrijkste slagader in het menselijk lichaam kan het 
vanaf dat moment plotseling begeven, waarna de overlevingskans van de 
patiënt gering is. Ruim zes jaar na de diagnose scheurde het aneurysma en 
overleed Albert Einstein. De volgende dag verwoordde de New York 
Times de doodsoorzaak als volgt: '… a big blister on the aorta, which 
broke finally like a worn-out inner tube.' Ook de Franse wiskundige Jean 
Fourier en de Amerikaanse comédienne Lucille Ball zijn als gevolg van 
een gebarsten aneurysma gestorven. 
Traditioneel worden aneurysma’s behandeld door middel van een 
open chirurgische ingreep. Deze techniek houdt in dat de aorta en de 
iliacale arteriën worden blootgelegd, afgeklemd en het aneurysmatische 
gedeelte van de aorta door een vaatprothese wordt vervangen. In het begin 
van de jaren negentig werd door Juan Parodi, een Argentijnse vaatchirurg, 
een nieuwe endovasculaire techniek geïntroduceerd voor het behandelen 
van AAA’s. Met deze methode wordt er een endoprothese, endoluminaal 
via de femorale of iliacale arterie, naar de plaats van het aneurysma 
gebracht. Op deze manier wordt het AAA afgeschermd van de bloed 
circulatie. Voordelen van deze endovasculare benadering ten opzichte van 
de open ingreep zijn het minder invasieve karakter van deze techniek, wat 
voornamelijk van belang is voor patiënten met meerdere comorbiditeiten 
die een hoog sterfterisico hebben bij de traditionele behandeling. Ten 
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tweede wordt de operatieve trauma en het bloedverlies tijdens de operatie 
sterk gereduceerd. Tenslotte heeft deze techniek geleid tot een 
vermindering van de opnameduur (van tien naar drie dagen) en de 
herstelperiode (van zes weken naar elf dagen).  
De toepasbaarheid en uitkomsten van de endovasculaire 
behandeling van AAA’s hangen af van patiëntgerelateerde kenmerken 
(hoofdstuk 2), karakteristieken van de verschillende endoprothesen 
(hoofdstuk 3), de anatomie van het aneurysma (hoofdstuk 4), en de 
opvolgingsstrategie van de behandelde patiënten (hoofdstuk 5). 
In het tweede hoofdstuk onderzochten we de invloed van 
patiëntkarakteristieken, diabetes mellitus, hoge leeftijd (80+), en de 
inname van cholesterolverlagende medicijnen (statines) op de uitkomsten 
na endovasculaire behandeling van AAA’s. Onze analyses toonden aan dat 
patiënten met diabetes een verhoogde kans hebben op sterfte binnen de 
dertig dagen na de interventie. De overleving op lange termijn was echter 
vergelijkbaar tussen patiënten met en zonder diabetes. Er is nog verder 
onderzoek noodzakelijk voor een betere evaluatie van de invloed van de 
verschillende types diabetes, en de verschillende behandelstrategieën voor 
deze ziekte, op de uitkomsten na de endovasculaire ingreep.  
Het onderzoek op tachtigplussers bevestigde dat de endovasculaire 
behandeling toepasbaar is voor deze steeds groter wordende oudere 
populatie met beperkte levensverwachting, weliswaar indien ze 
anatomisch in aanmerking komen voor deze techniek. De verlaagde 
vroege sterftekansen en korter herstelperiode compenseren de kans op late 
complicaties geassocieerd met deze techniek vergeleken met open 
chirurgie.  
Statines werden meer voorgeschreven bij jonge patiënten, en het 
gebruik ervan was geassocieerd met een verminderde opnameduur. Het 
perioperatieve gebruik van statines hing samen met een gunstig effect op 
de overleving na de endovasculaire behandeling van aneurysma’s. Dit 
effect bleef behouden na correctie voor verschillen in karakteristieken 
tussen de statinegebruikers en niet-gebruikers. 
De invloed van typische endoprothese gerelateerde karakteristieken 
werden onderzocht in hoofdstuk 3. Het doel van ons eerste onderzoek was 
om een uitgebreid overzicht te geven van alle types endoprotheses en hun 
relaties met al de verschillende mogelijke complicaties na de 
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endovasculaire behandeling van AAA. Wij concludeerden dat de 
verschillende stent-graft merken aanzienlijk verschilden in hun 
toepasbaarheid en complicaties tijdens follow-up. De verschillen in 
uitkomst bleven behouden na correctie voor factoren zoals 
patiëntenkarakteristieken, morfologie en ervaring van het specialistische 
team. Hoewel, geen enkele stent-graft als beste naar voren kwam, was het 
geruststellend dat de nieuwe generatie het beter deed dan de eerste 
generatie commercieel beschikbare endoprotheses.  
Als we kijken naar de patiënten behandeld met eerste generatie 
endoprothesen die op de markt verschenen, merken we op dat levenslange 
controle noodzakelijk is bij deze patiënten vanwege het mogelijke risico 
op complicaties tijdens de follow-up periode. Dit risico is met name hoog 
bij patiënten met een aneurysma groter dan 5 cm. Daar lange termijn 
effecten van de nieuwe generatie endoprotheses nog onbekend zijn, raden 
wij nauwkeurige opvolging aan voor alle patiënten die een endovasculaire 
procedure ondergaan.  
Tot slot, hebben we een analyse uitgevoerd voor de Excluder, een 
derde generatie endograft. Ook bij dit merk endoprotheses, net als bij de 
EUROSTAR-populatie als geheel, observeerden we een hogere ratio 
aneurysma-gerelateerde sterfte bij patiënten met grote aneurysma’s (> 5 
cm). Postoperatieve groei van het AAA werd in een klein percentage van 
de patiënten waargenomen, maar bleek niet rechtstreeks samen te hangen 
met de aneurysma-gerelateerde sterfte. 
In het vierde hoofdstuk nemen we de anatomische kenmerken 
onder de loep. We keken in het bijzonder naar kenmerken van de infra-
renale nek. Dit is de afstand tussen de onderste nierarterie en het begin van 
het aneurysma. Na de endovasculaire procedure kan er verwijding van de 
infra-renale nek optreden die kan leiden tot migratie van de endoprothese. 
Dit werd bevestigd door onze studie, maar nekdilatatie was niet het enige 
kenmerk dat bijdroeg tot proximale verschuiving van de stent-graft. De 
initiële diameter en lengte van de infra-renale nek, het fixatie systeem van 
de endoprothese, en de progressieve degeneratie van de vaatwand zijn 
factoren die ook een belangrijke rol kunnen spelen. Om goede resultaten te 
verkrijgen na de endovasculaire operatie van een AAA kan men zich best 
aan de voorgeschreven anatomische criteria van de infra-renale nek 
houden. 
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Ook de lengte van de infra-renale nek beinvloedt de uitkomsten na 
deze operatie techniek. We namen waar dat patiënten met een infra-renale 
neklengte korter dan 15 mm een hoger risico hadden op het krijgen van 
een proximale endoleak (lekkage in de aneurysmazak vanaf de bovenste 
aanhechting van de stent). Het verhoogde risico op endoleaks moet 
worden afgewogen tegen de risico’s van alternatieve 
behandelingsmogelijkheden.  
De intensiteit van het controleschema gedurende de jaren na de 
ingreep werd geanalyseerd in hoofdstuk 5. Uit dit onderzoek bleek dat 
patiënten met meer comorbiditeiten, intensiever werden gevolgd. Ondanks 
deze meer intensieve aanpak, traden er nog steeds meer complicaties op in 
deze patiëntencategorie. Meer onderzoek is noodzakelijk om de 
effectiviteit van verschillende follow-up frequenties te bepalen. 
Voor de toekomst moet aan de patiëntenselectie voor de 
endovasculaire behandeling van AAA groot belang worden toegekend. 
Het preoperatief zo nauwkeurig mogelijk identificeren van patienten met 
een hoog risico op sterfte na de operatie is noodzakelijk. Het maken van 
een precieze, eenvoudige predictieregel kan leiden tot een betere selectie 
van patiënten die de meeste baat hebben aan deze endovasculaire techniek.  
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The members of the European Collaborators on Stent-graft Technique 
for Abdominal aortic aneurysm Repair (EUROSTAR) Registry were as 
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Treasurer and Executive Director Data Registry Centre: Jaap Buth, The 
Netherlands  
Secretary: Vincent Riambau, Spain  
Membership Director: Claude Mialhe, Monaco  
Publications Director: Lars Norgren, Sweden  
Sponsorship Director: Jean-Pierre Becquemin, France 
 
Data Registry Center Team 
Lina Leurs, The Netherlands 
Roel Hobo, The Netherlands 
Robert Laheij, The Netherlands  
 
International Advisory Board  
R.N. Baird, U.K.  
J.D. Blankensteijn, The Netherlands  
P. Cao, Italy  
H.G. Kretschmer, Austria  
F.L. Moll, The Netherlands  
H. Myhre, Norway  
A. Nevelsteen, Belgium  
W. Stelter, Germany  
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Collaborating centers of the EUROSTAR registry 
 
Austria: Vienna University Hospital, Vienna. 
Belgium: ASZ Aalst, Aalst; Onze Lieve Vrouwe Ziekenhuis, Aalst; 
A.Z.Middelheim, Antwerpen; Sint Vincentiusziekenhuis, Antwerpen; 
University Hospital Antwerp UIA/UZA, Antwerpen; Monica 
Ziekenhuis/OLV Middelares/Eeuwfeestkliniek, Antwerpen; St. 
Augustinus Hospital, Antwerpen/Wilrijk; Clinique Saint Joseph, Arlon; 
A.Z. St. Lucas - St Jozef, Assebroek/Brugge; Hopital Princesse Paola Aye 
Reseau Hosp de Medecine Sociale, Baudour; Imelda Hospital, Bonheiden; 
A.Z. Klina, Brasschaat; A.Z. St. Jan AV, Brugge; Hospital Erasme, 
Brussels; Academisch Ziekenhuis V.U.B., Brussels; Clinique de l'Europe 
St. Michel, Brussels; CHU Brugmann, Brussels; Hopitaux D' Iris Sud, 
Brussels; University Hospital Saint Luc, Bruxelles; Clinique Saint Jean, 
Bruxelles; CHU, Charleroi; A.Z. Sint Blasius, Dendermonde; A.Z. St. 
Maarten, Duffel; A.Z. St. Dimpna, Geel; St. Jan Ziekenhuis, Genk; vzw 
Volkskliniek, Gent; A.Z.Sint-Lucas, Gent; A.Z. St. Jan Palfijn, Gent; 
Universitair Ziekenhuis, Gent; AZ Maria Middelares-St Jozef, Gent; St. 
Joseph Hospital, Gilly; Hopital de Jolimont, Haint Saint Paul; Regionaal 
Ziekenhuis Sint Maria - Roos der koningin, Halle; Virga Jesseziekenhuis, 
Hasselt; St. Elisabeth, Herentals; CAZ-St. Franciskus-ziekenhuis, 
Heusden-Zolder; Regionaal Ziekenhuis Jan Yperman, Ieper; V.Z.W. 
Gezondheidszorg Oostkust, Knokke; AZ Groenige, Campus O.-L.-Vrouw, 
Kortrijk; Centre Hospitalier de Trivoli, La Louviere; University Hospital, 
Leuven;  Heilig Hart, Leuven; University Hospital , Liege; Clinique 
Saint-Joseph, Liege; Notre-Dame des Bruyeres, Liege-Chenee; Maria 
Ziekenhuis NoordLimburg Campus Lommel, Lommel; Clinique Reine 
Astrid, Malmedy; Onze Lieve Vrouwziekenhuis,  Mechelen; Heilig Hart, 
Menen; Fusieziekenhuis Jan Palfijn, Merksem; C.H.R. St Jospeh 
Warquignies, Mons; De Mont Godinne, Mont Godinne; CHM CNDT, 
Mouscron; C.H.R.N., Namur; Clinique St. Elisabeth, Namur; Clinique 
Saint-Pierre, Ottignies; Algemeen Ziekenhuis Heilige Familie, Reet; 
Stedelijk Ziekenhuis, Roeselare; H.H.R. Hartziekenhuis, Roeselare; 
C.H.R. Val de Sambre, Sambreville; St. Trudo Hospital, St.Truiden; St 
Andriesziekenhuis, Tielt; Cliniques Notre Dame Et St Georges, Tournai; 
C.H.R. de Tournai, Tournai; St. Josef Hospital, Turnhout; St. Elisabeth, 
Turnhout; St. Augustinuskliniek, Veurne; Sint-Josefkliniek, Vilvoorde.  
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Denmark: Rigshospitalet, Copenhagen; Odense Universital Hospital, 
Odense. 
France: Hospital Notre Dame, Draguignan; Hopital E. Herriot, Lyon; 
Hospital Henri Mondor, Paris Creteil Cedex. 
Germany: Surgical University Clinic Bonn, Bonn; Augusta Hospital, 
Dusseldorf; Stadtischen Kliniken Frankfurt an Main-Hochst, Frankfurt; 
Cardioangiologisches Centrum Bethanien, Frankfurt; Sankt Katharinen, 
Frankfurt; Altona General Hospital, Hamburg; Klinikum Kempten-OA 
gGmbH,  Kempten; Bundeswehrzentral K.H. Koblenz,  Koblenz; Park-
Krankenhaus, Leipzig; Philipps-University of Marburg, Marburg; 
Kliniken Rechts der Isar Munchen, Munchen; Pius Hospital, Oldenburg; 
University Ulm, Ulm. 
Greece: Athens University Medical School Psihico, Athens. 
Ireland: St. James Hospital, Dublin. 
Israel: Sheba Medical Centre, Tel Aviv. 
Italy: Policlinico Monteluce, Perugia; Ospedale S. Giovanni, Roma, 
Ospedale di Circolo, Varese. 
Luxembourg: Centre Hospitalier de Luxembourg, Luxembourg. 
Monaco: Centre Cardio-Thoracique, Monaco. 
Norway: Aker University Hospital, Oslo; Ulleval Hospital, Oslo; 
University Hospital of Trondheim, Trondheim. 
Poland: L'Academie de medecine de Lublin, Lublin; Medical University 
of Warsaw, Warsaw; MSWiA Hospital, Warsaw; Central Military 
Hospital, Warsaw. 
Spain: University Hospital of Barcelona, Barcelona; Ciutat Sanitaria i 
Universitaria de Bellvitge, Barcelona; Hospital Sta.Creu i S.Pau, 
Barcelona; Hospital de Gipuzkoa, Donostia; San Sebastian Hospital Juan 
Canalejo, La Coruna; USP-Hospital Santa Teresa, La Coruña; Hospital de 
Leon, Leon; Hospital Xeral Lugo, Lugo; University Hospital de la 
Princesa, Madrid; Virgen de la salud (Toledo), Madrid; Hospital Ramon y 
Cajal, Madrid; Fundacion Jimenez Diaz,Clinica de la Conception, Madrid; 
University Hospital of Getafel, Madrid; H.R. Carlos Haya, Malaga; 
University Hospital of Navarra, Pamplona; Hospital Clinico Valladolid, 
Valladolid. 
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Sweden: Lund University Hospital, Lund; Orebro Medical Centre 
Hospital, Orebro; Karolinska Hospital, Stockholm. 
Switzerland: Clinic for Cardiovascular Surgery, Bern. 
The Netherlands: Medisch Centrum Alkmaar, Alkmaar; Academisch 
Medisch Centrum, Amsterdam; Vrije Universiteit Amsterdam, 
Amsterdam; Onze Lieve Vrouwe Gasthuis, Amsterdam; Gelre Ziekenhuis 
Apeldoorn, Apeldoorn; Rijnstate Ziekenhuis, Arnhem; Amphia Hospital, 
Breda; Reinier de Graaf Groep, Delft; Medisch Centrum Haaglanden, 
Westeinde; Leijenburg Ziekenhuis, Den Haag; Slingerland Ziekenhuis, 
Doetinchem; Albert Schweitzer Hospital locatie Amstelwijck, Dordrecht; 
Ny Smellinghe Hospital, Drachten; Catharina-ziekenhuis, Eindhoven; 
Medisch Spectrum Twente, Enschede; St. Anna Ziekenhuis, Geldrop; 
Academisch Ziekenhuis Groningen, Groningen; Martini Ziekenhuis, 
Groningen; Medisch Centrum Leeuwarden, Leeuwarden;  Academisch 
Ziekenhuis Maastricht, Maastricht; St. Antonius Ziekenhuis, Nieuwegein; 
Canisus-Wilhelmina Ziekenhuis, Nijmegen; Academisch Ziekenhuis 
Nijmegen, Nijmegen; St. Clara Ziekenhuis, Rotterdam; Dijkzicht 
Ziekenhuis, Rotterdam; Franciscus Gasthuis Rotterdam, Rotterdam; 
Elisabeth Ziekenhuis, Tilburg; TweeSteden ziekenhuis, Tilburg; 
Universitair Medisch Centrum, Utrecht; St. Josef Ziekenhuis, Veldhoven; 
Isala Klinieken Lokatie Sophia, Zwolle. 
Turkey: Istanbul Memorial Hospital, Istanbul; University of Istanbul 
Cerrahpa'a Medical F, Istanbul. 
United Kingdom: Royal Bournemouth Hospital, Bournemouth; Bristol 
Royal Infirmary, Bristol; Countess of Chester Hospital, Chester; Gartnavel 
Hospital, Glasgow; Hull Royal Infirmary, Hull; Royal University 
Hospital, Liverpool; Withington Hospital, Manchester; Freeman Hospital 
Northern Vascular Centre, New Castle-Upon-Tyne. 
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